<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001090" GROUP_ID="ANAESTH" ID="976199103013234834" MERGED_FROM="" MODIFIED="2013-09-13 10:05:32 +0100" MODIFIED_BY="Jane Cracknell" REVIEW_NO="122" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2013-09-13 10:05:32 +0100" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2009-03-22 10:38:18 +0000" MODIFIED_BY="[Empty name]">Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock</TITLE>
<CONTACT MODIFIED="2013-09-13 10:05:32 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="17396" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marissa</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Alejandria</LAST_NAME><EMAIL_1>issa.alejandria@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Section of Infectious Diseases</DEPARTMENT><ORGANISATION>Department of Medicine, Philippine General Hospital, University of the Philippines</ORGANISATION><CITY>Manila</CITY><ZIP>1000</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+632 525 4098</PHONE_1><FAX_1>+632 525 4098</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-09-13 10:05:32 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="17396" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marissa</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Alejandria</LAST_NAME><EMAIL_1>issa.alejandria@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Section of Infectious Diseases</DEPARTMENT><ORGANISATION>Department of Medicine, Philippine General Hospital, University of the Philippines</ORGANISATION><CITY>Manila</CITY><ZIP>1000</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+632 525 4098</PHONE_1><FAX_1>+632 525 4098</FAX_1></ADDRESS></PERSON><PERSON ID="14306" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mary Ann</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Lansang</LAST_NAME><EMAIL_1>mlansang@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Section of Infectious Diseases</DEPARTMENT><ORGANISATION>Department of Medicine, Philippine General Hospital, University of the Philippines</ORGANISATION><CITY>Manila</CITY><ZIP>1000</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 5254098</PHONE_1><FAX_1>+63 2 5254098</FAX_1><FAX_2>+63 2 8449904</FAX_2></ADDRESS></PERSON><PERSON ID="17052" ROLE="AUTHOR"><FIRST_NAME>Leonila</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Dans</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>leonila.dans@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of the Philippines College of Medicine</ORGANISATION><ADDRESS_1>Philippine General Hospital</ADDRESS_1><ADDRESS_2>Taft Avenue</ADDRESS_2><CITY>Manila</CITY><ZIP>1000</ZIP><REGION>National Capital Region</REGION><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 5240892</PHONE_1><PHONE_2>+63 2 5218450 Extn:2101</PHONE_2><FAX_1>+63 2 5260150</FAX_1></ADDRESS></PERSON><PERSON ID="CFB01CB882E26AA200BB9F5B396A91E8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jacinto</FIRST_NAME><MIDDLE_INITIALS>Blas</MIDDLE_INITIALS><LAST_NAME>Mantaring III</LAST_NAME><EMAIL_1>jojo@mantaring.org</EMAIL_1><EMAIL_2>jojomant@yahoo.com</EMAIL_2><MOBILE_PHONE>+639178989529</MOBILE_PHONE><ADDRESS><DEPARTMENT>Section of Newborn Medicine, Department of Pediatrics</DEPARTMENT><ORGANISATION>University of the Philippines</ORGANISATION><ADDRESS_1>Philippine General Hospital</ADDRESS_1><ADDRESS_2>Taft Ave</ADDRESS_2><CITY>Manila</CITY><ZIP>1000</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="Jane Cracknell">
<UP_TO_DATE>
<DATE DAY="1" MONTH="12" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2013-09-13 09:46:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-13 09:46:52 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>We reran the search from October 2008 to December 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-09-13 09:46:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<OL>
<LI>We included one new completed polyclonal IVIG trial previously classified as ongoing (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>).</LI>
<LI>One small trial on polyclonal IVIG in children is awaiting translation and full assessment (<LINK REF="STD-Yildizdas-2005" TYPE="STUDY">Yildizdas 2005</LINK>).</LI>
<LI>There is a substantial change in the conclusions of the review with the inclusion of the large polyclonal IVIG trial in neonates (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>). There is now sufficient evidence that standard polyclonal IVIG in neonates does not reduce mortality.</LI>
</OL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-02 18:15:00 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-02 18:15:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Search reran up to October 2008; 16 new studies included: 14 polyclonal (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>;<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>;<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>;<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>;<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>;<LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>;<LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>;<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>;<LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>;<LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>;<LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>) and 2 monoclonal (<LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>;<LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-15 19:39:29 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="4" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MINOR" MODIFIED="2008-11-30 05:59:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of the Philippines, Manila</NAME>
<COUNTRY CODE="PH">Philippines</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>European Commission (Directorate General XII)</NAME>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-09-13 09:51:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-09-02 11:04:05 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-07-09 04:16:10 +0100" MODIFIED_BY="[Empty name]">Intravenous immunoglobulins for treating patients with severe sepsis and septic shock</TITLE>
<SUMMARY_BODY MODIFIED="2013-09-02 11:04:05 +0100" MODIFIED_BY="[Empty name]">
<P>Sepsis is the inflammatory response of the body to severe infection, which can be caused by a variety of micro-organisms including bacteria, viruses and fungi. Signs of sepsis include fever, hypothermia, rapid heart rate and respiration; and a laboratory finding of increased or decreased white blood cell count. Deaths as a result of sepsis and septic shock remain high despite giving antibiotics, especially if the functions of a persons's vital organs such as the lungs, heart and kidneys are affected. Several studies have looked into other agents than antibiotics to help the body fight the effects of sepsis. Intravenous immunoglobulin preparations contain antibodies that help the body to neutralize bacterial toxins. There are two types of preparations. These are polyclonal immunoglobulins that contain several antibodies directed at endotoxin and inflammatory mediators, and monoclonal immunoglobulins which target a specific inflammatory mediator or antigen. Intravenous immunoglobulins are blood products, specifically pooled sera derived from human donor blood.</P>
<P>For this updated Cochrane review, we searched the medical literature databases to January 2012. We included 43 randomized controlled trials (RCTs); 25 were RCTs of polyclonal intravenous immunoglobulins (IVIGs) with 17 in adults (1958 participants) and eight in newborn infants (3831 participants) including a large polyclonal IVIG trial on infants with sepsis that was published in 2011. The remaining 18 trials (a total of 13,413 participants) were of monoclonal antibodies. Both standard and immunoglobulin M (IgM)-enriched polyclonal immunoglobulins decreased the number of deaths in adults but not in infants. However, no reductions in adult deaths were seen with polyclonal IVIG using high quality trials only. Among newborn infants with sepsis, there is definitive evidence that standard polyclonal IVIG does not reduce the number of deaths. In the monoclonal immunoglobulin trials, anti-endotoxin antibodies showed no benefit while the anti-cytokines showed a very small reduction in deaths among adults with sepsis.</P>
<P>The polyclonal immunoglobulin trials in adults were small compared to the trials of monoclonal agents. The reduction in deaths observed with polyclonal IgM-enriched preparations as add-on therapy for sepsis needs to be confirmed in large studies that use high quality methods.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-02 11:48:36 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-09-02 10:43:03 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-09-02 10:43:47 +0100" MODIFIED_BY="[Empty name]">
<P>To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-02 11:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 6), MEDLINE (1966 to December 2012), and EMBASE (1988 to December 2012). We contacted investigators in the field for unpublished data. The original search was performed in 1999 and updated in 2002 and 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-04-06 00:33:42 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials comparing IVIG (monoclonal or polyclonal) with placebo or no intervention in patients of any age with bacterial sepsis or septic shock.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-02 10:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed the studies for inclusion and undertook methodologic quality assessment and data abstraction. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-02 11:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>We included 43 studies that met our inclusion criteria in this updated review out of 88 potentially eligible studies. The studies included a large polyclonal IVIG trial in neonates that was concluded in 2011 and classified as ongoing in the 2010 version of this review. Pooled analysis of polyclonal and monoclonal IVIG was not done due to clinical heterogeneity. Subgroup analysis of 10 polyclonal IVIG trials (n = 1430) and seven trials on IgM-enriched polyclonal IVIG (n = 528) showed significant reductions in mortality in adults with sepsis compared to placebo or no intervention (relative risk (RR) 0.81; 95% confidence interval (CI) 0.70 to 0.93 and RR 0.66; 95% CI 0.51 to 0.85, respectively). Subgroup analysis of polyclonal IVIG in neonates, which now includes the recently concluded large polyclonal IVIG trial, showed no significant reduction in mortality for standard IVIG (RR 1.00; 95% CI 0.92 to 1.08; five trials, n = 3667) and IgM-enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; three trials, n = 164). Sensitivity analysis of trials with low risk of bias showed no reduction in mortality with polyclonal IVIG in adults (RR 0.97; 95% CI 0.81 to 1.15; five trials, n = 945) and neonates (RR 1.01; 95% CI 0.93 to 1.09; three trials, n = 3561). Mortality was not reduced among patients (eight trials, n = 4671) who received anti-endotoxin antibodies (RR 0.99; 95% CI 0.91 to1.06) while anti-cytokines (nine trials, n = 7893) demonstrated a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-04-01 16:44:32 +0100" MODIFIED_BY="[Empty name]">
<P>Polyclonal IVIG reduced mortality among adults with sepsis but this benefit was not seen in trials with low risk of bias. Among neonates with sepsis, there is sufficient evidence that standard polyclonal IVIG, as adjunctive therapy, does not reduce mortality based on the inclusion of the large polyclonal IVIG trial on neonates. For Ig-M enriched IVIG, the trials on neonates and adults were small and the totality of the evidence is still insufficient to support a robust conclusion of benefit. Adjunctive therapy with monoclonal IVIGs remains experimental.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-09-13 09:51:12 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-09-02 11:19:21 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-09-02 11:06:24 +0100" MODIFIED_BY="[Empty name]">
<P>Sepsis is a systemic inflammatory response of the body to severe infection caused by various micro-organisms including bacteria, viruses and fungi. It is detected through a constellation of signs such as fever, hypothermia, tachycardia and rapid respiration; and a laboratory finding of an increased or decreased white blood cell count. Overwhelming sepsis can lead to multiorgan dysfunction and shock. Despite the development of new and effective antibiotics, hospital mortality from sepsis ranges from 18% in a developed country (<LINK REF="REF-Sundararajan-2006" TYPE="REFERENCE">Sundararajan 2006</LINK>) to 87% in a developing country setting (<LINK REF="REF-Tanriover-2006" TYPE="REFERENCE">Tanriover 2006</LINK>), with a stepwise increase in mortality as sepsis progresses to septic shock (<LINK REF="REF-Rangel_x002d_Frausto-1995" TYPE="REFERENCE">Rangel-Frausto 1995</LINK>). Two tertiary hospitals in metropolitan Manila, Philippines reported mortality rates of 34% and 50% among sepsis patients (<LINK REF="REF-Alejandria-2000" TYPE="REFERENCE">Alejandria 2000</LINK>; <LINK REF="REF-Villa-1995" TYPE="REFERENCE">Villa 1995</LINK>), which increased to 59% among patients with severe sepsis (<LINK REF="REF-Taguiang_x002d_Abu-2008" TYPE="REFERENCE">Taguiang-Abu 2008</LINK>). A recent multinational prospective cohort study on the management of severe sepsis in 150 intensive care units in 16 Asian countries reported a hospital mortality of 44.5% out of 1285 adult patients (<LINK REF="REF-Phua-2011" TYPE="REFERENCE">Phua 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-04-06 00:40:07 +0100" MODIFIED_BY="[Empty name]">
<P>The cascade of harmful effects from sepsis and septic shock has been postulated to be largely due to the lipid-A component of the endotoxin molecule in gram-negative bacteria. Thus the use of antibodies against different components of the endotoxin molecule as adjunctive therapy for sepsis has been the target of various investigations. A number of these studies have been randomized controlled trials of various types of human immunoglobulin preparations in the treatment of patients with septic shock. The most commonly used interventions in these studies were monoclonal and polyclonal immunoglobulin preparations given intravenously. Monoclonal preparations contain immunoglobulins developed from a single cell line targeting a specific antigen; while polyclonal preparations are from pooled human sera containing different immunoglobulins (Ig), mainly IgG and IgM, not necessarily directed at specific antigen sites. Intravenous immunoglobulins are biological products derived from human blood.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-02 11:13:12 +0100" MODIFIED_BY="[Empty name]">
<P>It is postulated that neutralizing and opsonizing antibodies contained in polyclonal immunoglobulin preparations inactivate bacterial endotoxins and exotoxins, stimulate leukocytes, and increase serum bactericidal activity. It is also hypothesized that immunoglobulins interfere with cytokine effects by modulating the release of cytokine and cytokine antagonists by endotoxins, attenuating the effects of the complement cascade (<LINK REF="REF-Werdan-2001" TYPE="REFERENCE">Werdan 2001</LINK>). Results from trials on the effects of the different types of immunoglobulin preparations in reducing mortality from septic shock have been conflicting. A meta-analysis (<LINK REF="STD-Lacy-1995" TYPE="STUDY">Lacy 1995</LINK>) reviewing the prophylactic effect of IVIG on infection in preterm infants did not recommend its routine use. Another meta-analysis (<LINK REF="STD-Jenson-1997" TYPE="STUDY">Jenson 1997</LINK>), however, concluded that there was a significant benefit to giving IVIG shortly after birth in preventing sepsis among premature low birth-weight newborns and in reducing deaths among neonates with early-onset sepsis. An update of a Cochrane review (<LINK REF="REF-Ohlsson-2013" TYPE="REFERENCE">Ohlsson 2013</LINK>) concluded that there is insufficient evidence to support the routine use of polyclonal IVIG for infants with suspected or proven neonatal infection.</P>
<P>Adverse effects from IVIG therapy have also been reported and can be classified into three types according to their onset. These are immediate, delayed, and late onset. Immediate adverse effects occur during infusion, for example anaphylactoid reactions; delayed adverse effects occur hours or days after infusion, for example pulmonary, renal, haematologic and neurologic events; and late adverse effects include transmission of infectious agents such as hepatitis C and prion diseases (<LINK REF="REF-Nydegger-1999" TYPE="REFERENCE">Nydegger 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-02 11:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>The use of IVIG in sepsis has major implications for developing countries such as the Philippines where sepsis is a common cause of hospital mortalities and where medical practitioners use IVIG indiscriminately for both prophylaxis and the treatment of infections and sepsis. A survey of prescribing patterns for immunoglobulin use among paediatricians in three hospitals in Manila, Philippines showed that neonatal sepsis was the third most common condition for which IVIG was used (<LINK REF="REF-Zabala-1999" TYPE="REFERENCE">Zabala 1999</LINK>). Considering the high cost of IVIG, potential adverse effects, and conflicting reports on its benefits in sepsis, we should continually assess the evidence from randomized controlled trials.</P>
<P>This review updates our existing Cochrane review, which was first published in 1999 and was updated in 2002 (<LINK REF="REF-Alejandria-2002" TYPE="REFERENCE">Alejandria 2002</LINK>) and 2010. The 2010 update included the large polyclonal IVIG trial on adults that was conducted in 1995 (<LINK REF="REF-Werdan-1997" TYPE="REFERENCE">Werdan 1997</LINK> abstract) and published 10 years after its completion (<LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>). This was the main point of difference between our 2002 review (<LINK REF="REF-Alejandria-2002" TYPE="REFERENCE">Alejandria 2002</LINK> ) and the subsequent meta-analysis by Pildal and Goetzsche in 2004 (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>). In this update (2013) we have included the large polyclonal IVIG trial on neonates which was completed and published in 2011 (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-09-02 10:44:35 +0100" MODIFIED_BY="[Empty name]">
<P>To estimate the effects of intravenous immunoglobulin (IVIG) as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2013-09-02 11:22:14 +0100" MODIFIED_BY="Jane Cracknell">
<CRIT_STUDIES MODIFIED="2009-03-11 00:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials (RCTs) comparing IVIG with a control group that received placebo or no intervention. We excluded quasi-randomized studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-02 11:22:02 +0100" MODIFIED_BY="[Empty name]">
<P>We included studies on patients of any age with sepsis or septic shock caused by bacteria.</P>
<P>The 1992 and 2001 consensus conference definitions of sepsis, severe sepsis and septic shock (<LINK REF="REF-Bone-1992" TYPE="REFERENCE">Bone 1992</LINK>; <LINK REF="REF-Levy-2003" TYPE="REFERENCE">Levy 2003</LINK>) are as follows.</P>
<P>Sepsis is the presence of two or more of the following systemic inflammatory responses to a documented infection: a) temperature &gt; 38 °C or &lt; 36 °C; b) heart rate &gt; 90 beats/min; c) respiratory rate &gt; 20 breaths/min or PaCo<SUB>2</SUB> &lt; 32 mmHg; d) white blood cell count &gt; 12,000/mm, &lt; 4000/mm, or &gt; 10% immature forms.</P>
<P>Severe sepsis is sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion abnormalities may include lactic acidosis, oliguria, or an acute alteration in mental status.</P>
<P>Septic shock is a subset of severe sepsis, defined as persistence of sepsis-induced hypotension despite adequate fluid resuscitation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-09-02 11:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>The experimental intervention was any monoclonal or polyclonal intravenous immunoglobulin (IVIG) for the treatment of sepsis and septic shock.<BR/>The control group received placebo or no immunoglobulin.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-06 01:16:43 +0100" MODIFIED_BY="Jane Cracknell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-04-06 01:15:55 +0100" MODIFIED_BY="Jane Cracknell">
<OL>
<LI>All-cause mortality at the end of the follow-up period</LI>
<LI>Short-term mortality: mortality measured at 30 days (30-day mortality)</LI>
<LI>Long-term mortality: mortality measured at time periods greater than 30 days</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-06 01:16:43 +0100" MODIFIED_BY="Jane Cracknell">
<OL>
<LI>Bacteriological failure rate</LI>
<LI>Development of organ failure</LI>
<LI>Length of hospital stay among survivors</LI>
<LI>Mortality from septic shock</LI>
<LI>Adverse effects</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(2012, Issue 6) (using the search terms listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>); MEDLINE (1966 to December 2012) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>); EMBASE (1988 to December 2012) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). The topic search terms were used in combination with the Cochrane highly sensitive search strategy for identifying RCTs.</P>
<P>We used the following free text and MeSH terms to search all trials registers and databases: immunoglobulin* near (monoclon* or polyclon*), IVIG, immunoglobulins-intravenous, sepsis, septic shock, septicaemia or septicaemia.</P>
<P>We did not apply language restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-09-02 11:29:47 +0100" MODIFIED_BY="Jane Cracknell">
<P>We reviewed citations in the trial reports identified by the above methods. Investigators or organizations working in this field were also contacted for more information on published and unpublished RCTs. We requested extraction of information from foreign language trials that met the inclusion criteria.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-03 01:35:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-09-02 11:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (MAL, MMA) independently assessed the titles (and abstracts when available) identified in the search printouts for eligibility. Articles that might have met the selection criteria or could have referred to a possible trial were all retrieved and examined.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-02 11:32:33 +0100" MODIFIED_BY="[Empty name]">
<P>Data abstraction forms and operational definitions for outcomes and explanatory variables were developed. Two authors (LFD, JVM) independently abstracted information from each study prior to pooling of results. Data abstraction included the time period and geographical location of the study, baseline patient characteristics, inclusion and exclusion criteria, type of IVIG preparation and the dosing regimen, and the type of placebo used, if any. Information on each of the following outcome measures were also abstracted: mortality, bacteriological failures, duration of hospitalisation, and the number or per cent of affected patients.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-02 11:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (LFD, JVM) independently appraised the quality of the included studies by assessing allocation concealment, generation of the allocation sequence, and inclusion of all randomized participants. The 2010 update of this review used the standards set by the Cochrane Anaesthesia Group while the previously published version of this review (<LINK REF="REF-Alejandria-2002" TYPE="REFERENCE">Alejandria 2002</LINK>) used the criteria set by the Cochrane Infectious Diseases Group, available on the Group Module in <I>The Cochrane Library</I>. In addition to the standards set by both review groups, we assessed the comparability of the baseline characteristics and the care received by the treatment and control groups in terms of co-interventions, frequency of follow up, and general quality of care.</P>
<P>In this update, the risk of bias assessment was updated using the Cochrane Collaboration's tool in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The following domains were used: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias, for example comparability of baseline characteristics and the care received by the treatment and control groups in terms of co-interventions, frequency of follow up, and general quality of care. Judgments on the risk of bias for each component were as follows.</P>
<P>1. Generation of allocation sequence</P>
<UL>
<LI>Low risk: if appropriate methods such as random numbers generated by a computer or table of random numbers, drawing of lots, coin toss, or throwing dice were used.</LI>
<LI>High risk: if sequences such as case record number; date of birth; day, month, or years of admission were used.</LI>
<LI>Unclear risk: if the methods were not described.</LI>
</UL>
<P>2. Concealment of allocation</P>
<UL>
<LI>Low risk: if measures were used to prevent foreknowledge of assignment, such as centralized randomization; or numbered, sealed, opaque envelopes.</LI>
<LI>HIgh risk: if researchers and participants could foresee an upcoming assignment e.g. by alternation.</LI>
<LI>Unclear risk: if the methods were not described.</LI>
</UL>
<P>3. Blinding of participants and personnel</P>
<UL>
<LI>Low risk: no blinding, or incomplete blinding but review authors judge that the outcome is not likely to be influenced by lack of blinding, or blinding of participants and key personnel ensured and unlikely that the blinding could have been broken.</LI>
<LI>High risk: no blinding, or incomplete blinding and the outcome is likely to be influenced by lack of blinding, or blinding of participants and key personnel attempted but likely that the blinding could have been broken and the outcome is likely to be influenced by lack of blinding.</LI>
<LI>Unclear risk: insufficient information to permit judgment, or the study did not address the outcome.</LI>
</UL>
<P>4. Blinding of outcome assessment</P>
<UL>
<LI>Low risk: blinding of outcome assessment ensured and unlikely that blinding could have been broken; outcome detection methods are the same for both groups.</LI>
<LI>High risk: no blinding of outcome assessment and the outcome measurement is likely to be influenced by lack of blinding, or blinding of outcome assessment done but likely that the blinding could have been broken and the outcome measurement is likely to be influenced by lack of blinding.</LI>
<LI>Unclear risk: insufficient information to permit judgment.</LI>
</UL>
<P>5. Incomplete outcome data</P>
<UL>
<LI>Low risk: no missing outcome data; reasons for missing data unlikely to be related to true outcome; missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups; for dichotomous data, the proportion of missing outcomes compared with observed event risk not likely to have a clinically relevant impact on the intervention effect estimate; for continuous data, plausible effect size among missing outcomes not likely to have a clinically relevant impact on the observed effect size; intention-to-treat analysis was done.</LI>
<LI>High risk: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous data, proportion of missing outcomes compared with observed event risk likely to cause clinically relevant bias in the intervention effect estimate; for continuous data, plausible effect size among missing outcomes likely to cause a clinically relevant bias in the observed effect size; efficacy analysis done with substantial departure of the intervention received from that assigned during randomization; intention-to-treat analysis was not done.</LI>
<LI>Unclear risk: insufficient reporting of attrition and exclusions to permit judgment (e.g. number of participants randomized not stated; reasons for missing data not stated).</LI>
</UL>
<P>6. Selective outcome reporting</P>
<UL>
<LI>Low risk: study protocol is available and all of the study's pre-specified outcomes that are of interest in the review were reported in a pre-specified way; study protocol is not available but published reports include all expected outcomes, including those that were pre-specified.</LI>
<LI>HIgh risk: not all of the study's pre-specified primary outcomes were reported; one or more primary outcomes are reported using measurements, analysis methods or subsets of the data that were not pre-specified; one or more reported primary outcomes were not pre-specified, unless clear justification is provided; one or more outcomes of interest in the review are reported incompletely; failure to include a key outcome that would be expected to have been reported in such a study.</LI>
<LI>Unclear risk: insufficient information to permit judgment.</LI>
</UL>
<P>7. Other sources of bias</P>
<UL>
<LI>Low risk: study appears free of other sources of bias, e.g. treatment and control groups were treated equally in terms of other therapies and co-interventions received, frequency of follow up, and general quality of care; the magnitude of any difference in baseline characteristics of the treatment and control groups was not significant in terms of known determinants of outcome.</LI>
<LI>HIgh risk: study had a potential source of bias related to study design used or has been claimed to be fraudulent; study had significant differences between the treatment and control groups in terms of baseline characteristics that are known predictors of outcome; overt differences in the general quality of care received by the groups, such as differential administration of co-interventions.</LI>
<LI>Unclear risk: insufficient information to assess whether an important risk of bias exists, or insufficient evidence or rationale that an identified problem will introduce bias.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-02 11:49:04 +0100" MODIFIED_BY="[Empty name]">
<P>For statistical analysis of dichotomous outcomes, relative risk (RR) and risk difference (RD) with 95% confidence interval (CI) were calculated using the fixed-effect model. For continuous outcomes, the mean difference (MD) with 95% CI was calculated.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-03-29 12:38:51 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted authors of studies with unclear or missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-11-27 08:02:25 +0000" MODIFIED_BY="[Empty name]">
<P>To test for statistical heterogeneity across studies we used the Chi<SUP>2</SUP> statistic. A value of P &lt; 0.10 was used to reject the null hypothesis of homogeneity between studies. To quantify the degree of inconsistency, we used the I<SUP>2</SUP> statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-03-30 22:35:20 +0000" MODIFIED_BY="[Empty name]">
<P>We constructed a funnel plot to assess for evidence of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-02 11:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>We synthesised and analysed the data using Review Manager 5.2 (<LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>). We combined dichotomous data using the Mantel-Haenszel method, and we analysed continuous data using the inverse variance approach. Depending on the degree of heterogeneity of the data, we used either a fixed-effect model or a random-effects model (Der Simonian and Laird model).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-03 01:35:57 +0100" MODIFIED_BY="[Empty name]">
<P>Recognizing that polyclonal and monoclonal IVIG preparations differ structurally and that they act through different immunopathologic mechanisms, a priori subgroup analyses were planned to compare the following explanatory variables: polyclonal IVIG versus placebo or no intervention; monoclonal IVIG versus placebo or no intervention; severity of sepsis; and duration of sepsis. We performed additional subgroup analyses post hoc according to the type of polyclonal IVIG and age group (standard IVIG and immunoglobulin M (IgM)-enriched for adults and neonates) and types of monoclonal antibodies (anti-endotoxins and anti-cytokines). A subgroup analysis of adult and neonatal polyclonal IVIG trials was performed because of the recognized inherent physiologic, pathophysiologic and prognostic differences between adults and neonates with sepsis. No subgroup analysis was done for the monoclonal antibody studies according to study participant (adult or neonate) because all the trials were performed on adults except for one study done with children. To explore the effects of patients' characteristics on IVIG effects, post hoc subgroup analysis of polyclonal trials on adults with surgical and non-surgical conditions was done.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-03-24 10:48:23 +0000" MODIFIED_BY="[Empty name]">
<P>We also conducted sensitivity analyses of the polyclonal and monoclonal studies by removing the trials with high risk of bias and by doing random-effects meta-analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-09-13 06:19:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-09-03 01:07:08 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-04-07 07:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>We retrieved 88 potentially eligible studies, 43 of which fulfilled the inclusion criteria. Of the 25 studies on polyclonal IVIG, 17 were on adults (10 standard IVIG, 7 IgM-enriched) and eight were on neonates (5 standard IVIG, 3 IgM-enriched). There were 18 studies on monoclonal preparations, eight on anti-endotoxins, nine on anti-cytokines, and one study on a human monoclonal antibody to Enterobacteriaceae common antigen. The search flow diagram shows the results of the search from 2003 to 2012 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-03 01:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the included studies are provided in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Forty-three published studies met the inclusion criteria.</P>
<SUBSECTION>
<HEADING LEVEL="5">Participants</HEADING>
<P>The clinical trials were performed mainly in intensive care units and academic medical centres, in 23 countries. The polyclonal IVIG trials were conducted in Argentina, Australia, Belgium, Denmark, Finland, Germany, Greece, Ireland, Japan, India, Ireland, Italy, Mexico, Netherlands, New Zealand, Norway, Saudi Arabia, Serbia, Sweden, Spain, Taiwan, Turkey, United Kingdom, and the United States of America. The monoclonal trials were mostly multi-centre studies conducted in Austria, Belgium, Canada, England, France, Germany, Greece, Israel, Italy, the Netherlands, Norway, South Africa, Spain, Sweden, Switzerland, and the United States of America.</P>
<P>There were eight polyclonal IVIG trials on neonatal sepsis (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>); one anti-endotoxin trial on children with meningococcal septic shock (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>); five polyclonal IVIG trials on adults with post-operative sepsis (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>); one polyclonal IVIG trial on adults with streptococcal toxic shock syndrome (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>); two polyclonal IVIG trials on neutropenic patients with haematologic malignancies and sepsis syndrome or septic shock (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>); and one anti-endotoxin study on obstetric and gynaecologic patients with septic shock (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>). The rest of the trials involved adults with sepsis or septic shock, either of gram-positive or gram-negative etiology.</P>
<P>The polyclonal IVIG trials on neonatal sepsis included pre-term infants (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>); full-term and pre-term infants (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>); and full-term neonates (<LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>). Most of the polyclonal IVIG trials on adults included participants who were aged 18 years and above, except for some trials which had participants &lt; 18 years old (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>). The monoclonal studies included adults 18 years and above except for one anti-endotoxin (HA-1A) trial, which included children aged from three months up to 18 years (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions</HEADING>
<P>The IVIG preparations used were monoclonal (18 studies) or polyclonal immunoglobulins (25 studies).</P>
<P>The monoclonal preparations were:</P>
<OL>
<LI>anti-endotoxins such as E5 (<LINK REF="STD-Angus-2000" TYPE="STUDY">Angus 2000</LINK>; <LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>; <LINK REF="STD-Greenman-1991" TYPE="STUDY">Greenman 1991</LINK>), anti-lipopolysaccharide (anti-LPS) (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>), and HA-1A (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>; <LINK REF="STD-McCloskey-1994" TYPE="STUDY">McCloskey 1994</LINK>; <LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK>);</LI>
<LI>anti-cytokines such as interleukin-1 (IL-1) (<LINK REF="STD-Fisher-1994a" TYPE="STUDY">Fisher 1994a</LINK>; <LINK REF="STD-Fisher-1994b" TYPE="STUDY">Fisher 1994b</LINK>; <LINK REF="STD-Opal-1997" TYPE="STUDY">Opal 1997</LINK>) and anti-tumour necrosis factor (TNF) alpha (<LINK REF="STD-Abraham-1995" TYPE="STUDY">Abraham 1995</LINK>; <LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>; <LINK REF="STD-Cohen-1996" TYPE="STUDY">Cohen 1996</LINK>; <LINK REF="STD-Dhainaut-1995" TYPE="STUDY">Dhainaut 1995</LINK>; <LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>; <LINK REF="STD-Reinhart-1996" TYPE="STUDY">Reinhart 1996</LINK>); and</LI>
<LI>human monoclonal antibody to Enterobacteriaceae common antigen (<LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>).</LI>
</OL>
<P>Polyclonal IVIG preparations were standard IVIG in 10 trials on adults (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-De-Simone-1988" TYPE="STUDY">De Simone 1988</LINK>; <LINK REF="STD-Dominioni-1991" TYPE="STUDY">Dominioni 1991</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>) and five trials on neonates (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>), and IgM-enriched immunoglobulin in seven trials on adults (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>) and three trials on neonates (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>).</P>
<P>For neonates, the dose of standard polyclonal IVIG ranged from 500 mg/kg as a single infusion over two hours (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) to 500 mg/kg infused over four to six hours then repeated 48 hours later (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) and up to 1 g/kg for three days (<LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>); while IgM-enriched IVIG was given at 5 ml/kg/day for three days (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>).</P>
<P>For adults, the dose of polyclonal IVIG varied depending on the type of IVIG, from 250 mg/kg over two days (Intraglobin) to 400 mg/kg/day for three days (Sandoglobin), and 1 g/kg on the first day then 500 mg/kg on days two and three (Endobulin). For Ig-M enriched IVIG (Pentaglobin) the dose used was 1300 ml infused within 72 hours (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Outcomes</HEADING>
<P>All polyclonal and monoclonal trials reported on all-cause mortality as a main outcome except for one polyclonal study on neonates (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>), which reported mortality from sepsis only. One polyclonal study on adults did not report mortality but data were obtained through communication with the authors (<LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>).</P>
<P>The polyclonal IVIG trials on neonates did not specify the cut-off and follow-up periods for mortality except for one trial which had weekly follow ups for six weeks after discharge (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>) and another which reported mortality at 56 days (<LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>). The large multi-centre trial (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) reported death or major disability at two years as the primary outcome and death in hospital as a secondary outcome.</P>
<P>Only two polyclonal trials in adults reported long-term mortality, at 60 days (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>) and 180 days ( <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>). The rest of the trials either reported short-term mortality, at 28 days (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) or 30 days (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), or did not specify the cut-off and follow-up periods. One trial in which the primary outcome was an increase in platelet count had a nine-day follow up (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>) while another trial where the main outcome was defervescence and eradication of symptoms had a seven-day follow up only (<LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>).</P>
<P>Monoclonal trials reported short-term all-cause mortality at 28 days except for trials which reported on 14-day (<LINK REF="STD-McCloskey-1994" TYPE="STUDY">McCloskey 1994</LINK>), 21-day (<LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>), and 30-day (<LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Greenman-1991" TYPE="STUDY">Greenman 1991</LINK>) mortality. Only one monoclonal HA-1A trial (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>) reported on long-term mortality, at 56 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sample size</HEADING>
<P>Of the eight polyclonal IVIG studies on neonates, one was a large multi-centre, multi-country trial (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) and seven were small studies, mainly single centre, with a sample size of &lt; 100 (range 31 to 60) participants. The polyclonal IVIG studies on adults were also small, with the exception of three standard IVIG trials (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) and one IgM-enriched immunoglobulin trial (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>) that had a sample size &gt; 100 participants.</P>
<P>Most of the monoclonal trials were relatively large multi-centre studies, except for two anti-endotoxin trials (<LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>; <LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>) and one anti-cytokine trial (<LINK REF="STD-Dhainaut-1995" TYPE="STUDY">Dhainaut 1995</LINK>) that had a sample size of &lt; 100 participants.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-03 01:07:08 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 44 studies for the following reasons:</P>
<OL>
<LI>the primary outcome measure was not mortality, in six studies (<LINK REF="STD-Christensen-1991" TYPE="STUDY">Christensen 1991</LINK>; <LINK REF="STD-De-Groote-1989" TYPE="STUDY">De Groote 1989</LINK>; <LINK REF="STD-Homan-1990" TYPE="STUDY">Homan 1990</LINK>; <LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>; <LINK REF="STD-Kett-1994" TYPE="STUDY">Kett 1994</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>);</LI>
<LI>the study was on an animal model (<LINK REF="STD-Fischer-1983" TYPE="STUDY">Fischer 1983</LINK>);</LI>
<LI>the study design was not an RCT (<LINK REF="STD-Bojic-1998" TYPE="STUDY">Bojic 1998</LINK>; <LINK REF="STD-Fisher-1993" TYPE="STUDY">Fisher 1993</LINK>; <LINK REF="STD-Freeman-1999" TYPE="STUDY">Freeman 1999</LINK>; <LINK REF="STD-Gunes-2006" TYPE="STUDY">Gunes 2006</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>; <LINK REF="STD-Okimoto-1985" TYPE="STUDY">Okimoto 1985</LINK>; <LINK REF="STD-Panko-1976" TYPE="STUDY">Panko 1976</LINK>; <LINK REF="STD-Tomii-1985" TYPE="STUDY">Tomii 1985</LINK>; <LINK REF="STD-Ueda-1985" TYPE="STUDY">Ueda 1985</LINK>; <LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>; <LINK REF="STD-Zeni-1997" TYPE="STUDY">Zeni 1997</LINK>);</LI>
<LI>the studies were either reviews or meta-analyses (<LINK REF="STD-Jenson-1997" TYPE="STUDY">Jenson 1997</LINK>; <LINK REF="STD-Kreymann-2007" TYPE="STUDY">Kreymann 2007</LINK>; <LINK REF="STD-Lacy-1995" TYPE="STUDY">Lacy 1995</LINK>; <LINK REF="STD-Laupland-2007" TYPE="STUDY">Laupland 2007</LINK>; <LINK REF="REF-Ohlsson-2013" TYPE="REFERENCE">Ohlsson 2013</LINK>; <LINK REF="REF-Soares-2012" TYPE="REFERENCE">Soares 2012</LINK>; <LINK REF="STD-Turgeon-2007" TYPE="STUDY">Turgeon 2007</LINK>; <LINK REF="STD-Werdan-1996" TYPE="STUDY">Werdan 1996</LINK>);</LI>
<LI>alternate allocation to treatment and control arms was used (<LINK REF="STD-El-Nawawy-2005" TYPE="STUDY">El Nawawy 2005</LINK>; <LINK REF="STD-Gokalp-1994" TYPE="STUDY">Gokalp 1994</LINK>; <LINK REF="STD-Marenovic-1998" TYPE="STUDY">Marenovic 1998</LINK>; <LINK REF="STD-Sidiropolous-1981" TYPE="STUDY">Sidiropolous 1981</LINK>);</LI>
<LI>lVIG was the control drug rather than the experimental drug (<LINK REF="STD-Cairo-1992" TYPE="STUDY">Cairo 1992</LINK>; <LINK REF="STD-Calandra-1988" TYPE="STUDY">Calandra 1988</LINK>; <LINK REF="STD-Haque-1995" TYPE="STUDY">Haque 1995</LINK>; <LINK REF="STD-Pilz-1997" TYPE="STUDY">Pilz 1997</LINK>);</LI>
<LI>the immunoglobulin was administered by the intramuscular route (<LINK REF="STD-Aitchison-1985" TYPE="STUDY">Aitchison 1985</LINK>);</LI>
<LI>the study population described was a subgroup of a larger published study (<LINK REF="STD-Kornelisse-1997" TYPE="STUDY">Kornelisse 1997</LINK>; <LINK REF="STD-Wortel-1992" TYPE="STUDY">Wortel 1992</LINK>);</LI>
<LI>the study participants were patients with specific infections not necessarily sepsis (<LINK REF="STD-Jesdinsky-1987" TYPE="STUDY">Jesdinsky 1987</LINK>);</LI>
<LI>the experimental treatment was a tumour necrosis factor, Fc fusion protein (<LINK REF="STD-Fisher-1996" TYPE="STUDY">Fisher 1996</LINK>; <LINK REF="STD-Pittet-1999" TYPE="STUDY">Pittet 1999</LINK>);</LI>
<LI>the study was an interim analysis (<LINK REF="STD-Dominioni-1991" TYPE="STUDY">Dominioni 1991</LINK>) of a clinical trial which we have included in our review (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>); and</LI>
<LI>duplicate publication (<LINK REF="STD-Schedel-1996" TYPE="STUDY">Schedel 1996</LINK>; <LINK REF="STD-Sidiropoulos-1986" TYPE="STUDY">Sidiropoulos 1986</LINK>).</LI>
</OL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-03 01:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of the quality of the individual studies is shown in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and summarized in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Polyclonal IVIG trials</HEADING>
<P>Eight trials were assessed as having low risk of bias. That is, they had adequate allocation concealment and blinding with an intention-to-treat analysis. Three of these trials were on polyclonal IVIG in neonates (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) and five were in adults (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>). Of the five trials on adults, three were on medical patients (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>), one on surgical patients (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), and one on mixed medical-surgical patients (<LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Monoclonal trials</HEADING>
<P>Four studies were assessed to have low risk of bias; that is, they had adequate allocation concealment and blinding, with an intention-to-treat analysis. Three were on the anti-cytokines anti-TNF alpha (<LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>; <LINK REF="STD-Cohen-1996" TYPE="STUDY">Cohen 1996</LINK>) and anti-TNF antibody fragment afelimomab (<LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>); and one was an anti-endotoxin trial, specifically HA-1a (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>).</P>
</SUBSECTION>
<ALLOCATION MODIFIED="2013-09-03 01:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 17 polyclonal IVIG trials on adults, nine had adequate allocation concealment (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>); two trials had inadequate allocation concealment (<LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>); and six had unclear allocation concealment (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-De-Simone-1988" TYPE="STUDY">De Simone 1988</LINK>; <LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>).</P>
<P>Of the eight polyclonal IVIG trials on neonates, four had adequate allocation concealment (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>); one trial had a high risk for bias due to inadequate allocation concealment (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>); and three had unclear allocation concealment (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>).</P>
<P>Seven monoclonal trials had unclear allocation concealment (<LINK REF="STD-Abraham-1995" TYPE="STUDY">Abraham 1995</LINK>; <LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>; <LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Dhainaut-1995" TYPE="STUDY">Dhainaut 1995</LINK>; <LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>; <LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>; <LINK REF="STD-Reinhart-1996" TYPE="STUDY">Reinhart 1996</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-02 12:02:17 +0100" MODIFIED_BY="[Empty name]">
<P>Nine polyclonal IVIG trials on adults (<LINK REF="STD-De-Simone-1988" TYPE="STUDY">De Simone 1988</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>) and three trials on neonates (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>) did not have a placebo in the control group, which precluded blinding.</P>
<P>Two monoclonal trials lacked blinding manoeuvres (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>; <LINK REF="STD-Reinhart-1996" TYPE="STUDY">Reinhart 1996</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-02 12:03:02 +0100" MODIFIED_BY="[Empty name]">
<P>Intention-to-treat analysis was not done in six polyclonal IVIG trials on adults (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>) and one trial on neonates (<LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>).</P>
<P>Intention-to-treat analysis was not performed in seven monoclonal trials (<LINK REF="STD-Abraham-1995" TYPE="STUDY">Abraham 1995</LINK>; <LINK REF="STD-Angus-2000" TYPE="STUDY">Angus 2000</LINK>; <LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Fisher-1994b" TYPE="STUDY">Fisher 1994b</LINK>; <LINK REF="STD-Greenman-1991" TYPE="STUDY">Greenman 1991</LINK>; <LINK REF="STD-Opal-1997" TYPE="STUDY">Opal 1997</LINK>; <LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-03 01:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>Only seven (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) of the 17 polyclonal IVIG trials in adults and four (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) of eight trials in neonates included adverse events in their reports.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-09-03 01:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two polyclonal IVIG trials in adults (<LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>) and one in neonates (<LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>) had significant differences in the baseline characteristics of the treatment and control groups, which could have influenced the outcome.</P>
<P>Three monoclonal studies were assessed as having a high risk of bias in terms of significant differences in the baseline characteristics of the treatment and control groups that could have influenced the outcome: monoclonal antibody to Enterobacteriaceae (<LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>); anti-TNF alpha (<LINK REF="STD-Dhainaut-1995" TYPE="STUDY">Dhainaut 1995</LINK>); and anti-LPS (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-09-13 06:19:33 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality across all IVIG preparations</HEADING>
<P>Forty-three trials fulfilled the inclusion criteria. A pooled analysis of all the IVIG preparations was not done because of clinical heterogeneity.</P>
<P>The outcomes were analysed according to the type of IVIG preparation because of the structural differences and the varying mechanisms of action of polyclonal and monoclonal IVIGs, as planned in the protocol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality by type of immunoglobulin and age group</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Polyclonal IVIG in adults</HEADING>
<P>Subgroup analysis of 17 polyclonal IVIG trials in adults with sepsis (n = 1958) demonstrated that polyclonal IVIG significantly reduced short-term mortality (RR 0.77; 95% CI 0.68 to 0.87) but with some degree of heterogeneity across the trials (P = 0.07, I<SUP>2 </SUP>= 36%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Further subgroup analysis according to type of polyclonal IVIG likewise showed significant reductions in mortality for those participants given standard polyclonal IVIG (RR 0.81; 95% CI 0.70 to 0.93; 10 trials, n = 1430) or IgM-enriched polyclonal IVIG (RR 0.66; 95% CI 0.51 to 0.85; 7 trials, n = 528). The trials of standard polyclonal IVIG had some degree of heterogeneity (P = 0.04, I<SUP>2 </SUP>= 48%) while the trials of IgM-enriched polyclonal IVIG were not heterogenous (P = 0.47, I<SUP>2 </SUP>= 0%). However, sensitivity analysis using the five trials with low risk of bias, three using standard polyclonal IVIG in adults (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) and two of IgM-enriched IVIG in adults (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005)</LINK>, did not show a significant reduction in mortality (RR 0.97; 95% CI 0.81 to 1.15; n = 945) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The test for heterogeneity was not significant (P = 0.34, I<SUP>2 </SUP>= 12%).</P>
<P>The trials that reported long-term mortality, at 60 days (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>) and 180 days (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>), likewise showed no significant reduction in mortality (29.6% versus 34.7%, P = 0.50; 2/10 versus 4/36, respectively).</P>
<P>Meta-analysis using a random-effects model showed significant reduction in mortality (RR 0.70; 95% CI 0.58 to 0.84) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) but this reduction was not seen when only trials with low risk of bias were analysed (RR 0.94; 95% CI 0.74 to 1.18) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Polyclonal IVIG in neonates</HEADING>
<P>Post hoc subanalysis of eight polyclonal IVIG trials in neonates with sepsis showed that polyclonal IVIG did not reduce mortality (RR 0.98; 95% CI 0.91 to 1.07); there was no significant heterogeneity (P = 0.71, I<SUP>2 </SUP>= 0%). Likewise, no significant reduction in mortality was observed with standard polyclonal IVIG (RR 1.00; 95% CI 0.92 to 1.08; n = 3667) or IgM-enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; n = 164) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Sensitivity analysis of three trials on standard IVIG with low risk of bias (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) also showed no significant reduction in mortality (RR 1.01; 95% CI 0.93 to 1.09; n = 3561) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Tests for heterogeneity were not significant for both the subgroup and sensitivity analyses.</P>
<P>Random-effects model meta-analysis likewise showed no significant reduction in mortality both for all eight trials on neonatal sepsis (RR 0.99; 95% CI 0.91 to 1.07) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and when only the trials with low risk of bias were analysed (RR 0.81; 95% CI 0.46 to 1.42) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Monoclonal immunoglobulins - anti-endotoxins</HEADING>
<P>The eight trials of anti-endotoxins (four E5 trials, three HA-1A trials, one anti-LPS trial) were heterogeneous (P = 0.02, I<SUP>2 </SUP>= 57%), precluding an overall estimate of effect (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The apparent source of heterogeneity was the HA-1A trial (<LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK>). This trial only analysed patients with confirmed gram-negative bacteraemia and showed a reduction in mortality while the rest of the trials did not show a survival benefit. A sensitivity analysis of one study with low risk of bias (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>) and five studies with uncertain risk of bias (<LINK REF="STD-Angus-2000" TYPE="STUDY">Angus 2000</LINK>; <LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>; <LINK REF="STD-Greenman-1991" TYPE="STUDY">Greenman 1991</LINK>; <LINK REF="STD-McCloskey-1994" TYPE="STUDY">McCloskey 1994</LINK>) revealed no significant survival benefit (RR 1.01; 95% CI 0.94 to 1.09; n = 4443) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Likewise, a subanalysis of the four trials on E5 monoclonal antibody (<LINK REF="STD-Angus-2000" TYPE="STUDY">Angus 2000</LINK>; <LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>; <LINK REF="STD-Greenberg-1992" TYPE="STUDY">Greenberg 1992</LINK>; <LINK REF="STD-Greenman-1991" TYPE="STUDY">Greenman 1991</LINK>) showed no reduction in mortality (RR 0.98; 95% CI 0.88 to 1.10; n = 1975) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Tests for heterogeneity were not significant for both the sensitivity (P = 0.26, I<SUP>2 </SUP>= 23%) and subgroup (P = 0.64, I<SUP>2 </SUP>= 0%) analyses. The three trials of HA-1A antibody (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>; <LINK REF="STD-McCloskey-1994" TYPE="STUDY">McCloskey 1994</LINK>; <LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK>) were significantly heterogeneous (P = 0.005, I<SUP>2 </SUP>= 81%), which could be due to differences in study population and methodologic quality. The trial of <LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK> involved children with a presumptive diagnosis of meningococcal septic shock; <LINK REF="STD-McCloskey-1994" TYPE="STUDY">McCloskey 1994</LINK> included patients with gram-negative bacteraemia and septic shock; while <LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK> selectively analysed patients with confirmed gram-negative bacteraemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Monoclonal immunoglobulins - anti-cytokines</HEADING>
<P>Pooled analysis of the nine trials on anti-cytokines (six anti-TNF alpha trials, three recombinant human IL-1 receptor antagonist (rh IL-1ra) trials) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) revealed a small but significant reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97; n = 7893) with no significant heterogeneity (P = 0.76, I<SUP>2 </SUP>= 0%). Sensitivity analysis of three trials with low risk of bias (<LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>; <LINK REF="STD-Cohen-1996" TYPE="STUDY">Cohen 1996</LINK>; <LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>) and four studies with uncertain risk of bias (<LINK REF="STD-Abraham-1995" TYPE="STUDY">Abraham 1995</LINK>; <LINK REF="STD-Fisher-1994a" TYPE="STUDY">Fisher 1994a</LINK>; <LINK REF="STD-Fisher-1994b" TYPE="STUDY">Fisher 1994b</LINK>; <LINK REF="STD-Opal-1997" TYPE="STUDY">Opal 1997</LINK>) showed a marginal reduction in mortality (RR 0.91; 95% CI 0.86 to 0.97; n = 7648) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). Likewise, sensitivity analysis of the three studies with low risk of bias (<LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>; <LINK REF="STD-Cohen-1996" TYPE="STUDY">Cohen 1996</LINK>; <LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>) showed a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.99; n = 5065). Tests of heterogeneity were not significant for both sensitivity analyses. It is important to note that the marginal benefit was contributed mainly by one large study (n = 2634) on anti-TNF antibody F(ab')<SUB>2</SUB> fragment afelimomab (<LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>), which showed a marginal reduction in the overall mortality and in the subgroup analysis of patients with elevated IL-6 levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Monoclonal antibody for Enterobacteriaceae common antigen</HEADING>
<P>We included one trial on a human monoclonal IgM antibody specific for Enterobacteriaceae common antigen (ECA), which is a specific glycophospholipid surface antigen found in organisms belonging to the Enterobacteriaceae family (<LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>). This trial did not demonstrate reduced mortality in patients with presumed and proven gram-negative sepsis (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality from sepsis</HEADING>
<P>Mortality from sepsis or septic shock was reported in only six trials. A subanalysis of the four adult trials on polyclonal IVIG (<LINK REF="STD-Dominioni-1991" TYPE="STUDY">Dominioni 1991</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>) demonstrated a significant decrease in mortality from septic shock (RR 0.45; 95% CI 0.29 to 0.69) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). The trials were significantly heterogeneous (P = 0.03, I<SUP>2 </SUP>= 66%) probably due to differences in study population (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). The largest trial, with a low risk of bias (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>), was conducted on neutropenic patients with haematologic malignancies and did not show any reduction in mortality from sepsis; the small trials on surgical patients (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>) and adults with gram-negative septic shock (<LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>) showed reductions in mortality. The monoclonal trial of E5 antibody (<LINK REF="STD-Bone-1995" TYPE="STUDY">Bone 1995</LINK>) and the polyclonal IVIG trial on neonates (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>) did not reduce mortality from sepsis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Length of hospital stay among survivors was reported as a secondary outcome measure in 11 polyclonal IVIG trials and one monoclonal IVIG trial (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>). A subanalysis of the six polyclonal trials in adults (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Grundmann-1988" TYPE="STUDY">Grundmann 1988</LINK>; <LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>) showed no significant reduction in the length of hospital stay in the IVIG group (MD -3.00; 95% CI -6.37 to 0.38) and there was no significant heterogeneity (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; subgroup1). These six trials were assessed as having uncertain risk of bias.</P>
<P>Subanalysis of five polyclonal IVIG trials on neonates demonstrated a significant reduction in mortality in the IVIG group (MD -5.84; 95% CI -9.72 to -1.95) but there was moderate heterogeneity (P = 0.11, I<SUP>2 </SUP>= 55%). Sensitivity analysis of trials with low risk of bias (<LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) and uncertain risk of bias (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>) did not demonstrate any reduction in the duration of hospital stay (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). The large multi-centre trial on polyclonal IVIG (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) likewise did not show any significant difference in the duration of hospital stay, with a median duration of 64 days (interquartile range 37 to 92 days) in the IVIG group and 64 days (interquartile range 37 to 93 days) in the placebo group.</P>
<P>The bacteriological failure rate was reported in only one polyclonal IVIG trial involving adult medical and surgical patients (<LINK REF="STD-De-Simone-1988" TYPE="STUDY">De Simone 1988</LINK>). It showed a significantly higher bacteriological eradication rate in the IVIG group compared to the control group (40% versus 8%, P &lt; 0.01).</P>
<P>Severity and duration of sepsis were not uniformly defined or stated in the various trials hence no subgroup analyses could be done for these outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Only seven polyclonal IVIG trials in adults and four trials in neonates included adverse events in their reports. Of the four trials on neonates, two reported no adverse events attributable to IVIG (<LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Shenoi-1999" TYPE="STUDY">Shenoi 1999</LINK>) and one trial (<LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>) reported two suspected infusion-related adverse reactions, specifically hypotension and hypoglycaemia. In the large polyclonal IVIG trial on neonates (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>), no significant differences in adverse events were found.</P>
<P>In adults, adverse events reported as likely to be related to polyclonal IVIG were allergic reactions (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>); skin reactions such as erythema and exanthem (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>); pruritus (<LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>); nausea and vomiting (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>); dyspnoea (<LINK REF="STD-Masaoka-2000" TYPE="STUDY">Masaoka 2000</LINK>); congestion (<LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>); shock (<LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>); and fever and chills (<LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>). Two trials reported no adverse events attributable to IVIG (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>) and one trial reported adverse events but none that were assessed as related to IVIG (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-13 09:51:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-03 01:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>The use of novel immunotherapeutic agents to combat the intense endotoxin and inflammatory mediator excesses in sepsis has been of major interest in the past decade. This updated meta-analysis conclusively showed that standard polyclonal IVIGs did not decrease mortality among neonates with sepsis, with the inclusion of the large multi-centre high quality trial on polyclonal standard IVIG (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Likewise, among adults with sepsis no reduction in mortality was observed with standard polyclonal IVIG in high quality trials (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). However, for IgM-enriched polyclonal IVIGs, the evidence of benefit remains insufficient and inconclusive for both adults and neonates with sepsis because of the paucity of large, high quality trials (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>None of the monoclonal IVIG preparations to date show clinically significant benefit for patients with sepsis. The pooled as well as subgroup analyses of randomized controlled trials of these experimental agents do not demonstrate a significant reduction in mortality among patients with severe sepsis or septic shock. Furthermore, the large trials on E5 (<LINK REF="STD-Angus-2000" TYPE="STUDY">Angus 2000</LINK>) and anti-TNF alpha (<LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>) failed to demonstrate any significant benefit in the overall mortality analysis and the post hoc subgroup analysis based on presence of shock, co-morbidity, organ failure, site of infection, and type of organism. A trial on human monoclonal IgM antibody that is specific against Enterobacteriaceae likewise did not decrease mortality (<LINK REF="STD-Albertson-2003" TYPE="STUDY">Albertson 2003</LINK>). One large trial on the anti-TNF antibody F(ab')<SUB>2</SUB> fragment afelimomab (<LINK REF="STD-Panacek-2004" TYPE="STUDY">Panacek 2004</LINK>) showed only marginal benefit both in the overall mortality analysis and for the patients with elevated IL-6 levels. See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-09-13 09:51:12 +0100" MODIFIED_BY="[Empty name]">
<P>We have updated our search from 2003 to 2012 and have included all possible trials on polyclonal and monoclonal preparations for adults and neonates with sepsis.</P>
<P>Investigators have postulated that polyclonal IVIG contains immunoglobulin G (IgG) and even IgM (in some preparations), which could boost the immune response of septic patients. Some authors have stressed the potential benefits for immunocompromised patients, such as neonates, who have immunoglobulin and complement deficiencies; and intensive care unit patients, who develop relative immunodepression as a consequence of severe underlying illnesses, surgery, or chemotherapy (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-De-Simone-1988" TYPE="STUDY">De Simone 1988</LINK>; <LINK REF="STD-Dominioni-1991" TYPE="STUDY">Dominioni 1991</LINK>; <LINK REF="STD-Kornelisse-1997" TYPE="STUDY">Kornelisse 1997</LINK>; <LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>). In addition, premature infants are significantly compromised because IgG from the mother is transferred to the infant only after the 32nd week of gestation (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>). Thus, it has been postulated that the administration of immunoglobulin improves the opsonization and phagocytic functions of the neonates' antibodies (<LINK REF="STD-Weisman-1992" TYPE="STUDY">Weisman 1992</LINK>).</P>
<P>Antibacterial activity is reported to be much higher with IgM-enriched preparations compared to the standard IVIG (<LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>; <LINK REF="STD-Wesoly-1990" TYPE="STUDY">Wesoly 1990</LINK>). The proposed mechanism of action is neutralization of endotoxin in the patient's circulation thus preventing the harmful consequences induced by the lipid-A component of the endotoxin molecule (<LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>).</P>
<P>Another subgroup of septic patients for whom IVIG is proposed to be of likely benefit is those with severe invasive Group A streptococcal infections of varying serotypes. The postulated mechanisms of action include enhancement of bacterial opsonization, complement activation, antigen neutralization, and cytokine modulation resulting in suppression of pro-inflammatory responses (<LINK REF="REF-Norrby_x002d_Teglund-2003" TYPE="REFERENCE">Norrby-Teglund 2003</LINK>).</P>
<P>It should be noted that there is considerable heterogeneity in the nature and mode of action of the monoclonal antibodies; for example HA-1A and E5 are postulated to act specifically against the lipid-A moiety of the endotoxin, and anti-LPS against the lipopolysaccharide (LPS) molecule of gram-negative bacteria. Likewise, the anti-cytokines act on various inflammatory mediators such as TNF alpha and IL-1 (<LINK REF="REF-Dahlberg-1997" TYPE="REFERENCE">Dahlberg 1997</LINK>).</P>
<P>In spite of the differing modes of action and varying potential benefits for different groups of patients, we included the different immunotherapeutic agents in our meta-analyses and performed subgroup analyses. In the actual emergent situation of sepsis and septic shock the clinician opts for these agents without the benefit of laboratory results that might be predictive of a good outcome (for example gram-positive versus gram-negative bacterial aetiology, and levels of specific antibodies or cytokines). More importantly, there is still no validated bedside marker that could aid the physician in identifying specific subgroups of patients that could respond to these immunoadjuvants.</P>
<P>It has been argued by sepsis trialists that perhaps the optimum therapy would be a combination of various immunotherapeutic agents that target different points of the sepsis cascade (<LINK REF="REF-Abraham-1994" TYPE="REFERENCE">Abraham 1994</LINK>; <LINK REF="REF-Bone-1991" TYPE="REFERENCE">Bone 1991</LINK>; <LINK REF="REF-Nydegger-1997" TYPE="REFERENCE">Nydegger 1997</LINK>; <LINK REF="REF-Werdan-2001" TYPE="REFERENCE">Werdan 2001</LINK>). However, to date there are no randomized controlled trials on such combinations. At this point, adjuvant therapy with monoclonal IVIGs for the treatment of sepsis remains largely experimental, with no robust demonstrable evidence of benefit.</P>
<P>Evidence-based guidelines on sepsis recommend early goal-directed therapy that involves goal-oriented manipulation of cardiac preload, afterload, and contractility to achieve a balance between systemic oxygen delivery and demand (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>). This is in addition to controlling the source of infection and providing prompt, rational antibiotic use. A randomized controlled trial has shown that early goal-directed resuscitation in the emergency room, for patients presenting with septic shock, significantly improved survival (<LINK REF="REF-Rivers-2001" TYPE="REFERENCE">Rivers 2001</LINK>).</P>
<P>Other investigators have suggested further improvements in the design of clinical trials on sepsis, for example refining the clinical definition of sepsis, lengthening the duration of observation, and defining other endpoints of benefit (<LINK REF="REF-Sibbald-1995" TYPE="REFERENCE">Sibbald 1995</LINK>). Only a few of the trials included in this review reported long-term mortality, using variable cut-offs ranging from 56 to 180 days. These trials also did not show significant reductions in mortality. A recent systematic review (<LINK REF="REF-Annane-2009" TYPE="REFERENCE">Annane 2009</LINK>) suggested six key points for the design and conduct of future sepsis trials, to minimize the sources of heterogeneity.</P>
<OL>
<LI>Avoid mixing patients with severe sepsis and with septic shock.</LI>
<LI>Restrict the time window to less than 24 hrs from onset of the first organ dysfunction or shock.</LI>
<LI>Include only definite sepsis.</LI>
<LI>Use the sepsis-related organ failure assessment score for eligibility.</LI>
<LI>Include a first interim analysis after enrolment of 25% of the planned sample size to check the actual baseline risk of death and to recalculate the number of patients needed.</LI>
<LI>Strictly control for concomitant evidence-based interventions as recommended in the 'Surviving Sepsis Campaign' guidelines, such as early goal-directed therapy, source control, and prompt administration of antibiotics (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>).</LI>
</OL>
<P>Potential negative effects from administration of IVIG, such as possible risk of transmission of hepatitis C and prion diseases from poor quality IVIG preparations, have also been pointed out (<LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>; <LINK REF="REF-Nydegger-1999" TYPE="REFERENCE">Nydegger 1999</LINK>). Not all polyclonal studies reported on adverse effects. Of the adverse effects described most were immediate and delayed reactions to the infusion, for example allergic and skin reactions. None of the trials looked at late adverse effects such as transmission of infectious agents.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-09-03 01:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>While this updated meta-analysis provides some evidence of benefit from polyclonal IVIGs in adult patients with sepsis, it should be noted that most of the studies on polyclonal IVIG are small studies, which is in contrast to the 'large', multi-centre studies for monoclonal antibody preparations. Sensitivity analysis of five published trials with low risk of bias (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) did not show a reduction in mortality in adults. Hence caution must be taken in the interpretation of statistically significant results from the pooled analysis of small studies (<LINK REF="REF-Cappelleri-1995" TYPE="REFERENCE">Cappelleri 1995</LINK>; <LINK REF="REF-Villar-1995" TYPE="REFERENCE">Villar 1995</LINK>), particularly those with poor methodologic quality. For instance, some of the small studies were noted to have methodologic flaws. Wortel in a letter to the editor (<LINK REF="REF-Wortel-1993" TYPE="REFERENCE">Wortel 1993</LINK>) noted some methodological deficiencies, such as multiple interim analyses, in one of the studies showing a significant reduction in mortality (<LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>).</P>
<P>For the meta-analysis of polyclonal IVIG trials on adults, there was evidence of significant funnel plot asymmetry (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) when using Egger's statistic (bias -1.3, P = 0.01) but not when using the Begg-Mazumdar statistic (Kendall's tau -0.07, P = 0.66). While publication bias may partly explain the asymmetry, it is likely that the poor methodologic quality of the small studies is also contributing to the asymmetry. As stated above, the sensitivity analysis of studies with low risk of bias showed no reduction in mortality for both adults and neonates. Thus small study effects and poor methodologic quality are likely to contribute to the lack of robustness of the observed reduction in mortality seen in the pooled analysis of all the studies. It is also of note that, except for one trial (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>), the high quality polyclonal IVIG trials in adults (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) were all published after the year 2000, after the first version of our review (<LINK REF="REF-Alejandria-2000" TYPE="REFERENCE">Alejandria 2000</LINK>). This updated review confirms the lack of robust strong evidence on the effectiveness of IVIG in reducing mortality among patients with sepsis.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2013-09-03 01:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>The addition of the large trial on standard polyclonal IVIG (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>) to our meta-analysis of polyclonal IVIG for neonatal sepsis conclusively showed no benefit in reducing mortality, in contrast to a previous meta-analysis (<LINK REF="STD-Jenson-1997" TYPE="STUDY">Jenson 1997</LINK>). A comparison of the studies that were included in our meta-analysis and those in Jenson et al showed that the latter review did not include thee trials that had no significant reduction in mortality among neonates (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>; <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Erdem-1993" TYPE="STUDY">Erdem 1993</LINK>); in addition, we excluded a study by Sidiropolous (<LINK REF="STD-Sidiropolous-1981" TYPE="STUDY">Sidiropolous 1981</LINK>) which used alternate allocation of the interventions. Our meta-analysis is in agreement with another Cochrane review (<LINK REF="REF-Ohlsson-2013" TYPE="REFERENCE">Ohlsson 2013</LINK>), which focused on polyclonal IVIG for suspected or subsequently proven infection in neonates and analysed a similar set of studies. Ohlsson et al concluded that the evidence is insufficient to support the routine administration of IVIG to prevent mortality in infants with suspected or proven neonatal infection. Another meta-analysis (<LINK REF="STD-Kreymann-2007" TYPE="STUDY">Kreymann 2007</LINK>), which included more trials, showed significant reductions in mortality for both standard (RR 0.63; 95% CI 0.42 to 0.96; 7 trials, n = 358) and IgM-enriched polyclonal IVIG trials (RR 0.50; 95% CI 0.34 to 0.73; 5 trials, n = 352). However, the additional trials in this meta-analysis were also of small sample size and either used alternate allocation (<LINK REF="STD-El-Nawawy-2005" TYPE="STUDY">El Nawawy 2005</LINK>; <LINK REF="STD-Gokalp-1994" TYPE="STUDY">Gokalp 1994</LINK>; <LINK REF="STD-Sidiropolous-1981" TYPE="STUDY">Sidiropolous 1981</LINK>) or had unclear allocation concealment (<LINK REF="STD-Gunes-2006" TYPE="STUDY">Gunes 2006</LINK>), which could have led to an overestimate of the treatment effects. The completion of the large polyclonal IVIG trial on neonates has provided definitive high quality evidence that standard polyclonal IVIG does not effectively reduce mortality among neonates with sepsis (<LINK REF="STD-Brocklehurst-2011" TYPE="STUDY">Brocklehurst 2011</LINK>). One small study from Turkey on polyclonal IVIG in 60 neonates with blood culture confirmed sepsis that is awaiting quality assessment is unlikely to change the conclusions (<LINK REF="STD-Yildizdas-2005" TYPE="STUDY">Yildizdas 2005</LINK>).</P>
<P>In contrast to the meta-analysis on neonatal sepsis, the meta-analysis on adult patients showed a significant reduction in mortality with the use of polyclonal IVIG. The results of our meta-analysis of 17 trials is consistent with the results of three meta-analyses on polyclonal IVIG for adults with sepsis (<LINK REF="STD-Kreymann-2007" TYPE="STUDY">Kreymann 2007</LINK>; <LINK REF="STD-Laupland-2007" TYPE="STUDY">Laupland 2007</LINK>; <LINK REF="STD-Turgeon-2007" TYPE="STUDY">Turgeon 2007</LINK>), which all showed a survival benefit among patients who received polyclonal IVIG despite the variations in the number of trials included. Additionally, our subgroup analysis by type of polyclonal IVIG is in agreement with the subanalysis by Kreymann (<LINK REF="STD-Kreymann-2007" TYPE="STUDY">Kreymann 2007</LINK>), which also showed reductions in mortality for both standard IVIG and IgM-enriched polyclonal immunoglobulin. On the other hand, the meta-analysis of Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>) showed no reduction in mortality in a sensitivity analysis of two high quality trials in adults (<LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>); one in neonates (<LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>); and another trial that was an unpublished study (<LINK REF="REF-Werdan-1997" TYPE="REFERENCE">Werdan 1997</LINK> abstract). While we included the same trials, we also subanalysed the trials into adults and neonates. Our sensitivity analysis of high quality trials in adults, which includes a large study on polyclonal IVIG that was published 10 years after its completion (<LINK REF="STD-Werdan-2007" TYPE="STUDY">Werdan 2007</LINK>) plus two studies published after 2004 (<LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>), also showed no reduction in mortality. The sensitivity analysis according to methodologic quality likewise demonstrated a lack of robustness of the survival benefit that was initially seen when all the trials were pooled.</P>
<P>Another meta-analysis included in a recent health technology assessment report (<LINK REF="REF-Soares-2012" TYPE="REFERENCE">Soares 2012</LINK>), which simultaneously analysed the type of IVIG, dosing regimen and quality indicators, reached similar conclusions as our review despite some variations in the assessment and interpretation of quality and in the studies included and excluded. The modelling process identified trial quality, publication bias, small study effects and dosing regimen as factors contributing to the heterogeneity of the treatment effects of IVIG. Value of information analysis and a cost-effectiveness decision model identified uncertainties in the mechanism of action of IVIG, dose and duration of IVIG therapy, and the heterogenous nature of severe sepsis as important issues that need to be addressed in future reviews and basic research. This information is needed to inform the design of a definitive RCT and re-evaluate its impact on the expected value of the information before investing resources on such potentially costly research.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-13 06:20:57 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-03 01:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Intravenously administered polyclonal immunoglobulins, particularly standard polyclonal IVIG, do not provide benefit as adjuvant therapy in sepsis in terms of reducing mortality among neonates and adults with sepsis. Likewise, intravenous monoclonal immunoglobulins do not show clinically significant survival benefits. There is no good evidence that a combination of immunotherapeutic agents that target different mediators in the sepsis cascade is effective.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-13 06:20:57 +0100" MODIFIED_BY="[Empty name]">
<P>Large, multi-centre studies are needed to confirm the effectiveness of IgM-enriched polyclonal immunoglobulins in reducing mortality in adults. The current evidence for benefit is inconsistent and inconclusive. Among adults, septic patients other than surgical patients could be included in future trials. Further studies are also needed on the subgroup of patients with necrotizing fasciitis and streptococcal toxic shock syndrome (STSS) to provide evidence on clinical efficacy of IVIG in STSS. This is especially important because the European RCT on STSS was prematurely terminated (<LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>), and yet IVIG continues to be recommended as a promising adjuvant in STSS and necrotizing fasciitis. In addition, future trials should include the sepsis bundle of evidence-based interventions as the standard of care, for example early goal-directed therapy for severe sepsis and septic shock and antibiotic administration within one hour (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>), to determine whether the addition of IVIG to the sepsis bundle of care would contribute to a further reduction in mortality.</P>
<P>In summary, the design of future trials might be improved by the following:</P>
<OL>
<LI>refining the clinical definition of sepsis and including only patients with definite sepsis, using standardized scoring systems, e.g. Sequential Organ Failure Assessment;</LI>
<LI>stratifying patients to address intrinsic differences in the patient population and the severity of sepsis;</LI>
<LI>adding endpoints besides the measurement of all-cause mortality, such as the resolution or reversal of organ failure;</LI>
<LI>lengthening the duration of observation and follow up;</LI>
<LI>systematic reporting of adverse events; and</LI>
<LI>instituting the sepsis bundle of care as the standard intervention in the control group.</LI>
</OL>
<P>A recent health technology assessment report, however, argues that basic research on the mechanism of action of IVIG in severe sepsis should be reviewed and be done to appropriately guide the design of a future multi-centre RCT rather than immediately embarking on a large RCT on the clinical effectiveness of IVIG (<LINK REF="REF-Soares-2012" TYPE="REFERENCE">Soares 2012</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-03 02:03:52 +0100" MODIFIED_BY="Jane Cracknell">
<P>We would like to thank Dr Nicola Petrucci (content editor) and Professor Nathan Pace (statistical editor) for their help and advice in updating the review.</P>
<P>We thank Dr Robert Booy and Dr Simon Nadel for their helpful comments; Dr Antje Timmer of Canada, Dr Dimitrinka Nikolava, and Rene Spallek for facilitating with translations. We also express our gratitude to the Department of Clinical Epidemiology of the University of the Philippines, Manila staff Ciela Sarmiento, Lucy Valdez and Pamela Tagle for their logistic and secretarial support. We thank Dr Shenoi for providing us with a copy of their study, Dr Masaoka and Dr El-Nawawy for graciously providing additional data and clarifying the methods of their clinical trials. We also express our gratitude to Dr Pildal for providing us with the full texts of the clinical trials on polyclonal IVIG that were not included in the 2002 version of the review (<LINK REF="REF-Alejandria-2002" TYPE="REFERENCE">Alejandria 2002</LINK>).</P>
<P>The review was transferred to the Cochrane Anaesthesia Group in May 2005.</P>
<P>The original review (<LINK REF="REF-Alejandria-2002" TYPE="REFERENCE">Alejandria 2002</LINK>) was produced with the Cochrane Infectious Diseases Group (CIDG), supported by the Department for International Development (UK) and the European Union (Directorate General XII). However, the funders take no responsibility for the data presented or the views expressed.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-09-03 02:06:20 +0100" MODIFIED_BY="[Empty name]">
<P>Marissa M Alejandria: none known</P>
<P>Mary Ann D Lansang: none known</P>
<P>Leonila F Dans: travel grant from Novartis to attend a meeting of pediatric rheumatologists to discuss the management of systemic onset juvenile idiopathic arthritis in November 2012.</P>
<P>Jacinto Blas Mantaring III: Dr Mantaring is the chair of the National Institutes of Health Ethics review board and a member of the Technical review board, who receives an honorarium for reviewing studies and attending meetings. He is also asked by government agencies, WHO and pharmaceutical companies to give lectures, conduct workshops and prepare educational materials on a variety of topics mostly related to research methods, evidence-based medicine and ethics as well as topics on neonatal care.</P>
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the review (for example through employment, consultancy, stock ownership, honoraria, expert testimony).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-09 15:47:10 +0100" MODIFIED_BY="Jane Cracknell">
<P>Marissa M Alejandria (MAM), Mary Ann D Lansang (MAL), Leonila F Dans (LFD), Jacinto Blas Mantaring III (JBM)</P>
<P>Conceiving the review: MAL</P>
<P>Co-ordinating the review: MAL, MMA</P>
<P>Undertaking manual searches: MMA</P>
<P>Screening search results: MAL, MMA</P>
<P>Organizing retrieval of papers: MMA</P>
<P>Screening retrieved papers against inclusion criteria: MAL, MMA</P>
<P>Appraising quality of papers: LFD, JBM</P>
<P>Abstracting data from papers: LFD, JBM, MMA</P>
<P>Writing to authors of papers for additional information: MMA</P>
<P>Providing additional data about papers: not applicable</P>
<P>Obtaining and screening data on unpublished studies: not applicable </P>
<P>Data management for the review: MMA</P>
<P>Entering data into Review Manager (<LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>): MMA</P>
<P>RevMan statistical data: MMA</P>
<P>Other statistical analysis not using RevMan: not done</P>
<P>Double entry of data: not done</P>
<P>Interpretation of data: MMA, MAL, JBM, LFD</P>
<P>Statistical inferences:</P>
<P>Writing the review: MMA, MAL</P>
<P>Securing funding for the review:</P>
<P>Performing previous work that was the foundation of the present study:</P>
<P>Guarantor for the review (one author): MMA</P>
<P>Person responsible for reading and checking review before submission: MMA, MAL</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-03 02:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>The title has been modified to include the term 'severe sepsis'. We included adverse effects in the list of outcome measures. We did a post hoc subgroup analysis of the included trials for adults and neonates.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-09-03 02:53:02 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-09-03 02:47:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abraham-1995" MODIFIED="2013-07-09 10:16:43 +0100" MODIFIED_BY="[Empty name]" NAME="Abraham 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-09 10:16:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al</AU>
<TI>Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study group</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>934-41</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:39:42 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:39:42 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7884952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-14 05:26:12 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abraham-1998" MODIFIED="2008-11-30 02:38:54 +0000" MODIFIED_BY="[Empty name]" NAME="Abraham 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-30 02:38:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al</AU>
<TI>Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>929-33</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:41:29 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:41:29 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9734938"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albertson-2003" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Albertson 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matsuchak G, et al</AU>
<TI>Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>419-27</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:42:41 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:42:41 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12576946 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angus-2000" MODIFIED="2013-07-09 10:16:43 +0100" MODIFIED_BY="[Empty name]" NAME="Angus 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-09 10:16:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, et al</AU>
<TI>E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>1723-30</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:44:48 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:44:48 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10755499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behre-1995" MODIFIED="2013-09-03 02:39:22 +0100" MODIFIED_BY="[Empty name]" NAME="Behre 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-09-03 02:39:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al</AU>
<TI>Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial</TI>
<SO>Antiinfective Drugs and Chemotherapy</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>129-34</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:48:12 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:48:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00168897"/>
<IDENTIFIER MODIFIED="2008-11-25 13:48:04 +0000" MODIFIED_BY="Jane Cracknell" TYPE="EMBASE" VALUE="1996075665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-1995" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bone 1995" YEAR="1989">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al</AU>
<TI>A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>994-1005</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:50:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:50:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7774238"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brocklehurst-2011" MODIFIED="2013-09-03 02:42:44 +0100" MODIFIED_BY="[Empty name]" NAME="Brocklehurst 2011" YEAR="">
<REFERENCE MODIFIED="2013-09-03 02:42:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The INIS Collaborative Group</AU>
<TI>Treatment of neonatal sepsis with intravenous immune globulin</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<PG>1201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-08 15:27:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The INIS Study Collaborative Group</AU>
<TI>The INIS Study. International Neonatal Immunotherapy Study: Non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo-controlled, multicentre randomised trial</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burns-1991" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Burns 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burns ER, Lee V, Rubinstein A</AU>
<TI>Treatment of septic thrombocytopenia with immune globulin</TI>
<SO>Journal of Clinical Immunology</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>363-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:51:04 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:51:04 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 1761642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1996" MODIFIED="2009-11-28 10:05:33 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 1996" YEAR="1993">
<REFERENCE MODIFIED="2009-11-28 10:05:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen JY</AU>
<TI>Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis</TI>
<SO>Journal of the Formosan Medical Association: Taiwan Yi Zhi</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>839-44</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:53:26 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:53:26 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8990771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1996" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1996" YEAR="1991">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J, Carlet J</AU>
<TI>INTERSEPT: an international, multicenter, placebo-controlled-trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>1431-40</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:55:05 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:55:05 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 8797612 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Darenberg-2003" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Darenberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al; StreptIg Study Group</AU>
<TI>Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind placebo-controlled trial</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>333-40</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:57:17 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:57:17 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12884156 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derkx-1999" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Derkx 1999" YEAR="1991">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derkx B, Wittes J, McCloskey R</AU>
<TI>Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>770-7</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:00:12 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:00:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10825037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Simone-1988" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="De Simone 1988" YEAR="1984">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Simone C, Delogu G, Corbetta G</AU>
<TI>Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients</TI>
<SO>Critical Care Medicine</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>23-6</PG>
<IDENTIFIERS MODIFIED="2008-11-25 13:58:38 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 13:58:38 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3276446"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhainaut-1995" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Dhainaut 1995" YEAR="1992">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, et al</AU>
<TI>CDP 571, a humanized antibody to human tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>1461-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:12:04 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:12:04 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7664546 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominioni-1996" MODIFIED="2008-11-25 14:13:38 +0000" MODIFIED_BY="Jane Cracknell" NAME="Dominioni 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-25 14:13:38 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R</AU>
<TI>High-dose intravenous IgG for treatment of severe surgical infections</TI>
<SO>Digestive Surgery</SO>
<YR>1996</YR>
<VL>13</VL>
<PG>430-4</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:13:38 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:13:38 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00169903"/>
<IDENTIFIER MODIFIED="2008-11-25 14:13:32 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1996308558"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erdem-1993" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Erdem 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Erdem G, Yurdakök M, Tekinalp G, Ersoy F</AU>
<TI>The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants</TI>
<SO>The Turkish Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>35</VL>
<PG>277-81</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:15:19 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:15:19 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 8160279"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1994a" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Fisher 1994a" YEAR="1994">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al; IL-1RA Sepsis Syndrome Study Group</AU>
<TI>Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized open-label, placebo-controlled multicenter trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>12-21</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:16:44 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:16:44 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8124953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1994b" MODIFIED="2008-11-30 04:55:13 +0000" MODIFIED_BY="[Empty name]" NAME="Fisher 1994b" YEAR="1994">
<REFERENCE MODIFIED="2008-11-30 04:55:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al</AU>
<TI>Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<PG>1836-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1992" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Greenberg 1992" YEAR="1986">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ</AU>
<TI>Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram-negative sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>730-5</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:23:08 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:23:08 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1597023"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenman-1991" MODIFIED="2013-08-09 15:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="Greenman 1991" YEAR="1987">
<REFERENCE MODIFIED="2013-08-09 15:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al</AU>
<TI>A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>1097-102</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:24:43 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:24:43 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1865542"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grundmann-1988" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="Jane Cracknell" NAME="Grundmann 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grundmann R, Hornung M</AU>
<TI>Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis - a prospective randomized study</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1988</YR>
<VL>272</VL>
<PG>339-49</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:25:53 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:25:53 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3293080"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haque-1988" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="Jane Cracknell" NAME="Haque 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haque KN, Zaidi MH, Bahakim H</AU>
<TI>IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis</TI>
<SO>American Journal of Diseases of Childhood</SO>
<YR>1988</YR>
<VL>142</VL>
<PG>1293-6</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:26:41 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:26:41 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3195529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hentrich-2006" MODIFIED="2008-11-30 04:57:57 +0000" MODIFIED_BY="[Empty name]" NAME="Hentrich 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-30 04:57:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hentrich M, Fehnle K, Ostermann H, Klenast J, Cornely O, Salat C, et al</AU>
<TI>IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<PG>1319-25</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:28:01 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:28:01 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16540956"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Just-1986" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Just 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Just HM, Metzger M, Vogel W, Pelka RB</AU>
<TI>Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study</TI>
<TO>Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station.</TO>
<SO>Klinische Wochenschrift</SO>
<YR>1986</YR>
<VL>64</VL>
<PG>245-56</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:29:18 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:29:18 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3713101"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karatzas-2002" MODIFIED="2009-02-03 22:25:00 +0000" MODIFIED_BY="Nathan L Pace" NAME="Karatzas 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-03 22:25:00 +0000" MODIFIED_BY="Nathan L Pace" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G</AU>
<TI>The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>543-4</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:29:51 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:29:51 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12512504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lachman-1984" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lachman 1984" YEAR="1983">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lachman E, Pitsoe SB, Gaffin SL</AU>
<TI>Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<PG>981-3</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:31:28 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:31:28 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6143965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindquist-1981" MODIFIED="2008-11-30 02:38:18 +0000" MODIFIED_BY="[Empty name]" NAME="Lindquist 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-11-30 02:38:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindquist L, Lundbergh P, Maasing R</AU>
<TI>Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia</TI>
<SO>Vox Sanguinis</SO>
<YR>1981</YR>
<VL>40</VL>
<PG>329-37</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:33:48 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:33:48 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6166128 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mancilla_x002d_Ramirez-1992" MODIFIED="2009-11-04 13:38:10 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mancilla-Ramirez 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancilla-Ramírez J, González-Yunes R, Castellanos-Cruz C, García-Roca P, Santos-Preciado JI</AU>
<TI>Intravenous immunoglobulin in the treatment of neonatal septicemia</TI>
<TO>Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.</TO>
<SO>Boletín Médico del Hospital Infantil de México</SO>
<YR>1992</YR>
<VL>49</VL>
<PG>4-11</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:35:43 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:35:43 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1304766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Masaoka-2000" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Masaoka 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al</AU>
<TI>The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2000</YR>
<VL>48</VL>
<PG>199-217</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:37:45 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:37:43 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00418781"/>
<IDENTIFIER MODIFIED="2008-11-25 14:37:38 +0000" MODIFIED_BY="Jane Cracknell" TYPE="EMBASE" VALUE="2000159529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCloskey-1994" MODIFIED="2013-09-03 02:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="McCloskey 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-03 02:44:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR</AU>
<TI>Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>1-5</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:38:40 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:38:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8198341"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opal-1997" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Opal 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al</AU>
<TI>Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>1115-24</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:40:34 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:40:34 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9233735"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panacek-2004" MODIFIED="2013-09-03 02:44:57 +0100" MODIFIED_BY="[Empty name]" NAME="Panacek 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-03 02:44:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al; Monoclonal Anti-TNF: Randomized Controlled Sepsis Study Investigators</AU>
<TI>Efficacy and safety of the monoclonal anti--tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>2173-82</PG>
<IDENTIFIERS MODIFIED="2013-08-09 15:55:22 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2013-08-09 15:55:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15640628 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinhart-1996" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Reinhart 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, et al</AU>
<TI>Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose ranging study</TI>
<SO>Critical Care Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>733-42</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:44:09 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:44:09 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8706447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2005" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Rodriguez 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al</AU>
<TI>Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery</TI>
<SO>Shock</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>298-304</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:45:10 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:45:10 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15803051 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samatha-1997" MODIFIED="2008-11-25 14:47:55 +0000" MODIFIED_BY="Jane Cracknell" NAME="Samatha 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-25 14:47:55 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samatha S, Jalalu MP, Hegde RK, Vishwanath D, Maiya PP</AU>
<TI>Role of IgM-enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis</TI>
<SO>Karnataka Pediatric Journal</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schedel-1991" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Schedel 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, et al</AU>
<TI>Treatment of Gram-negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>1104-13</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:49:44 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:49:44 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 1884609"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shenoi-1999" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Shenoi 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shenoi A, Nagesh NK, Maiya PP, Bhat SR, Subba Rao SD</AU>
<TI>Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis</TI>
<SO>Indian Pediatrics</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>1113-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:50:42 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:50:42 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10745332"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tugrul-2002" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Tugrul 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al</AU>
<TI>The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>357-62</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:52:18 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:52:18 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12225613"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisman-1992" MODIFIED="2013-09-03 02:45:52 +0100" MODIFIED_BY="[Empty name]" NAME="Weisman 1992" YEAR="1985">
<REFERENCE MODIFIED="2013-09-03 02:45:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE, Stoll BJ, Kueser TJ, Rubio TT, Frank CG, Heiman HS, et al</AU>
<TI>Intravenous immune globulin therapy for early onset sepsis in premature neonates</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>121</VL>
<PG>434-43</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:53:19 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:53:19 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1517923 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Werdan-2007" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Werdan 2007" YEAR="91-95">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Werdan K, Pilz G, Bujdoso O, Frauberger P, Neeser G, Schmeider RE, et al</AU>
<TI>Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<PG>2693-701</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:54:25 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:54:25 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18074471"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wesoly-1990" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Wesoly 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wesoly C, Kipping N, Grundmann R</AU>
<TI>Immunoglobulin therapy of postoperative sepsis</TI>
<TO>Immunglobulintherapie der postoperativen Sepsis</TO>
<SO>Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR</SO>
<YR>1990</YR>
<VL>23</VL>
<PG>213-6</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:56:17 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:56:17 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00075746"/>
<IDENTIFIER MODIFIED="2008-11-25 14:56:11 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2095647"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yakut-1998" MODIFIED="2013-08-09 15:56:20 +0100" MODIFIED_BY="[Empty name]" NAME="Yakut 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-08-09 15:56:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yakut M, Cetiner S, Akin A, Tan A, Kaymakcioglu N, Simsek A, et al</AU>
<TI>Effects of immunoglobulin G on surgical sepsis and septic shock</TI>
<TO>Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi</TO>
<SO>Bulletin of Gulhane Military Medical Academy</SO>
<YR>1998</YR>
<VL>40</VL>
<PG>76-81</PG>
<IDENTIFIERS MODIFIED="2008-11-30 13:12:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-30 13:12:16 +0000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00200598"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegler-1991" MODIFIED="2013-09-03 02:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ziegler 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-09-03 02:47:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al</AU>
<TI>Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.l</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>429-36</PG>
<IDENTIFIERS MODIFIED="2008-11-25 14:59:31 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 14:59:31 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1988827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-03 02:53:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aitchison-1985" MODIFIED="2013-09-03 02:47:26 +0100" MODIFIED_BY="[Empty name]" NAME="Aitchison 1985" YEAR="">
<REFERENCE MODIFIED="2013-09-03 02:47:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aitchison JM, Arbuckle DD</AU>
<TI>Anti-endotoxin in the treatment of surgical septic shock. Results of a randomized double-blind trial</TI>
<SO>South African Medical Journal</SO>
<YR>1985</YR>
<VL>68</VL>
<PG>787-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:03:11 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:03:11 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3906941 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bojic-1998" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Bojic 1998" YEAR="">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bojic I, Begovic V, Trnjak Z, Dokik M</AU>
<TI>The significance of immunoglobulins in the treatment of patients with sepsis and septic shock</TI>
<SO>Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review</SO>
<YR>1998</YR>
<VL>55 (2 Suppl)</VL>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:05:58 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:05:58 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9623363 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cairo-1992" MODIFIED="2013-09-03 02:47:52 +0100" MODIFIED_BY="[Empty name]" NAME="Cairo 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-09-03 02:47:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cairo MS, Worcester CC, Rucker RW, Hanten S, Amlie RN, Sender L, et al</AU>
<TI>Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>120</VL>
<PG>281-5</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:07:03 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:07:03 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1735830 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calandra-1988" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Calandra 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calandra T, Glauser MP, Schellekens J, Verhoef J</AU>
<TI>Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective double-blind, randomized trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>312-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:08:09 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:08:09 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3136210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1991" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Christensen 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen RD, Brown MS, Hall DC, Lassiter HA, Hill HR</AU>
<TI>Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<PG>606-14</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:09:37 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:09:37 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1901083"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Groote-1989" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="De Groote 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP</AU>
<TI>Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs. placebo</TI>
<SO>JAMA</SO>
<YR>1989</YR>
<VL>262</VL>
<PG>249-51</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:10:31 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:10:31 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2739019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominioni-1991" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Dominioni 1991" YEAR="1986">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, et al</AU>
<TI>Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater</TI>
<SO>Archives of Surgery</SO>
<YR>1991</YR>
<VL>126</VL>
<PG>236-40</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:24:57 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:24:57 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1992998"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Nawawy-2005" MODIFIED="2008-11-30 06:03:08 +0000" MODIFIED_BY="[Empty name]" NAME="El Nawawy 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-30 06:03:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N</AU>
<TI>Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit</TI>
<SO>Journal of Tropical Pediatrics</SO>
<YR>2005</YR>
<VL>51</VL>
<PG>271-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:26:46 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:26:46 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15917261 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1983" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fischer 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer GW, Hunter KW, Hemming VG, Wilson SR</AU>
<TI>Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies</TI>
<SO>Vox Sanguinis</SO>
<YR>1983</YR>
<VL>44</VL>
<PG>296-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:27:47 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:27:47 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6344430"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1993" MODIFIED="2009-11-28 10:08:00 +0000" MODIFIED_BY="[Empty name]" NAME="Fisher 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-11-28 10:08:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al</AU>
<TI>Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>318-27</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:29:14 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:29:14 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8440099 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1996" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fisher 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al</AU>
<TI>Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>1697-702</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:31:22 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:31:22 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00125377"/>
<IDENTIFIER MODIFIED="2008-11-25 15:31:15 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8637514"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1999" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Freeman 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Freeman BD, Eichacker PQ, Natanson C</AU>
<TI>The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies</TI>
<SO>Inflammation: Basic Principles and Clinical Correlates</SO>
<YR>1999</YR>
<PG>965-76</PG>
<EN>3rd</EN>
<ED>Gallin JI, Snyderman R</ED>
<PB>Lippincott Williams &amp; Williams</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gokalp-1994" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Gokalp 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gökalp AS, Toksoy HB, Türkay S, Bakici MZ, Kaya R</AU>
<TI>Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates</TI>
<SO>Clinical Pediatrics</SO>
<YR>1994</YR>
<VL>33</VL>
<PG>349-52</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:33:12 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:33:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8200169 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunes-2006" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Gunes 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunes T, Koklu E, Buyukkayhan D, Kurtoglu S, Karakukcu M, Patiroglu T</AU>
<TI>Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>39-42</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:35:19 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:35:19 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 16494703 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haque-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Haque 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haque KN, Remo C, Bahakim H</AU>
<TI>Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis</TI>
<SO>Clinical and Experimental Immunology</SO>
<YR>1995</YR>
<VL>101</VL>
<PG>328-33</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:36:37 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:36:37 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7648717"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-1990" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Homan 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan SE, Hall RT, Hall SL, Meade VM, Kurth CG</AU>
<TI>Safety of intravenous immunoglobulin in neonates at risk for sepsis</TI>
<SO>American Journal of Perinatology</SO>
<YR>1990</YR>
<VL>7</VL>
<PG>267-72</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:37:47 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:37:47 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2121151"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaspers-1987" MODIFIED="2013-09-03 02:49:39 +0100" MODIFIED_BY="[Empty name]" NAME="Jaspers 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-09-03 02:49:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaspers L, Marget W, Mar PJ, Hoffmann K, Langecker P, Ruckdeschel G, et al</AU>
<TI>Antibody to lipid A in the treatment of septic shock</TI>
<SO>Infection</SO>
<YR>1987</YR>
<VL>15 Suppl 2</VL>
<PG>89-95</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:38:52 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:38:52 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3301683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenson-1997" MODIFIED="2008-11-25 15:39:50 +0000" MODIFIED_BY="Jane Cracknell" NAME="Jenson 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-25 15:39:50 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenson HB, Pollock BH</AU>
<TI>Meta-analyses of intravenous immune globulin for prevention and treatment of neonatal sepsis</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>2</NO>
<PG>E2</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:39:50 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:39:50 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9099759 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jesdinsky-1987" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Jesdinsky 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J</AU>
<TI>Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1987</YR>
<VL>65</VL>
<PG>1132-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:41:24 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:41:24 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3323648"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Jones 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones EB</AU>
<TI>Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial</TI>
<SO>Burns</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>267-72</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:42:08 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:42:08 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7662126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaul-1999" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kaul 1999" YEAR="1994">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al</AU>
<TI>Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>800-7</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:44:02 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:44:02 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10825042"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kay-1996" MODIFIED="2008-12-02 12:44:46 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-12-02 12:43:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kay CA</AU>
<TI>Can better measures of cytokine responses be obtained to guide cytokine inhibition?</TI>
<SO>Knoll AG, Ludwigshafen, Germany. Presentation and handout. Cambridge Health Institutes' Designing Better Drugs and Trials for Sepsis/SIRS: Reducing mortality to patients and suppliers</SO>
<YR>Washington, DC, February 20-21, 1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kett-1994" MODIFIED="2013-09-03 02:50:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kett 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-03 02:50:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kett DH, Quartin AA, Sprung CL, Fisher CJ Jr, Peña MA, Heard SO, et al</AU>
<TI>An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody</TI>
<SO>Critical Care Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>1227-34</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:46:56 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:46:56 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8045141"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornelisse-1997" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kornelisse 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornelisse RF, Hazelzet JA, Hop WC, Spanjaard L, Suur MH, van der Voort E, et al</AU>
<TI>Meningococcal septic shock in children: clinical and laboratory features, outcome and development of a prognostic score</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>640-6</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:51:09 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:51:09 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9314453 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreymann-2007" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Kreymann 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreymann KG, de Heer G, Nierhaus A, Kluge S</AU>
<TI>Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<PG>2677-85</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:52:28 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:52:28 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18074464"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacy-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Lacy 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacy JB, Ohlsson A</AU>
<TI>Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analyses</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>1995</YR>
<VL>72</VL>
<PG>F151-5</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:39:52 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:39:52 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7796228 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laupland-2007" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Laupland 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laupland KB, Kirkpatrick AW, Delaney A</AU>
<TI>Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<PG>2686-92</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:55:40 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:55:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18074465 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marenovic-1998" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Marenovic 1998" YEAR="">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marenovic T, Filipovic D, Lukic Z, Dokic G</AU>
<TI>High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis</TI>
<SO>Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review</SO>
<YR>1998</YR>
<VL>55 (2 Suppl)</VL>
<PG>71-4</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:56:57 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:56:53 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9623362 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okimoto-1985" MODIFIED="2013-08-09 16:00:23 +0100" MODIFIED_BY="[Empty name]" NAME="Okimoto 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-08-09 16:00:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okamoto Y, Maehara K, Mase K, Iida Y, Yasunaga K, Okubo H, et al</AU>
<TI>Clinical studies on the effectiveness of SM-4300, a new non-modified gamma globulin preparation suitable for intravenous use, in refractory infections</TI>
<SO>The Japanese Journal of Antibiotics</SO>
<YR>1985</YR>
<VL>38</VL>
<PG>2515-25</PG>
<IDENTIFIERS MODIFIED="2013-08-09 16:00:23 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2013-08-09 16:00:23 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="4079018"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panko-1976" MODIFIED="2008-11-25 16:00:07 +0000" MODIFIED_BY="Jane Cracknell" NAME="Panko 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-11-25 16:00:07 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panko GF</AU>
<TI>Use of staphylococcal plasma and antistaphylococcal immunoglobulin in treatment of staphylococcal sepsis</TI>
<SO>Khirurgiia</SO>
<YR>1976</YR>
<VL>9</VL>
<PG>95-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:00:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:00:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="979012 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pilz-1997" MODIFIED="2008-11-25 16:00:47 +0000" MODIFIED_BY="Jane Cracknell" NAME="Pilz 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-25 16:00:47 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pilz G, Appel R, Kreuzer E, Werdan K</AU>
<TI>Comparison of early IgM-enriched immunoglobulin vs. polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>111</VL>
<PG>419-26</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:00:47 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:00:47 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9041991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pittet-1999" MODIFIED="2013-08-09 16:00:36 +0100" MODIFIED_BY="[Empty name]" NAME="Pittet 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-08-09 16:00:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton K, Barker C, et al</AU>
<TI>Impact of immunomodulating therapy on morbidity in patients with severe sepsis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>852-7</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:02:52 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:02:52 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10471608"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schedel-1996" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Schedel 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schedel I, Dreichhausen U</AU>
<TI>[Therapy of gram-negative septicotoxic diseases with pentaglobin - immunoglobulin with increased IgM content: a prospective randomized clinical study]</TI>
<SO>Anesteziologiia i Reanimatologiia</SO>
<YR>1996</YR>
<VL>199</VL>
<PG>4-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:05:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:05:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00129822"/>
<IDENTIFIER MODIFIED="2008-11-25 16:04:58 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8967617"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sidiropolous-1981" MODIFIED="2013-09-03 02:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Sidiropolous 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-09-03 02:52:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sidiropolous D, Bohme U, von Muralt G, Morell A, Barandun S</AU>
<TI>Immunoglobulin substitution in the treatment of neonatal septicemia</TI>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1981</YR>
<VL>111</VL>
<PG>1649-55</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:06:40 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:06:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7302548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sidiropoulos-1986" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Sidiropoulos 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sidiropoulos D, Boehme U, Von Muralt G, Morell A, Barandun S</AU>
<TI>Immunoglobulin supplementation in prevention or treatment of neonatal sepsis</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>S193-94</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:07:45 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:07:45 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3714523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomii-1985" MODIFIED="2008-11-30 06:06:15 +0000" MODIFIED_BY="[Empty name]" NAME="Tomii 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-11-30 06:06:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomii M, Kobayashi Y, Fujimori I</AU>
<TI>Clinical study of SM-4300 in the field of medicine</TI>
<SO>The Japanese Journal of Antibiotics</SO>
<YR>1985</YR>
<VL>38</VL>
<PG>2503-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 15:48:57 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 15:48:57 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3935825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turgeon-2007" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Turgeon 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, et al</AU>
<TI>Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<PG>193-203</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:08:55 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:08:55 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 17283351 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ueda-1985" MODIFIED="2013-09-03 02:53:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ueda 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-09-03 02:53:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ueda T, Fujimoto M, Sakai K, Sasaki T, Morimoto Y, Mitsuyoshi H, et al</AU>
<TI>A clinical trial of SM-4300 against severe infections in surgery</TI>
<SO>The Japanese Journal of Antibiotics</SO>
<YR>1985</YR>
<VL>38</VL>
<PG>2647-59</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:11:00 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:11:00 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3908740"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2008-11-25 16:12:31 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-25 16:12:31 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Dou L, Zhang H, Zhao B, Wang D, Cao S</AU>
<TI>Treatment of septic thrombocytopenia with immunoglobulin</TI>
<SO>Chinese Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>905-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:12:31 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:12:31 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00613262"/>
<IDENTIFIER MODIFIED="2008-11-25 16:12:26 +0000" MODIFIED_BY="Jane Cracknell" TYPE="EMBASE" VALUE="2006513788"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Werdan-1996" MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Werdan 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-09 10:16:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Werdan K, Pilz G</AU>
<TI>Supplemental immune globulins in sepsis: a critical appraisal</TI>
<SO>Clinical and Experimental Immunology</SO>
<YR>1996</YR>
<VL>104 Suppl 1</VL>
<PG>83-90</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:14:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:14:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8625550"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wortel-1992" MODIFIED="2008-11-30 06:07:18 +0000" MODIFIED_BY="[Empty name]" NAME="Wortel 1992" YEAR="1988">
<REFERENCE MODIFIED="2008-11-30 06:07:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wortel CH, von der Möhlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ, et al</AU>
<TI>Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>1367-74</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:15:32 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:15:32 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1431255"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yavuz-2012" MODIFIED="2013-04-02 17:25:34 +0100" MODIFIED_BY="[Empty name]" NAME="Yavuz 2012" YEAR="2010">
<REFERENCE MODIFIED="2013-04-02 17:25:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yavuz L, Aynali G, Aynali A, Alacala A, Kutuk S, Ceylan BG</AU>
<TI>The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients</TI>
<SO>The Journal of International Medical Research</SO>
<YR>2012</YR>
<VL>40</VL>
<PG>1166-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeni-1997" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Zeni 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeni F, Freeman BD, Natanson C</AU>
<TI>Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>1095-100</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:17:21 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:17:21 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9233726 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Yildizdas-2005" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Yildizdas 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildizidas D, Yapicioglu H, Tumgor G, Erbey F</AU>
<TI>Does polyclonal intravenous immunoglobulin reduce mortality in septic children in pediatric intensive care unit?</TI>
<TO>Cocuk yogun bakim unitesi'nde sepsis nedeni ile izlenen hastalarda poliklonal intravenoz immunglobulin tedavisi mortaliteyi azaltiyor mu?</TO>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>2005</YR>
<VL>48</VL>
<PG>136-41</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:19:43 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:19:43 +0000" MODIFIED_BY="Jane Cracknell" TYPE="CENTRAL" VALUE="CN-00569372"/>
<IDENTIFIER MODIFIED="2008-11-25 16:19:37 +0000" MODIFIED_BY="Jane Cracknell" TYPE="EMBASE" VALUE="2005248022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2012-06-23 01:21:02 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abraham-1994" MODIFIED="2008-11-25 16:28:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Abraham 1994" TYPE="JOURNAL_ARTICLE">
<AU>Abraham E, Raffin TA</AU>
<TI>Sepsis therapy trials - continued disappointment or reason for hope?</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<PG>1876-78</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:28:34 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:28:34 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8196148 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alejandria-2000" MODIFIED="2008-11-30 13:38:20 +0000" MODIFIED_BY="[Empty name]" NAME="Alejandria 2000" TYPE="JOURNAL_ARTICLE">
<AU>Alejandria MM, Lansang MA, Fonbuena GE, Fadreguilan E, Timbreza F, de Luna M, et al</AU>
<TI>Epidemiology and predictors of mortality from sepsis in medical patients at UP-PGH</TI>
<SO>Philippine Journal of Microbiology and Infectious Diseases</SO>
<YR>2000</YR>
<VL>29</VL>
<PG>23-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Annane-2009" MODIFIED="2009-11-27 09:34:41 +0000" MODIFIED_BY="[Empty name]" NAME="Annane 2009" TYPE="JOURNAL_ARTICLE">
<AU>Annane D</AU>
<TI>Improving clinical trials in the critically ill: unique challenge -sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37 Suppl 1</VL>
<PG>117-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bone-1991" MODIFIED="2008-11-25 16:30:40 +0000" MODIFIED_BY="Jane Cracknell" NAME="Bone 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC</AU>
<TI>A critical evaluation of new agents for the treatment of sepsis</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>1686-90</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:30:40 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:30:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1886193 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bone-1992" MODIFIED="2013-09-03 02:54:26 +0100" MODIFIED_BY="[Empty name]" NAME="Bone 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al</AU>
<TI>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<PG>1644-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cappelleri-1995" MODIFIED="2009-11-28 10:19:51 +0000" MODIFIED_BY="[Empty name]" NAME="Cappelleri 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, et al</AU>
<TI>Large trials vs meta-analysis of smaller trials - how do their results compare?</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>276</VL>
<PG>1332-8</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:31:51 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:31:51 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8861993"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahlberg-1997" MODIFIED="2008-06-22 17:17:56 +0100" MODIFIED_BY="[Empty name]" NAME="Dahlberg 1997" TYPE="BOOK_SECTION">
<AU>Dahlberg PS, David DL</AU>
<TI>Endotoxins and sepsis</TI>
<SO>Sepsis and multiorgan failure</SO>
<YR>1997</YR>
<PG>45-61</PG>
<ED>Fein AM, Abrahan EM et al</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2008" MODIFIED="2013-09-03 02:55:11 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dellinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al</AU>
<TI>Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<PG>17-60</PG>
<IDENTIFIERS MODIFIED="2013-09-03 02:55:11 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2013-09-03 02:55:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18058085"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2013" MODIFIED="2013-02-09 23:04:39 +0000" MODIFIED_BY="[Empty name]" NAME="Dellinger 2013" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal S, et al</AU>
<TI>Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012</TI>
<SO>Critical Care Medicine</SO>
<YR>2013</YR>
<VL>41</VL>
<PG>580-637</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-03 02:55:55 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>[updated March 2011]</YR>
<PB>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2003" MODIFIED="2009-11-28 10:20:27 +0000" MODIFIED_BY="[Empty name]" NAME="Levy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al</AU>
<TI>2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>1250-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norrby_x002d_Teglund-2003" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Norrby-Teglund 2003" TYPE="JOURNAL_ARTICLE">
<AU>Norrby-Teglund A, Ihendyane N, Darenberg J</AU>
<TI>Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>35</VL>
<PG>683-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:45:57 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:45:57 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="14620155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nydegger-1997" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Nydegger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nydegger UE</AU>
<TI>Sepsis and polyspecific intravenous immunoglobulins</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>93-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:47:10 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:47:10 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9263117 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nydegger-1999" MODIFIED="2009-03-11 01:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="Nydegger 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nydegger UE, Sturzenegger M</AU>
<TI>Adverse effects of intravenous immunoglobulin therapy</TI>
<SO>Drug Safety</SO>
<YR>1999</YR>
<VL>21</VL>
<PG>171-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohlsson-2013" MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ohlsson 2013" TYPE="COCHRANE_REVIEW">
<AU>Ohlsson A, Lacy JB</AU>
<TI>Intravenous immunoglobulin for suspected or proven infection in neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2013-09-13 09:51:02 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD001239.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phua-2011" MODIFIED="2013-08-09 16:02:50 +0100" MODIFIED_BY="[Empty name]" NAME="Phua 2011" TYPE="JOURNAL_ARTICLE">
<AU>Phua J, Du B, Tang Y, Divatia JV, Tan CC, Gomersall CD, et al</AU>
<TI>Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d3245</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pildal-2004" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Pildal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pildal J, Gøtzsche PC</AU>
<TI>Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>38-46</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:48:00 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:48:00 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15206051"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rangel_x002d_Frausto-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Rangel-Frausto 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP</AU>
<TI>The natural history of the systemic inflammatory response syndrome (SIRS)</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>968-74</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:48:39 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:48:39 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7799491 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.2" MODIFIED="2013-02-09 23:08:36 +0000" MODIFIED_BY="Jane Cracknell" NAME="RevMan 5.2" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rivers-2001" MODIFIED="2013-09-03 02:57:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rivers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al; Early Goal-Directed Therapy Collaborative Group</AU>
<TI>Early goal-directed therapy in the treatment of severe sepsis and septic shock</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>1368-77</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:49:49 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:49:49 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1794169 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sibbald-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Sibbald 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sibbald WJ, Vincent JL</AU>
<TI>Round table conference on clinical trials for the treatment of sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>394-9</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:50:32 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:50:32 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7867364"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Soares-2012" MODIFIED="2013-08-09 16:04:36 +0100" MODIFIED_BY="[Empty name]" NAME="Soares 2012" TYPE="JOURNAL_ARTICLE">
<AU>Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, et al</AU>
<TI>An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review,meta-analysis and value of information analysis</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>7</NO>
<PG>1-186</PG>
<IDENTIFIERS MODIFIED="2013-08-09 16:04:36 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2013-08-09 16:04:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="22361003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sundararajan-2006" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Sundararajan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sundararajan V, Korman T, Macisaac C, Presneill JJ, Cade JF, Visvanathan K</AU>
<TI>The microbiology and outcome of sepsis in Victoria, Australia</TI>
<SO>Epidemiology and Infection</SO>
<YR>2006</YR>
<VL>134</VL>
<PG>307-14</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:51:35 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:51:35 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16490135"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taguiang_x002d_Abu-2008" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Taguiang-Abu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Taguiang-Abu CU, Alejandria MM</AU>
<TI>Clinical determinants of outcome of severe sepsis among adult patients at the Philippine General Hospital Intensive Care Units</TI>
<SO>Philippine Journal of Internal Medicine</SO>
<YR>2008</YR>
<VL>46</VL>
<PG>103-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanriover-2006" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Tanriover 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tanriover MD, Guven GS, Sen D, Unal S, Uzun O</AU>
<TI>Epidemiology and outcome of sepsis in a tertiary care hospital in a developing country</TI>
<SO>Epidemiology and Infection</SO>
<YR>2006</YR>
<VL>134</VL>
<PG>315-22</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:54:29 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:54:29 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16490136 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Villa-1995" MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Villa 1995" TYPE="JOURNAL_ARTICLE">
<AU>Villa L, Baleva E, Tiu D, Coronel R</AU>
<TI>Sepsis profile among patients in a tertiary care hospital</TI>
<SO>St Luke's Medical Journal</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1995" MODIFIED="2013-08-09 16:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Villar 1995" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Carroli G, Belizan JM</AU>
<TI>Predictive ability of meta-analyses of randomized controlled trials</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>772-6</PG>
<IDENTIFIERS MODIFIED="2008-11-25 16:56:36 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-11-25 16:56:36 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7891492 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Werdan-1997" MODIFIED="2009-11-28 10:22:05 +0000" MODIFIED_BY="[Empty name]" NAME="Werdan 1997" TYPE="OTHER">
<AU>Werdan K, Pilz G; the SBITs Study Group</AU>
<TI>Polyvalent immune globulins [Abstract 18]</TI>
<SO>Shock</SO>
<YR>1997</YR>
<VL>7 Suppl 5</VL>
<PG>1918</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Werdan-2001" MODIFIED="2008-12-06 01:45:13 +0000" MODIFIED_BY="[Empty name]" NAME="Werdan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Werdan K</AU>
<TI>Pathophysiology of septic shock and multiorgan dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins</TI>
<SO>Therapeutic Apheresis</SO>
<YR>2001</YR>
<VL>5</VL>
<PG>115-22</PG>
<IDENTIFIERS MODIFIED="2008-12-06 01:45:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 01:45:13 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11354295"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wortel-1993" MODIFIED="2013-09-03 02:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wortel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wortel CH</AU>
<TI>Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective randomized clinical trial (Letter to the Editor)</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>163-5</PG>
<IDENTIFIERS MODIFIED="2008-12-06 01:47:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 01:47:17 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8420724"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zabala-1999" MODIFIED="2008-09-10 04:00:28 +0100" MODIFIED_BY="Marissa M. Alejandria" NAME="Zabala 1999" TYPE="CONFERENCE_PROC">
<AU>Zabala MLB, Dans LF</AU>
<TI>Prescribing patterns for immunoglobulin use among pediatricians in 3 Metro Manila hospitals</TI>
<SO>Conference Proceedings 2nd World Congress of Pediatric Infectious Diseases</SO>
<YR>1999 Nov 2-6</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-08-09 15:35:37 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alejandria-2002" MODIFIED="2013-08-09 15:35:37 +0100" MODIFIED_BY="[Empty name]" NAME="Alejandria 2002" TYPE="COCHRANE_REVIEW">
<AU>Alejandria MM, Lansang MA, Dans LF, Mantaring JBV</AU>
<TI>Intravenous immunoglobulin for treating sepsis and septic shock</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-08-09 15:35:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-09 15:35:37 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001090"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-09-03 02:26:59 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-03 02:23:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-02 12:13:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abraham-1995">
<CHAR_METHODS MODIFIED="2013-09-02 12:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-11 13:27:56 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients with sepsis or septic shock ,18 years of age or older<BR/>31 hospitals in USA and Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:08:29 +0000" MODIFIED_BY="[Empty name]">
<P>TNF alpha MAb (single infusion of 15 mg/kg or 7.5 mg/kg) versus placebo (2.5 g/L human albumin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 04:46:31 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:12:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abraham-1998">
<CHAR_METHODS MODIFIED="2013-09-02 12:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults &gt; 18 years old with septic shock of 12 hours or less duration<BR/>105 hospitals in USA and Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:09:14 +0000" MODIFIED_BY="[Empty name]">
<P>TNF alpha MAb 7.5 mg/kg single infusion versus placebo (0.25% human serum albumin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-27 09:09:35 +0000" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality, 7-day and 14-day all-cause mortality<BR/>Reversal of septic shock at day 7<BR/>Resolution of baseline organ failure at day 7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 04:47:13 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:13:52 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Albertson-2003">
<CHAR_METHODS MODIFIED="2013-09-02 12:13:52 +0100" MODIFIED_BY="Jane Cracknell">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:10:16 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients, 18 years or older, with sepsis from presumed or proven gram-negative infection in 33 US medical centres</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:10:27 +0000" MODIFIED_BY="[Empty name]">
<P>300 mg MAB-T88 in albumin IV single dose versus placebo (human serum albumin in an equivalent volume)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-23 09:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-29 23:59:13 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:14:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angus-2000">
<CHAR_METHODS MODIFIED="2013-09-02 12:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre -136 medical centres in the USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:11:22 +0000" MODIFIED_BY="[Empty name]">
<P>Adults 18 years or older with severe sepsis and documented or probable gram-negative infection, from April 1993-97</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:11:34 +0000" MODIFIED_BY="[Empty name]">
<P>E5 2mg/kg/day, 2 doses by IV infusion 24 hrs apart versus placebo consisting of 0.1 mg/ml human serum albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>14-day and 28-day mortality, adverse event rates, 14-day and 28-day mortality in the subgroup without shock at presentation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 04:49:46 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>2 planned interim analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:08:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Behre-1995">
<CHAR_METHODS MODIFIED="2009-11-04 14:04:36 +0000" MODIFIED_BY="Jane Cracknell">
<P>Randomized controlled trial, single centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:11:59 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with haematologic malignancies, neutropenia and sepsis syndrome or septic shock in Germany<BR/>Aug 1992 to Sept 1994</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:12:25 +0000" MODIFIED_BY="[Empty name]">
<P>IgM-enriched Ig (Pentaglobin) loading dose of 0.2 l, then 0.1 l every 6 hrs for 72 hrs as slow IV infusion for a total dose of 1.3 litres versus 5% human albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-03 02:08:20 +0100" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality<BR/>Endotoxin plasma concentrations<BR/>IgM and IgG antibodies against lipid-A and re LPS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-14 14:22:14 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:11:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bone-1995">
<CHAR_METHODS MODIFIED="2013-09-02 12:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:13:36 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with:</P>
<OL>
<LI>known or suspected gram-negative infection</LI>
<LI>clinical evidence of sepsis</LI>
<LI>signs of end-organ dysfunction</LI>
</OL>
<P>53 hospitals in USA from Feb 1989 - Jan 1991</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>E5 2 mg/kg/day, 2 doses 24 hrs apart versus placebo (0.1 mg human albumin/ml of buffer solution used for E5)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30-day all-cause mortality <BR/>Resolution and prevention of organ failure<BR/>Proportion discharged from the hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 04:51:41 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:09:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brocklehurst-2011">
<CHAR_METHODS MODIFIED="2012-06-23 01:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 02:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>Infants receiving antibiotics with clinical evidence of definite or highly probable sepsis and there is substantial uncertainty that IVIG is indicated and birthweight is &lt; 1500 g or infant already has positive blood culture or infant is receiving artificial ventilation</P>
<P>3493 infants from 113 hospitals (UK, Australia, Argentina, New Zealand, Serbia, Greece, Denmark, Belgium, Ireland)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-08 16:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>500 mg/kg (10ml/kg) of IVIG or identical colourless placebo (0.2% albumin solution in normal saline) infused over 4 to 6 hrs, repeated 48 hrs later</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-23 01:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: mortality or major disability, at 2 yrs corrected for gestational age<BR/>Secondary: mortality, chronic lung disease or major cerebral abnormality before hospital discharge<BR/>Health service utilization: length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-23 01:21:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-30 04:22:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burns-1991">
<CHAR_METHODS MODIFIED="2009-11-27 09:15:36 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-11 06:35:09 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with documented sepsis and thrombocytopenia related directly to the infection; patients were in the medical and surgical ICUs<BR/>New York</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:47:27 +0000" MODIFIED_BY="Jane Cracknell">
<P>IVIG (Sandoglobulin) 400 mg/kg/day for 3 days versus albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-27 09:14:38 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome measure of the study was an increase in platelet count by day 9 of the study<BR/>Secondary outcome - mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:22:46 +0000" MODIFIED_BY="[Empty name]">
<P>Five patients had clinically significant bleeding (four in the placebo group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-30 04:26:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1996">
<CHAR_METHODS MODIFIED="2009-11-27 09:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:48:54 +0000" MODIFIED_BY="Jane Cracknell">
<P>Neonates (full-term and premature newborns) with sepsis and bacteraemia<BR/>1 hospital in Taiwan; Jan 1993 - April 1995</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:49:03 +0000" MODIFIED_BY="Jane Cracknell">
<P>Standard IVIG (Intraglobin) 500 mg/kg 2 hr single infusion versus 0.9% sodium chloride placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-09 22:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality with weekly follow up for 6 weeks after discharge<BR/>Duration of hospitalisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:26:32 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects were not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-1996">
<CHAR_METHODS MODIFIED="2013-09-03 02:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:16:56 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients with sepsis or septic shock<BR/>40 hospitals in 14 countries from May 1991 - July 1993 (England, France, Germany, Sweden, Norway, Belgium, Austria, Italy, Switzerland, Netherlands, Spain, Israel, South Africa, Greece</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:17:11 +0000" MODIFIED_BY="[Empty name]">
<P>Anti-TNF alpha (15 mg/kg or 3 mg/kg as single infusion) versus placebo (0.25% human albumin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day all-cause mortality<BR/>Shock reversal and frequency of organ failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 04:55:01 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-28 09:43:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Darenberg-2003">
<CHAR_METHODS MODIFIED="2008-09-10 04:55:38 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:43:32 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients 18 years and above with streptococcal toxic shock syndrome<BR/>17 hospitals in Sweden, Norway, Finland and The Netherlands<BR/>Jan 1999 - May 2001</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:49:27 +0000" MODIFIED_BY="Jane Cracknell">
<P>IVIG (Endobulin S/D; Baxter) at 1 g/kg on day 1 and 0.5 g/kg on days 2 and 3 versus 1% albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-22 10:58:48 +0000" MODIFIED_BY="[Empty name]">
<P>28-day mortality, mortality at day 180<BR/>Time to resolution of shock</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 06:43:33 +0000" MODIFIED_BY="[Empty name]">
<P>Trial was terminated prematurely due to slow patient recruitment</P>
<P>Adverse events were reported but none were assessed to be related to the study drug </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-28 09:44:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Simone-1988">
<CHAR_METHODS MODIFIED="2009-11-28 09:43:58 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:44:27 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with severe sepsis (gram-positive and gram-negative) and septic shock (14 underwent surgery, 5 with neoplasia, 2 with trauma)<BR/>ICU in Milan, Italy from Jan 1984 - March 1985</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:44:52 +0000" MODIFIED_BY="[Empty name]">
<P>Standard IVIG (Sandoglobin) slow infusion 0.4 g/kg on day of admission, 0.2 g/kg after 48 hrs and 0.4 g/kg as needed clinically plus antibiotics versus antibiotics alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All-cause mortality<BR/>Mortality from septic shock<BR/>Bacteriologic failure rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 06:51:30 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:16:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Derkx-1999">
<CHAR_METHODS MODIFIED="2013-09-02 12:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:45:34 +0000" MODIFIED_BY="[Empty name]">
<P>Children with ages &gt;3 months to &lt;18 years old with presumptive diagnosis of meningococcal septic shock<BR/>April 1991 - May 1995<BR/>26 paediatric ICUs in the Netherlands, Great Britain, France, Spain, Norway</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:45:46 +0000" MODIFIED_BY="[Empty name]">
<P>HA-1A 5 mg/kg BW IV single dose versus placebo (3.5 g serum albumin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day and 56-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 09:44:25 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:15:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dhainaut-1995">
<CHAR_METHODS MODIFIED="2013-09-02 12:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult patients with septic shock within a 12-hour period<BR/>7 ICUs in France (5) and Belgium (2) from Sept 1992 - May 1993</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:46:28 +0000" MODIFIED_BY="[Empty name]">
<P>Anti-TNF alpha (single dose of either 0.1, 0.3, 1.0 or 3.0 mg/kg) versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-28 09:46:38 +0000" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality<BR/>Cytokine and TNF alpha concentrations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:29:32 +0000" MODIFIED_BY="Marissa M. Alejandria">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:16:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dominioni-1996">
<CHAR_METHODS MODIFIED="2013-09-02 12:16:29 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-15 04:35:05 +0000" MODIFIED_BY="[Empty name]">
<P>Surgical patients with sepsis scores of 17 or greater, 15-80 years old<BR/>ICUs of Italy, 1986-94</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:47:08 +0000" MODIFIED_BY="[Empty name]">
<P>Polyclonal IgG given at 0.4g/kg on days 0, 1 then 0.2g/kg on day 5 versus human albumin in 5% dextrose water</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 13:51:48 +0000" MODIFIED_BY="Jane Cracknell">
<P>All-cause mortality<BR/>Mortality from septic shock, multiorgan failure<BR/>Duration of ICU stay of survivors and non-survivors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 06:19:52 +0000" MODIFIED_BY="[Empty name]">
<P> No adverse events attributable to IVIG</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-27 09:18:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erdem-1993">
<CHAR_METHODS MODIFIED="2009-11-27 09:18:45 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized, single centre - Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pre-term infants 31-37 weeks with neonatal sepsis diagnosed by Tollner's Sepsis Scoring System</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:52:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>IgM-enriched IVIG (Pentaglobin) 5ml/kg/d for 3 days versus no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-15 11:07:55 +0000" MODIFIED_BY="[Empty name]">
<P>Mortality from sepsis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 14:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:17:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisher-1994a">
<CHAR_METHODS MODIFIED="2013-09-02 12:17:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:52:42 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult patients with sepsis syndrome 18 years old and above<BR/>12 academic medical centre ICUs in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:53:00 +0000" MODIFIED_BY="Jane Cracknell">
<P>Human interleukin-1 receptor antagonist (rhIL-1ra) 100 mg loading dose followed by 72-hr IV infusion of either 1 of 3 doses of 17, 67, or 133 mg/hr versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-14 06:55:17 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:17:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisher-1994b">
<CHAR_METHODS MODIFIED="2013-09-02 12:17:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre, multi-national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:53:11 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult patients with sepsis or septic shock<BR/>63 academic medical centres in USA, Canada and Europe</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:49:23 +0000" MODIFIED_BY="[Empty name]">
<P>Human IL-1 receptor antagonist (rhIL-1ra) 100 mg loading dose followed by 8 hr infusion of either 1or 2 mg/kg/hr dosage regimens versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day all-cause mortality<BR/>Survival time in patients with organ dysfunction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 05:01:27 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:13:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenberg-1992">
<CHAR_METHODS MODIFIED="2009-11-27 09:19:49 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 02:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Adult patients with gram-negative infections<BR/>Surgical, neurosurgical, medical ICUs in a multi-disciplinary university hospital, United States<BR/>September 1986 - June 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:20:02 +0000" MODIFIED_BY="[Empty name]">
<P>E5 (2.5 and 7.5 mg/kg, given as 2 infusions 24 hrs. apart) versus placebo (5% dextrose in normal saline solution)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-27 09:20:11 +0000" MODIFIED_BY="[Empty name]">
<P>21-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-13 11:04:13 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:18:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenman-1991">
<CHAR_METHODS MODIFIED="2013-09-02 12:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:50:39 +0000" MODIFIED_BY="[Empty name]">
<P>Adults &gt;18 years of age with signs of gram-negative infection and a systemic septic response<BR/>33 university-affiliated centres, community and municipal hospitals in USA<BR/>February 1987 - June 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:53:42 +0000" MODIFIED_BY="Jane Cracknell">
<P>E5 2 mg/kg/day, 2 doses 24 hrs apart versus placebo (5% dextrose in normal saline)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-14 11:21:56 +0000" MODIFIED_BY="[Empty name]">
<P>30-day all-cause mortality<BR/>Resolution of organ failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-10 05:02:52 +0100" MODIFIED_BY="Marissa M. Alejandria"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:14:19 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Grundmann-1988">
<CHAR_METHODS MODIFIED="2009-11-28 09:51:01 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-30 16:00:38 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adults with post-operative gram-negative sepsis and endotoxaemia, 11-73 years old<BR/>Surgical intensive care unit in Germany over 18 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-03 02:14:19 +0100" MODIFIED_BY="[Empty name]">
<P>Standard IVIG (Intraglobin) 0.25 g/kg on day of study entry and the following day versus no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All-cause mortality<BR/>Duration of intensive care</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 06:56:19 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-28 09:51:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haque-1988">
<CHAR_METHODS MODIFIED="2008-09-13 12:45:48 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Neonates with first episode of sepsis<BR/>Maternity and Children's Hospital in Riyadh, Saudi Arabia for 6 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:51:45 +0000" MODIFIED_BY="[Empty name]">
<P>Standard IVIG (IgM enriched) 500 mg/kg single infusion for 2 hrs versus 10% dextrose placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-14 21:14:59 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:18:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hentrich-2006">
<CHAR_METHODS MODIFIED="2013-09-02 12:18:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-15 04:52:26 +0000" MODIFIED_BY="[Empty name]">
<P>Neutropenic patients with hematologic malignancies and sepsis syndrome or septic shock age <U>&gt;</U> 18 years old<BR/>6 university hospitals in Germany<BR/>July 1992 to December 1999</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:52:57 +0000" MODIFIED_BY="[Empty name]">
<P>1300 ml of IV IGMA (Pentaglobin, Biotest Pharma GmbH) infused within 72 hrs given as follows: 200 ml initially (0.5 ml/min) followed by 11 infusions 100 ml each given every 6 hrs versus 1300 ml of 5% human albumin given according to the same schedule as iv IGMA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-22 11:00:37 +0000" MODIFIED_BY="[Empty name]">
<P>28 and 60-day all-cause mortality<BR/>Sepsis-related 28-day mortality, mortality from septic shock</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-13 08:16:25 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>5 adverse events likely related to IVIG (2 Grade 4 allergic events, 1 Grade 1 allergic reaction, 1 Grade 1 erythema, 1 Grade 2 nausea and vomiting</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:15:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Just-1986">
<CHAR_METHODS MODIFIED="2008-09-10 05:06:02 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:52:39 +0000" MODIFIED_BY="[Empty name]">
<P>Intensive care patients &gt;15 years old with severe infections Germany, 65 out of 104 patients had surgery<BR/>June 1979 - July 1982</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:55:08 +0000" MODIFIED_BY="Jane Cracknell">
<P>IVIG 100 ml given at 0h, 12h, 24h and 36h combined with antibiotics versus antibiotics alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality<BR/>Duration of intensive care</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-03 02:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Bias: there were more patients in the IVIG group with post-operative complications<BR/>Only the 29 patients with definite sepsis out of 104 ICU patients were included in this meta-analysis</P>
<P>Adverse effects not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-27 09:21:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karatzas-2002">
<CHAR_METHODS MODIFIED="2008-09-10 05:06:32 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-13 13:27:07 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>Adult patients with severe sepsis in Greece</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 21:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>IgM enriched IVIG</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-27 09:21:35 +0000" MODIFIED_BY="[Empty name]">
<P>28-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 07:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>Adequate allocation concealment based on communication of Pildal and Goetzsche (2004) with Karatzas</P>
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-30 23:17:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lachman-1984">
<CHAR_METHODS MODIFIED="2009-11-27 09:21:46 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:53:36 +0000" MODIFIED_BY="[Empty name]">
<P>Obstetric and gynaecological patients with septic shock<BR/>Referral teaching hospital in South Africa from January 1 1983 to January 31 1984</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:53:50 +0000" MODIFIED_BY="[Empty name]">
<P>Anti-LPS IgG 2 units rapid infusion followed by continuous slow infusion at 1 unit/hr; booster doses as needed for complications versus normal freeze-dried plasma</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All-cause mortality<BR/>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 23:17:04 +0000" MODIFIED_BY="[Empty name]">
<P>Small sample size<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-30 05:28:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindquist-1981">
<CHAR_METHODS MODIFIED="2009-11-27 09:21:58 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:55:48 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult patients &gt;18 years old with suspected or confirmed septicaemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:55:59 +0000" MODIFIED_BY="Jane Cracknell">
<P>Pepsin-treated Gamma-Venin 0.15 g/kg infused over 1 hr repeated after 24 and 48 hr and once weekly throughout the antibiotic therapy versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality<BR/>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 05:28:34 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adequate allocation concealment based on communication of Pildal and Goetzsche (2004) with Lindquist.</P>
<P>Adverse reactions in the IVIG group: shock (2 patients), rigor, chills and elevation of temperature (5 patients), vomiting (1 patient), rigours, chills and somnolence (1 patient)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:17:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<CHAR_METHODS MODIFIED="2013-09-02 12:19:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>Randomized, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 02:17:07 +0100" MODIFIED_BY="[Empty name]">
<P>Neonates (full-term and near-term) with confirmed septicaemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:56:11 +0000" MODIFIED_BY="Jane Cracknell">
<P>IVIG 500 mg/kg single dose versus 10% maltose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality<BR/>Serum IgG levels<BR/>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-09 15:36:37 +0100" MODIFIED_BY="Jane Cracknell">
<P>Data obtained from abstract of the article and Cochrane review of Ohlsson and Lacy (<LINK REF="REF-Ohlsson-2013" TYPE="REFERENCE">Ohlsson 2013</LINK>) pending retrieval of the full text of the article</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:19:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masaoka-2000">
<CHAR_METHODS MODIFIED="2013-09-02 12:19:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:56:41 +0000" MODIFIED_BY="Jane Cracknell">
<P>Patients with sepsis or suspected sepsis, severe infections not responding to broad spectrum antibiotics.<BR/>141 centres in Japan, 16 to 70 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard IViG 5 g daily for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-22 07:27:33 +0100" MODIFIED_BY="[Empty name]">
<P>Defervescence and eradication of symptoms by day 7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 13:56:49 +0000" MODIFIED_BY="Jane Cracknell">
<P>Data on mortality was obtained through communication with Dr Masaoka</P>
<P>Adverse effects reported to be probably related to IVIG were nausea and vomiting (2), pruritus (1) and dyspnoea (1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:20:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCloskey-1994">
<CHAR_METHODS MODIFIED="2013-09-02 12:20:05 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:55:18 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients &gt;18 years of age with gram-negative bacteraemia and septic shock<BR/>513 community and university-affiliated hospitals in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:57:02 +0000" MODIFIED_BY="Jane Cracknell">
<P>HA-1A 100 mg single infusion versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>14-day all-cause mortality rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 05:29:57 +0000" MODIFIED_BY="Jane Cracknell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:20:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opal-1997">
<CHAR_METHODS MODIFIED="2013-09-02 12:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:57:20 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adults with severe sepsis or septic shock<BR/>91 academic medical centres, intensive care units in North America and Europe</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:22:55 +0000" MODIFIED_BY="[Empty name]">
<P>rhIL-1ra 100 mg IV bolus followed by 72-hr continuous IV infusion at 2.0 mg/kg/hr versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-11 05:14:28 +0000" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality rate</P>
<P>resolution of sepsis-specific organ dysfunction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 03:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>No significant difference in adverse events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:20:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panacek-2004">
<CHAR_METHODS MODIFIED="2013-09-02 12:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-27 09:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>2634 patients 18 years or older with severe sepsis secondary to documented infection, of whom 998 had elevated IL-6 levels</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Afelimomab (Fab'<SUB>2</SUB> fragment of a murine monoclonal antibody to human TNF&#945;) 1mg/kg versus placebo for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-23 12:07:54 +0100" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 08:48:47 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:21:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reinhart-1996">
<CHAR_METHODS MODIFIED="2013-09-02 12:21:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre, multi-national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 14:07:00 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adults with severe sepsis or septic shock<BR/>16 academic medical centres' intensive care units in 6 European countries (Germany, England, Switzerland, Spain, Austria, France)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>Anti-TNF (0.1, 0.3 or 1.0 mg/kg given in 9 doses at 8-hr intervals over 3 days) versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day mortality<BR/>Cytokine concentrations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-14 07:16:40 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:18:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodriguez-2005">
<CHAR_METHODS MODIFIED="2013-09-02 12:21:29 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 02:18:52 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with severe sepsis and septic shock of intra-abdominal origin admitted to the ICU within 24 hrs after the onset of symptoms, post-surgery<BR/>7 teaching hospitals in Spain and Argentina</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 09:59:20 +0000" MODIFIED_BY="[Empty name]">
<P>IgM-enriched polyvalent immunoglobulin 7 ml/kg/day for 5 days versus 5% human albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-11 08:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>30-day all-cause mortality</P>
<P>Duration of ICU stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 03:58:29 +0000" MODIFIED_BY="Jane Cracknell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-27 09:25:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samatha-1997">
<CHAR_METHODS MODIFIED="2009-11-27 09:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized, single centre - Bangalore, India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-13 13:35:13 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>Neonates with sepsis<BR/>Jan 1993 to Dec 1993 in the neonatal ICU<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:57:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>IgM-enriched immunoglobulin (Pentaglobin) 5 ml/kg/d as single dose infused at 1.7 ml/kg/hr for 3 consecutive days versus supportive treatment and antibiotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-15 11:21:00 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality</P>
<P>Duration of hospital stay, survivors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 09:12:13 +0000" MODIFIED_BY="[Empty name]">
<P>No complications attributable to IVIG</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-28 09:59:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schedel-1991">
<CHAR_METHODS MODIFIED="2009-11-27 09:25:32 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 09:59:49 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with gram-negative septic shock within 24 hours after the onset of symptoms (7-73 years old)<BR/>Clinical immunology ward in a university hospital in Germany, 33 months study period</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:25:49 +0000" MODIFIED_BY="[Empty name]">
<P>Standard IVIG (Pentaglobin) 600 ml as an 8 hr infusion then 300 ml on days 2 &amp; 3 in the period 24 hrs after the previous dose versus no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>6-week all-cause mortality<BR/>Mortality from sepsis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-22 11:03:05 +0000" MODIFIED_BY="[Empty name]">
<P>Multiple interim analyses</P>
<P>No side effects observed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:22:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shenoi-1999">
<CHAR_METHODS MODIFIED="2013-09-02 12:22:06 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-30 08:32:19 +0000" MODIFIED_BY="[Empty name]">
<P>Neonates with probable sepsis and birthweight of more than 1000 g<BR/>3 tertiary care neonatal ICUs in Bangalore, India from October 1995 to May 1996</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard IVIG (Sandoglobin) 1g/kg for 3 consecutive days vs placebo using 0.15% saline in 10% dextrose in non-identical vials</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality at the end of the study period<BR/>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:02:23 +0000" MODIFIED_BY="[Empty name]">
<P>No adverse effect was reported in the IVIG or placebo infusions in any of the 3 centres</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-30 05:35:55 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Tugrul-2002">
<CHAR_METHODS MODIFIED="2008-09-10 05:14:10 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:58:19 +0000" MODIFIED_BY="Jane Cracknell">
<P>Patients with severe sepsis in Turkey<BR/>Age range of patients 10 to 76 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:58:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>IgM-enriched IVIG at 5 ml/kg/day infused over 6 hrs and repeated for 3 consecutive days versus standard sepsis therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>28-day mortality<BR/>ICU length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 05:35:55 +0000" MODIFIED_BY="Jane Cracknell">
<P>Based on communication of Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>); open table of random numbers at allocation site</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:20:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisman-1992">
<CHAR_METHODS MODIFIED="2013-09-03 02:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-11 09:25:53 +0000" MODIFIED_BY="[Empty name]">
<P>Premature neonates with early-onset sepsis confirmed by blood culture<BR/>9 institutions in USA from June 1985 - April 1989</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-09 22:12:44 +0000" MODIFIED_BY="Jane Cracknell">
<P>Standard IVIG (lyophilised Sandoglobulin) 500mg/kg single infusion for 2 hrs versus albumin (lyophilised) in identical vials</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-03 02:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality at 3 days, 7 days and 56 days post-infusion<BR/>Duration of hospitalisation<BR/>Serum IgG levels<BR/>GBS type-specific serum IgG levels<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-28 10:00:43 +0000" MODIFIED_BY="[Empty name]">
<P>Six suspected infusion-related adverse reactions, four in the albumin group (hypotension) and two in the IVIG group (hypotension and hypoglycaemia); P=0.70</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:22:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Werdan-2007">
<CHAR_METHODS MODIFIED="2009-11-27 09:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 13:59:06 +0000" MODIFIED_BY="Jane Cracknell">
<P>Patients with score-defined sepsis (sepsis score 12 to 27) and score-defined sepsis-induced severity of diseases (APACHE II score 20-35) in 23 surgical and medical ICUs in university centres and large teaching hospitals in Germany from January 1991 to April 1995</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-27 09:27:31 +0000" MODIFIED_BY="[Empty name]">
<P>IVIG (5% Polyglobin N) administered as 12 ml (600 mg/kg) on day 0 and 6 ml (300 mg/kg) on day1 versus placebo consisting of 0.1% human serum albumin, identical in appearance to the IVIG</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 18:59:47 +0100" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality; 7-day mortality; 4-day pulmonary function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-03 02:22:03 +0100" MODIFIED_BY="[Empty name]">
<P>19 adverse events reported in 17 patients: 6 adverse events in 6 patients in the placebo group - 3 skin reactions, 1 respiratory insufficiency, 1 hypotension, 1 septic shock; 13 adverse events in 11 patients in the IVIG group - 6 skin reactions (erythema, exanthem), 1 anaphylactic reaction, 1 congestion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 02:22:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wesoly-1990">
<CHAR_METHODS MODIFIED="2009-11-27 09:27:50 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 02:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with post-operative sepsis<BR/>Department of Surgery in a university hospital in Germany during a 12-month period</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-11 08:26:25 +0000" MODIFIED_BY="[Empty name]">
<P>Standard IVIG (Pentaglobin) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-09 22:13:01 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality.<BR/>Duration of hospitalisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:06:27 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events not reported<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-28 10:01:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yakut-1998">
<CHAR_METHODS MODIFIED="2009-11-27 09:28:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized, single centre - Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult surgical patients with severe sepsis<BR/>1992-96</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-28 10:01:34 +0000" MODIFIED_BY="[Empty name]">
<P>IgG (Gamumine N) 0.4g/kg on days 0 and 1, 0.2 g/kg on days 2-4 versus human albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-11 08:32:59 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 12:22:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziegler-1991">
<CHAR_METHODS MODIFIED="2013-09-02 12:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, multi-centre, multi-national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-28 10:01:47 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients,18 years or older, with gram-negative bacteraemia<BR/>24 academic medical centres in USA, Canada and Europe</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:00:03 +0000" MODIFIED_BY="Jane Cracknell">
<P>HA-1A 100 mg single infusion for 15 -20 min versus 3.5 g human serum albumin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-28 10:01:55 +0000" MODIFIED_BY="[Empty name]">
<P>28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-30 04:07:10 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-03 02:26:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aitchison-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>The human anti-lipopolysaccharide specific globulin (LG-1) was administered intramuscularly and not by the intravenous route</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bojic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>This was not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cairo-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>Granulocyte transfusion was the intervention while IVIG was the drug in the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calandra-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:34 +0100" MODIFIED_BY="[Empty name]">
<P>The comparator group was IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christensen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>This was a pilot study where the primary outcome measure was not mortality but on the effect of IVIG on neutrophil kinetics and serum opsonic capacity. The survival of neonates in both the experimental and control groups was 100%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Groote-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure was not mortality; TNF levels were the main variables of interest in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dominioni-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>This is an interim analysis. We have included the full analysis of this trial (<LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Nawawy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:45 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation of treatment was used based on communication with the author</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fischer-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>An animal model was used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:23:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisher-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:23:55 +0100" MODIFIED_BY="[Empty name]">
<P>This was mainly a dose-ranging study with no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 02:26:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisher-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 02:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>Tumour necrosis factor:Fc fusion protein is not a monoclonal antibody</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>This was a meta-analysis of clinical trials of anti -inflammatory agents for sepsis rather than an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gokalp-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation was used and the study included patients with specific infection - Salmonella typhi, not necessarily sepsis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunes-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>This was a quasi-randomized trial. Infants were enrolled consecutively at the first episode of infection and divided into three groups by someone included in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haque-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>This was an RCT comparing standard IVIG to IgM-enriched IVIG. The two treatment groups were also compared to matched controls, but the latter were not part of the randomization scheme</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Homan-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was not mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:39 +0100" MODIFIED_BY="Marissa M. Alejandria" STUDY_ID="STD-Jaspers-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:39 +0100" MODIFIED_BY="Marissa M. Alejandria">
<P>This an interim analysis of 16 patients (9 anti-Lipid A, 6 placebo) with no indication in the 2008 search whether there was a full report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jenson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>This was not an RCT but a meta-analysis on prevention and treatment of neonatal sepsis with IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jesdinsky-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>This was an RCT on the use of IVIG in patients with specifically diffuse fibrinopurulent peritonitis and not necessarily sepsis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>IVIG was used for prophylaxis; outcome was not mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:24:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaul-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>This was not an RCT but an observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 02:25:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kay-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 02:25:02 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label phase 2 trial on an anti-TNF (MAK-195F Knoll); unable to retrieve this unpublished trial presented in a conference</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kett-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome measures were not morbidity nor mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 02:25:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kornelisse-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 02:25:14 +0100" MODIFIED_BY="[Empty name]">
<P>A subset of 49 children in this study were included in the large multi-centre RCT of HA-1A human mAb (<LINK REF="STD-Derkx-1999" TYPE="STUDY">Derkx 1999</LINK>) which has been reviewed in this meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kreymann-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:24 +0100" MODIFIED_BY="[Empty name]">
<P>This is a meta-analysis of polyclonal IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacy-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]">
<P>This was not an RCT but a meta-analysis of prophylaxis or treatment with IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laupland-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:30 +0100" MODIFIED_BY="[Empty name]">
<P>This is a meta-analysis of polyclonal IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marenovic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okimoto-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>There was no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panko-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:42 +0100" MODIFIED_BY="[Empty name]">
<P>This was not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pilz-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>This was an RCT comparing IgM-enriched immunoglobulin to polyvalent IgG as the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 02:26:05 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Pittet-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 02:26:05 +0100" MODIFIED_BY="Jane Cracknell">
<P>Tumour necrosis factor:Fc fusion protein is not a monoclonal antibody</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:54 +0100" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Schedel-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:54 +0100" MODIFIED_BY="Jane Cracknell">
<P>The RCT in this paper written in Russian was originally reported in <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:25:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sidiropolous-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sidiropoulos-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:01 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomii-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>This was not an RCT; there was no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turgeon-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:10 +0100" MODIFIED_BY="[Empty name]">
<P>This is a meta-analysis of polyclonal IVIG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ueda-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:13 +0100" MODIFIED_BY="[Empty name]">
<P>There was no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome is not mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Werdan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>This was a critical appraisal and not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 02:26:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wortel-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 02:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>This was a substudy of a large multi-centre trial on HA-1A by <LINK REF="STD-Ziegler-1991" TYPE="STUDY">Ziegler 1991</LINK>, which has been included in this meta-analysis. It focused mainly on the effect of HA-1A on mortality and cytokine levels of septic patients with endotoxaemia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-02 17:26:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yavuz-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-02 17:26:53 +0100" MODIFIED_BY="[Empty name]">
<P>This was not a randomized controlled trial but rather a retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:26:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeni-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:26:31 +0100" MODIFIED_BY="[Empty name]">
<P>This was not a randomized controlled trial but rather an editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-02-08 22:21:01 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-02-08 22:21:01 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Yildizdas-2005">
<CHAR_METHODS MODIFIED="2008-11-30 02:37:25 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective randomized</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 14:03:34 +0000" MODIFIED_BY="Jane Cracknell">
<P>84 children with sepsis in the paediatric intensive care unit , mean age 32.6, SD 32.1 months, 60 had blood culture proven sepsis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-29 13:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>IVIG 1g/kg/d for 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-29 13:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-08 22:21:01 +0000" MODIFIED_BY="Jane Cracknell">
<P>Duration of hospitalisation (10.8, SD 3.2 days versus 11, SD 3 days)</P>
<P>Mortality rate (8/30 versus 10/30)</P>
<P>Unable to retrieve full text. Unable to determine from the abstract whether randomization and allocation concealment is adequate</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-06-23 01:21:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-03 02:23:41 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-03 02:21:15 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-12 09:41:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION>
<P>"Patients were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-12 09:58:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION>
<P>Randomized blocks of eight kits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:35:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION>
<P>Patients were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 09:28:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Angus-2000">
<DESCRIPTION>
<P>"Patients were entered into the study only after review and approval of entry criteria by a screening authorization committee on call 24 hours a day"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:15:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behre-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:52:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bone-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:09:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION>
<P>Assignment sequence was generated by the National Perinatal Epidemiology Unit in Oxford, UK with balance within random block sizes of 2 to 8; in Australia and New Zealand, randomization list was generated by the National Health and Medical Research Council Clinical Trials Centre in Sydney</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 08:45:35 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Burns-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:17:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Patients were randomly divided into 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:25:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 08:10:09 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:14:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 09:59:39 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:22:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION>
<P>Patients were assigned to receive either placebo of one of 4 dosage regimens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 06:24:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION>
<P>"Patients were prospectively randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:25:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:17:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION>
<P>Independent co-ordinating centre prepared the randomization code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:27:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:28:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION>
<P>Computer-generated randomization code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:28:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:28:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION>
<P>Random list was prepared by a computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 21:19:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haque-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:21:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION>
<P>Computer-generated randomization list stratified by sepsis syndrome versus septic shock by an independent statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 13:55:17 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Just-1986">
<DESCRIPTION>
<P>Unspecified simple randomized allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 08:29:21 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:49:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION>
<P>Patients were randomly allocated to 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 09:10:24 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 12:23:02 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 08:51:10 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 10:33:22 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:31:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Opal-1997">
<DESCRIPTION>
<P>Computer-generated randomization process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 12:38:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:57:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION>
<P>Patients were randomly allocated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Computer-generated randomization list stratified by centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 07:52:24 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION>
<P>Patients were assigned by picking up lots</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:32:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION>
<P>Computer-generated randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION>
<P>Random number allocation was done at a co-ordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:26:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION>
<P>Computer-generated randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:21:15 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION>
<P>Drug vials were randomly selected in groups of 50 by institution, to contain either IVIG or albumin. Each enrolled patient received the next vial of drug available at the institution The pharmacy reconstituted the drug vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:34:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION>
<P>Serial random numbers were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 15:04:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 13:16:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 10:24:09 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-03 02:23:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:28:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:31:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:35:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 09:28:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Angus-2000">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:15:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behre-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 13:53:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bone-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-09 22:09:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION>
<P>Infants were randomized in blinded fashion. In Europe and Argentina, neonatal staff opened the next sequentially numbered pack, which was stored in the neonatal unit. In Australia and New Zealand, hospital pharmacy was contacted for the assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:14:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1991">
<DESCRIPTION>
<P>Sealed, opaque and sequentially numbered envelopes, based on the review of Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>) who communicated with Burns</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:16:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:26:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION>
<P>Pharmacist was the only individual aware of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-19 08:22:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION>
<P>Centralized randomization based on the review of Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>) who communicated with Norrby-Teglund for Darenberg</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 13:51:15 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION>
<P>Sealed envelopes</P>
<P>Assessed as unclear allocation concealment by Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>); sealed envelopes but unknown whether opaque and sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION>
<P>Independent co-ordinating centre created a treatment allocation code. Full randomization codes remained concealed until completion of the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:22:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:23:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:17:02 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION>
<P>Allocation concealment not stated. Based on the communication of Ohlsson and Lacy (<LINK REF="REF-Ohlsson-2013" TYPE="REFERENCE">Ohlsson 2013</LINK>) with Erdem, allocation was performed on an "alternating basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:27:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION>
<P>Treatment assigned by a telephone randomization system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:27:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION>
<P>Central, computerized telephone randomization system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 11:16:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:28:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION>
<P>Code was known only to the pharmacist and statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-19 08:23:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION>
<P>Randomized envelope technique</P>
<P>Assessed as unclear allocation concealment by Pildal and Goetzsche (randomized envelope technique but unknown whether envelopes were opaque and sequentially numbered) (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 21:19:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haque-1988">
<DESCRIPTION>
<P>Sealed envelope, unclear if opaque and sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:29:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION>
<P>Sealed envelopes with a unique patient number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 13:55:20 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Just-1986">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 09:53:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION>
<P>Computer-generated randomization sequence kept centralized apart from clinical centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:46:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:30:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION>
<P>Sealed, opaque, sequentially numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:22:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION>
<P>Sealed, opaque sequentially-numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 08:57:53 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION>
<P>Participants were registered with central committee and allocated by telephone or fax</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:20:17 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION>
<P>Independent randomization centre prepared the treatment allocation schedule. The randomization centre labelled the study material with sequential vial numbers according to the allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 09:43:19 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Opal-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-27 09:23:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION>
<P>Computer-generated sequence; randomization and assignment took place in the pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 14:58:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:31:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Central randomization process (contact by telephone to a central office)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-11 15:03:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 06:27:37 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:32:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION>
<P>Sealed, numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-31 10:26:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION>
<P>Open table of random numbers at allocation site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-13 06:55:53 +0100" MODIFIED_BY="Marissa M. Alejandria" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-30 08:34:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION>
<P>Identity of the medication that each patient received was marked on a card and a copy was forwarded as part of the confidential study documents to Troponwerke, Cologne</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-31 10:17:37 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION>
<P>Based on communication of Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>) - inadequate allocation concealment (alternation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-14 13:13:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:23:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION>
<P>Independent co-ordinating centre created the treatment allocation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-09-03 02:18:41 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-03-30 03:16:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION>
<P>Placebo-controlled (human albumin)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-03-30 03:17:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION>
<P>Placebo-controlled (human serum albumin)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-03-30 03:17:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION>
<P>Placebo-controlled (human serum albumin), blinded clinical evaluation committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 09:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angus-2000">
<DESCRIPTION>
<P>Placebo-controlled, identical in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-03-30 03:12:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behre-1995">
<DESCRIPTION>
<P>Placebo-controlled, 5% human albumin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 09:36:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bone-1995">
<DESCRIPTION>
<P>Identical placebo, persons administering therapy were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-08-08 16:28:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION>
<P>Identical placebo and IVIG prepared separately by pharmacists; syringes and tubing were masked with yellow tape</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 14:18:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-27 09:16:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 09:47:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION>
<P>Placebo-controlled; independent safety and efficacy committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 14:17:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 14:07:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 09:57:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION>
<P>Placebo-controlled; independent safety and efficacy monitoring committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 10:06:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION>
<P>Placebo-controlled, blinded clinical evaluation committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-03 02:12:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 21:20:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-03 02:13:19 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 10:20:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION>
<P>Placebo-controlled, independent safety and efficacy monitoring committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 10:57:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION>
<P>Placebo-controlled; all participating individuals except the pharmacist and statistician were blinded to the treatment patients received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 11:22:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 14:02:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-03 02:14:55 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Haque-1988">
<DESCRIPTION>
<P>IVIG and dextrose were dispensed in similar, unmarked bottles. The physician treating the infants was not aware of the contents. Assessed as non-blind by Pildal and Goetzsche (<LINK REF="REF-Pildal-2004" TYPE="REFERENCE">Pildal 2004</LINK>); pentaglobin is opaque while dextrose is not; no precautions to conceal this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:58:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:57:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Just-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 11:39:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:55:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:41:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 12:34:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-28 09:56:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Opal-1997">
<DESCRIPTION>
<P>Identically packaged placebo, blinded clinical evaluation committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 12:39:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-03 02:18:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:37:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 21:11:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 14:12:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-27 09:26:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION>
<P>Non-identical vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:31:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-27 09:27:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION>
<P>Placebo-controlled, identical vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:19:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 13:16:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-27 09:28:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION>
<P>Placebo-controlled, identical bottles</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-03-14 12:54:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-09-03 02:22:20 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-18 22:07:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION>
<P>intention-to-treat analysis not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-30 04:35:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-18 22:08:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Angus-2000">
<DESCRIPTION>
<P>Patients lost to follow up and with missing data were included in the denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:11:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behre-1995">
<DESCRIPTION>
<P>Interim analysis; no dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-30 04:36:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bone-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:49:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:50:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1991">
<DESCRIPTION>
<P>29 patients completed the full 9 days of follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-03 02:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Complete follow up; no dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:51:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:51:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:16:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:51:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:37:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:38:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION>
<P>Analysis was not intention to treat but ITT data could be derived (4 patients died - 2 IVIG treated, 2 control)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:17:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION>
<P>Complete follow up; no dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:38:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:39:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:39:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION>
<P>ITT data can be derived</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:39:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:40:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:18:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haque-1988">
<DESCRIPTION>
<P>Complete follow up; no dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:40:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Just-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:40:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:41:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:41:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:41:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-30 08:14:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION>
<P>ITT data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:42:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Opal-1997">
<DESCRIPTION>
<P>906 patients were enrolled at the time the study was terminated, complete information was available only for 696 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:42:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:43:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-19 22:43:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION>
<P>Complete follow up; no dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-03 02:19:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION>
<P>Of the 14 patients excluded from the final analysis, 7 patients received IVIG and no patient died. in the group of 7 patients who did not receive IVIG, 2 died</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-20 05:14:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION>
<P>Seven neonates eligible to enter the trial but could not afford the subsidized cost of the IVIG were enrolled into a separate control group and one baby who received only one dose of IVIG was excluded from the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-20 05:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-20 05:15:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-03 02:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-03-23 03:58:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-02-20 05:15:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-09-02 12:23:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION>
<P>Only 37% analysed from 543 patients given HA-1A for the primary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-09-03 02:23:27 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:56:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:57:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:58:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:18:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angus-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:13:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behre-1995">
<DESCRIPTION>
<P>Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:19:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bone-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:20:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:23:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1991">
<DESCRIPTION>
<P>Adverse events related to IVIG were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:28:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:22:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:23:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:29:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:29:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:30:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:31:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:32:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:33:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:34:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:35:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:36:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:37:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:38:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haque-1988">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:39:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:43:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Just-1986">
<DESCRIPTION>
<P>Only the 29 patients with definite sepsis out of 104 ICU patients were included in this meta-analysis</P>
<P>Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:44:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:47:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 05:28:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:48:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:50:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:52:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Opal-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:53:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:58:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Adverse effects were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:00:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:01:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:02:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:03:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:03:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:04:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 23:15:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:23:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:07:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-09-03 02:23:06 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:56:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:57:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abraham-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-29 23:58:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albertson-2003">
<DESCRIPTION>
<P>Higher percentage of chronic renal failure in the MAB-T88 group (5.6% versus 3.1%) and shock in the placebo group (85.8% versus 80.3%), but the number of patients requiring vasopressors was equal (49.2% versus 48.4%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Angus-2000">
<DESCRIPTION>
<P>2 planned interim analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:12:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behre-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:19:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bone-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:20:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brocklehurst-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:21:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:28:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>Patients with negative blood cultures were excluded from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:22:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:23:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Darenberg-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:29:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Simone-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:29:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derkx-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:12:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhainaut-1995">
<DESCRIPTION>
<P>Placebo group had a higher mean age and more patients with non-fatal underlying disease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:31:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominioni-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:33:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Erdem-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:34:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:34:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisher-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:35:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:36:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenman-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:37:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grundmann-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:38:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haque-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:39:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hentrich-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:15:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Just-1986">
<DESCRIPTION>
<P>There were more patients in the IVIG group with post-operative complications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:44:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karatzas-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:16:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lachman-1984">
<DESCRIPTION>
<P>There were more septic abortions and surgical interventions in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 05:28:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindquist-1981">
<DESCRIPTION>
<P>Critically ill patients unable to give informed consent were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:48:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:49:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masaoka-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCloskey-1994">
<DESCRIPTION>
<P>Baseline characteristics of treatment and control group not given</P>
<P>Trial stopped at the first interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opal-1997">
<DESCRIPTION>
<P>There were more patients with DIC in the placebo group but subgroup analysis showed no significant difference in mortality rate.</P>
<P>Interim analysis was done after about half of the target population had completed the trial. The study was terminated by the sponsor after the Safety and Efficacy Monitoring Board determined that the likelihood of reaching a statistically significant difference in outcome for the primary objective was low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Panacek-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 03:53:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reinhart-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:19:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>After blind interim analysis of the data from 56 patients, enrolment was stopped because a significant difference in mortality rate in a subgroup analysis of evaluable patients with appropriate antibiotic therapy was documented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:00:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samatha-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:19:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schedel-1991">
<DESCRIPTION>
<P>Multiple interim analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:20:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenoi-1999">
<DESCRIPTION>
<P>Placebo group had a higher number of babies with positive cultures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:03:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tugrul-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:04:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Werdan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 02:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wesoly-1990">
<DESCRIPTION>
<P>Control group had a higher mean age, fewer patients on antibiotics and fewer patients on artificial ventilation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-30 04:06:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yakut-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 12:23:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ziegler-1991">
<DESCRIPTION>
<P>Baseline characteristics not given for the 543 patients initially randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-09-03 02:38:20 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-09-03 02:36:12 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-09-03 02:29:11 +0100" MODIFIED_BY="Grade Profiler">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TD COLSPAN="6">
<P>
<B>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> neonates with sepsis, severe sepsis and septic shock<BR/>
<B>Intervention:</B> polyclonal IVIG<BR/>
<B>Comparison: </B>placebo or no intervention</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or no intervention</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Polyclonal IVIG </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality, neonates, standard polyclonal IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.92 to 1.08)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3667<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>380 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>380 per 1000</B>
<BR/>(349 to 410)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>280 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>280 per 1000</B>
<BR/>(258 to 302)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality, neonates, IgM-enriched polyclonal IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.57 </B>
<BR/>(0.31 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>164<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>274 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>156 per 1000</B>
<BR/>(85 to 285)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>267 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>152 per 1000</B>
<BR/>(83 to 278)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Low risk of bias neonate studies, mortality all-cause - standard IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.93 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3561<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>387 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>391 per 1000</B>
<BR/>(360 to 421)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>294 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>297 per 1000</B>
<BR/>(273 to 320)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Two studies are of low quality (Chen 1996; Shenoi 1999)<BR/>
<SUP>2</SUP> Two studies are of low quality (Erdem; Samatha)<BR/>
<SUP>3</SUP> Wide confidence intervals, small studies</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-09-03 02:36:23 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-09-03 02:30:41 +0100" MODIFIED_BY="Grade Profiler">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</TITLE>
<TABLE COLS="6" ROWS="27">
<TR>
<TD COLSPAN="6">
<P>
<B>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> adult patients with sepsis, severe sepsis and septic shock<BR/>
<B>Intervention:</B> polyclonal IVIG<BR/>
<B>Comparison: </B>placebo or no intervention</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or no intervention</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Polyclonal IVIG </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality, adults, standard polyclonal IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.81 </B>
<BR/>(0.7 to 0.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1430<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>365 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>296 per 1000</B>
<BR/>(256 to 340)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>423 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>343 per 1000</B>
<BR/>(296 to 393)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality, adults, IgM-enriched polyclonal IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.51 to 0.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>528<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>375 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>247 per 1000</B>
<BR/>(191 to 318)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>412 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
<BR/>(210 to 350)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Low risk of bias adult studies, by type of polyclonal IVIG, mortality all-cause</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.81 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>945<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>354 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>344 per 1000</B>
<BR/>(287 to 408)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>353 per 1000</B>
<BR/>(295 to 419)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Low risk of bias adult studies, mortality all-cause - standard IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.02 </B>
<BR/>(0.84 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>683<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>367 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>374 per 1000</B>
<BR/>(308 to 455)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>371 per 1000</B>
<BR/>(306 to 451)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Low risk of bias adult studies, mortality all-cause - IgM-enriched IVIG</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.56 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>262<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>323 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>265 per 1000</B>
<BR/>(181 to 384)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>382 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>313 per 1000</B>
<BR/>(214 to 455)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Only 3 studies on standard polyclonal IVIG are of high quality (Burns 1991; Darenberg 2003; Werdan 2007)<BR/>
<SUP>2</SUP> Only 2 studies on IgM-enriched IVIG are of high quality (Hentrich 2006; Rodriguez 2005)<BR/>
<SUP>3</SUP> There are only 2 studies, summary effect with wide confidence intervals</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-09-03 02:36:01 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-02-07 14:31:09 +0000" MODIFIED_BY="Grade Profiler">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</TITLE>
<TABLE COLS="6" ROWS="35">
<TR>
<TD COLSPAN="6">
<P>
<B>Anti-endotoxins compared to placebo for sepsis, severe sepsis, septic shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> patients with sepsis, severe sepsis, septic shock<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention: </B>anti-endotoxins<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anti-endotoxins </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxins versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.79 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4676<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>369 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>340 per 1000</B>
<BR/>(292 to 391)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>406 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>374 per 1000</B>
<BR/>(321 to 430)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxin E5 versus placebo, all- cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.88 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1975<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>385 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>377 per 1000</B>
<BR/>(338 to 423)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>406 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>398 per 1000</B>
<BR/>(357 to 447)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxin - HA-1A versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.8 </B>
<BR/>(0.54 to 1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2668<BR/>(3 studies<SUP>4</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>356 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>285 per 1000</B>
<BR/>(192 to 428)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>356 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>285 per 1000</B>
<BR/>(192 to 427)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxins Anti-LPS versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.15 </B>
<BR/>(0.02 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>33<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>474 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(9 to 502)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>474 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(9 to 502)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sensitivity analysis by quality, anti-endotoxin, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.94 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4443<BR/>(6 studies<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>367 per 1000</B>
<BR/>(342 to 397)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>380 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>384 per 1000</B>
<BR/>(357 to 414)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxin, all-cause mortality - low risk of bias studies</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.42 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>269<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>275 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>184 per 1000</B>
<BR/>(116 to 289)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>275 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>184 per 1000</B>
<BR/>(115 to 289)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-endotoxin, all-cause mortality - unclear risk of bias</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.95 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4174<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>370 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>381 per 1000</B>
<BR/>(351 to 410)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>403 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>415 per 1000</B>
<BR/>(383 to 447)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across the included studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Five studies with unclear allocation concealment<BR/>
<SUP>2</SUP> There is a significant subgroup difference<BR/>
<SUP>3</SUP> Unclear allocation concealment<BR/>
<SUP>4</SUP> Two studies with unclear allocation concealment<BR/>
<SUP>5</SUP> Significant heterogeneity of the three trials<BR/>
<SUP>6</SUP> One trial only, with wide confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-09-03 02:38:20 +0100" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-02-07 14:33:39 +0000" MODIFIED_BY="Grade Profiler">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</TITLE>
<TABLE COLS="6" ROWS="31">
<TR>
<TD COLSPAN="6">
<P>
<B>Anti-cytokines compared to placebo for sepsis, severe sepsis, septic shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> patients with sepsis, severe sepsis, septic shock<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> anti-cytokines<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anti-cytokines </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-cytokines versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.86 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7893<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>377 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>347 per 1000</B>
<BR/>(324 to 366)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 per 1000</B>
<BR/>(340 to 383)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anticytokine - anti-TNF-alpha versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.87 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>6200<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>382 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>352 per 1000</B>
<BR/>(333 to 378)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>405 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>373 per 1000</B>
<BR/>(352 to 401)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-cytokines - human interleukin-1receptor antagonist versus placebo, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.76 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1693<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>355 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>313 per 1000</B>
<BR/>(270 to 359)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>320 per 1000</B>
<BR/>(277 to 368)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sensitivity analysis by quality, anti-cytokine, all-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.86 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7752<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>376 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>342 per 1000</B>
<BR/>(323 to 365)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>331 per 1000</B>
<BR/>(313 to 353)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-cytokine, all-cause mortality - low risk of bias studies</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.86 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>5065<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>388 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>357 per 1000</B>
<BR/>(334 to 384)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 per 1000</B>
<BR/>(340 to 391)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Anti-cytokine, all-cause mortality - uncertain risk of bias</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.8 to 1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2687<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>347 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>309 per 1000</B>
<BR/>(278 to 347)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>351 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>312 per 1000</B>
<BR/>(281 to 351)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Six studies with unclear allocation concealment<BR/>
<SUP>2</SUP> Three studies with unclear allocation concealment<BR/>
<SUP>3</SUP> Unclear allocation concealment 4 studies</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-04-12 09:42:56 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-03-31 21:13:07 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>IVIG versus placebo or no intervention</NAME>
<DICH_OUTCOME CHI2="64.69810514532475" CI_END="0.9642926226562042" CI_START="0.8822415108456956" CI_STUDY="95" CI_TOTAL="95" DF="41" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9223551270034595" ESTIMABLE="YES" EVENTS_1="3372" EVENTS_2="3222" I2="36.62874684211247" I2_Q="75.09723052112692" ID="CMP-001.01" LOG_CI_END="-0.01579115580618774" LOG_CI_START="-0.05441251184088411" LOG_EFFECT_SIZE="-0.03510183382353592" METHOD="MH" MODIFIED="2012-08-08 17:38:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010562170284475592" P_Q="0.007224386651138004" P_Z="3.6704721001396933E-4" Q="12.04685287130465" RANDOM="YES" SCALE="45.32" SORT_BY="STUDY" STUDIES="42" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.010256128360857006" TOTALS="SUB" TOTAL_1="9732" TOTAL_2="8626" WEIGHT="400.0" Z="3.5627091924806487">
<NAME>All-cause mortality by type of IVIG, random effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.938018878984778" CI_END="0.8355934783256106" CI_START="0.5807689619027679" DF="16" EFFECT_SIZE="0.6966252629498071" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="347" I2="35.84093396655831" ID="CMP-001.01.01" LOG_CI_END="-0.07800495827795807" LOG_CI_START="-0.2359966017338375" LOG_EFFECT_SIZE="-0.1570007800058978" MODIFIED="2009-10-05 15:29:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07092564993901462" P_Z="9.80595908885725E-5" STUDIES="17" TAU2="0.04211237975339039" TOTAL_1="1015" TOTAL_2="943" WEIGHT="100.0" Z="3.8953436729353133">
<NAME>Polyclonal IVIG, adults</NAME>
<DICH_DATA CI_END="1.34641588167828" CI_START="0.3235255955663814" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.12917922572813692" LOG_CI_START="-0.4900913546443995" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="1" O_E="0.0" SE="0.3637626043496395" STUDY_ID="STD-Behre-1995" TOTAL_1="30" TOTAL_2="22" VAR="0.13232323232323234" WEIGHT="4.937513362756869"/>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="2" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="1.6936869754050279"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" ORDER="4" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="0.7821245852551894"/>
<DICH_DATA CI_END="1.3879016937774824" CI_START="0.43586536014554794" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.14235870577160212" LOG_CI_START="-0.36064764462173815" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="5" O_E="0.0" SE="0.29546842014263947" STUDY_ID="STD-De-Simone-1988" TOTAL_1="12" TOTAL_2="12" VAR="0.08730158730158731" WEIGHT="6.65521801988428"/>
<DICH_DATA CI_END="0.802984194413105" CI_START="0.3675499459107326" EFFECT_SIZE="0.5432649420160571" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.09529300309831536" LOG_CI_START="-0.4346836368258802" LOG_EFFECT_SIZE="-0.26498831996209776" ORDER="6" O_E="0.0" SE="0.1993597382623034" STUDY_ID="STD-Dominioni-1996" TOTAL_1="59" TOTAL_2="58" VAR="0.03974430524001412" WEIGHT="10.521781643593245"/>
<DICH_DATA CI_END="1.0285780969192506" CI_START="0.5091677901111401" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.012237271989362255" LOG_CI_START="-0.2931390775624573" LOG_EFFECT_SIZE="-0.14045090278654748" ORDER="8" O_E="0.0" SE="0.17937957936404844" STUDY_ID="STD-Grundmann-1988" TOTAL_1="24" TOTAL_2="22" VAR="0.03217703349282296" WEIGHT="11.593551866058101"/>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" ORDER="10" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="9.141653780856407"/>
<DICH_DATA CI_END="1.7009784942522388" CI_START="0.39579647297179105" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23069882279150838" LOG_CI_START="-0.4025280802046948" LOG_EFFECT_SIZE="-0.08591462870659325" MODIFIED="2008-09-13 06:49:25 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="11" O_E="0.0" SE="0.3719606173436925" STUDY_ID="STD-Just-1986" TOTAL_1="13" TOTAL_2="16" VAR="0.13835470085470086" WEIGHT="4.772494588303229"/>
<DICH_DATA CI_END="1.1822694599672872" CI_START="0.27618967020761315" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.07271647116439893" LOG_CI_START="-0.5587925685369879" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2009-10-05 15:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.37095153594075697" STUDY_ID="STD-Karatzas-2002" TOTAL_1="34" TOTAL_2="34" VAR="0.1376050420168067" WEIGHT="4.792402189423272"/>
<DICH_DATA CI_END="64.14118825764045" CI_START="0.11523954830411988" EFFECT_SIZE="2.71875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8071370012574697" LOG_CI_START="-0.9383984526600444" LOG_EFFECT_SIZE="0.4343692742987125" ORDER="13" O_E="0.0" SE="1.6127411162508312" STUDY_ID="STD-Lindquist-1981" TOTAL_1="31" TOTAL_2="28" VAR="2.600933908045977" WEIGHT="0.32586571394710945"/>
<DICH_DATA CI_END="0.9203155854314344" CI_START="0.4055968592076615" EFFECT_SIZE="0.6109640831758034" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="46" LOG_CI_END="-0.03606322318744081" LOG_CI_START="-0.3919054166778336" LOG_EFFECT_SIZE="-0.2139843199326372" MODIFIED="2008-09-13 16:43:13 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="15" O_E="0.0" SE="0.20902346590352275" STUDY_ID="STD-Masaoka-2000" TOTAL_1="230" TOTAL_2="202" VAR="0.043690809298321136" WEIGHT="10.037833967335718"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" ORDER="16" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="4.992463643491685"/>
<DICH_DATA CI_END="0.7827420455370592" CI_START="0.044754242705140404" EFFECT_SIZE="0.18716577540106952" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10638133712135041" LOG_CI_START="-1.349165787251096" LOG_EFFECT_SIZE="-0.7277735621862234" MODIFIED="2009-03-22 12:34:37 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.730017737888457" STUDY_ID="STD-Schedel-1991" TOTAL_1="34" TOTAL_2="35" VAR="0.53292589763178" WEIGHT="1.4977753645990757"/>
<DICH_DATA CI_END="1.8942671028263436" CI_START="0.26934115092396554" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27744121706681374" LOG_CI_START="-0.5696972884232897" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="20" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Tugrul-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.24761904761904763" WEIGHT="2.9726777429010487"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" MODIFIED="2008-06-24 22:43:53 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="16.4106590878382"/>
<DICH_DATA CI_END="1.0379469340474572" CI_START="0.32544001520134536" EFFECT_SIZE="0.5811965811965812" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.016175150391546773" LOG_CI_START="-0.48752904847139733" LOG_EFFECT_SIZE="-0.23567694903992528" ORDER="23" O_E="0.0" SE="0.29587833978809036" STUDY_ID="STD-Wesoly-1990" TOTAL_1="18" TOTAL_2="17" VAR="0.08754399195575667" WEIGHT="6.642775470387749"/>
<DICH_DATA CI_END="0.952349284331303" CI_START="0.09550582120988776" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.021203740232210368" LOG_CI_START="-1.0199701567692951" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="24" O_E="0.0" SE="0.5866803370473809" STUDY_ID="STD-Yakut-1998" TOTAL_1="21" TOTAL_2="19" VAR="0.3441938178780284" WEIGHT="2.229521997963797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.252952797633033" CI_END="1.0735672745031029" CI_START="0.9119684916518754" DF="7" EFFECT_SIZE="0.9894743695596211" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="715" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.03082926444997528" LOG_CI_START="-0.040020166208984964" LOG_EFFECT_SIZE="-0.00459545087950484" MODIFIED="2012-08-08 17:38:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6291246207534988" P_Z="0.7992984052117754" STUDIES="8" TAU2="0.0" TOTAL_1="1925" TOTAL_2="1906" WEIGHT="100.00000000000001" Z="0.2542552038253624">
<NAME>Polyclonal IVIG, neonates</NAME>
<DICH_DATA CI_END="1.0852452498970298" CI_START="0.9194106027857412" EFFECT_SIZE="0.9988923812794802" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="677" LOG_CI_END="0.03552789361414855" LOG_CI_START="-0.036490492205473325" LOG_EFFECT_SIZE="-4.8129929566238035E-4" MODIFIED="2012-08-08 17:38:39 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.042303956327205204" STUDY_ID="STD-Brocklehurst-2011" TOTAL_1="1759" TOTAL_2="1734" VAR="0.0017896247209340855" WEIGHT="96.78007694542295"/>
<DICH_DATA CI_END="20.81663045077274" CI_START="0.19215405727930934" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3184104324239632" LOG_CI_START="-0.7163504410960009" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="189" O_E="0.0" SE="1.1952286093343936" STUDY_ID="STD-Chen-1996" TOTAL_1="28" TOTAL_2="28" VAR="1.4285714285714284" WEIGHT="0.12124001273680232"/>
<DICH_DATA CI_END="1.863388515769675" CI_START="0.34346031146148137" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.27030341456536977" LOG_CI_START="-0.4641234405814825" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="190" O_E="0.0" SE="0.4314059701848262" STUDY_ID="STD-Erdem-1993" TOTAL_1="20" TOTAL_2="24" VAR="0.18611111111111114" WEIGHT="0.9306269634381412"/>
<DICH_DATA CI_END="1.3019564567260682" CI_START="0.021335412282242117" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11459645971618479" LOG_CI_START="-1.670898960483472" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="191" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Haque-1988" TOTAL_1="30" TOTAL_2="30" VAR="1.0999999999999999" WEIGHT="0.15745456199584718"/>
<DICH_DATA CI_END="6.030568663480067" CI_START="0.1488262509376406" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7803582666620361" LOG_CI_START="-0.8273204583610819" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="192" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" VAR="0.8918128654970761" WEIGHT="0.19421116794373017"/>
<DICH_DATA CI_END="1.6924505528238085" CI_START="0.23080437968970652" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.22851598905616716" LOG_CI_START="-0.6367559543680167" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="193" O_E="0.0" SE="0.5082650227325636" STUDY_ID="STD-Samatha-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.25833333333333336" WEIGHT="0.6704516833371555"/>
<DICH_DATA CI_END="2.4325889590333376" CI_START="0.4110846578853914" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38606873124701274" LOG_CI_START="-0.38606873124701274" LOG_EFFECT_SIZE="0.0" ORDER="194" O_E="0.0" SE="0.4535573676110726" STUDY_ID="STD-Shenoi-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.20571428571428568" WEIGHT="0.8419445328944606"/>
<DICH_DATA CI_END="2.1324645428702045" CI_START="0.11063178899537662" EFFECT_SIZE="0.4857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32888181875452704" LOG_CI_START="-0.9561200646985305" LOG_EFFECT_SIZE="-0.31361912297200173" MODIFIED="2009-03-22 12:41:18 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.7548164672022357" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" VAR="0.5697478991596638" WEIGHT="0.30399413223092026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.116931223003668" CI_END="1.0638003865790167" CI_START="0.7902822482964237" DF="7" EFFECT_SIZE="0.9168983374640124" ESTIMABLE="YES" EVENTS_1="860" EVENTS_2="854" I2="56.567414086815035" ID="CMP-001.01.03" LOG_CI_END="0.026860143804737453" LOG_CI_START="-0.10221777328473307" LOG_EFFECT_SIZE="-0.03767881473999781" MODIFIED="2009-03-15 00:52:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.024069286585710836" P_Z="0.252517315930301" STUDIES="8" TAU2="0.01962337645902436" TOTAL_1="2363" TOTAL_2="2313" WEIGHT="99.99999999999999" Z="1.1442564543300469">
<NAME>Anti-endotoxins</NAME>
<DICH_DATA CI_END="1.1071607470677283" CI_START="0.8244269757727571" EFFECT_SIZE="0.9553916403231472" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="219" LOG_CI_END="0.04421068004433363" LOG_CI_START="-0.08384780626984648" LOG_EFFECT_SIZE="-0.019818563112756402" ORDER="196" O_E="0.0" SE="0.07522218876068007" STUDY_ID="STD-Angus-2000" TOTAL_1="546" TOTAL_2="544" VAR="0.005658377681947383" WEIGHT="22.739028066725425"/>
<DICH_DATA CI_END="1.3179373374606722" CI_START="0.8875225274738863" EFFECT_SIZE="1.0815262718932444" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="109" LOG_CI_END="0.11989476181944855" LOG_CI_START="-0.05182061468590067" LOG_EFFECT_SIZE="0.03403707356677393" ORDER="197" O_E="0.0" SE="0.10086646216406454" STUDY_ID="STD-Bone-1995" TOTAL_1="264" TOTAL_2="266" VAR="0.010174043189494664" WEIGHT="19.293030194182624"/>
<DICH_DATA CI_END="1.045168063874159" CI_START="0.42353054853189753" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" ORDER="200" O_E="0.0" SE="0.23043977855938225" STUDY_ID="STD-Derkx-1999" TOTAL_1="131" TOTAL_2="138" VAR="0.053102491542497125" WEIGHT="7.904787289380735"/>
<DICH_DATA CI_END="1.6522614078856277" CI_START="0.34044249736476156" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.21807875909878463" LOG_CI_START="-0.4679562323153845" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="198" O_E="0.0" SE="0.40298034988465925" STUDY_ID="STD-Greenberg-1992" TOTAL_1="26" TOTAL_2="13" VAR="0.1623931623931624" WEIGHT="3.1584081348479147"/>
<DICH_DATA CI_END="1.3163553531431313" CI_START="0.6211244212890562" EFFECT_SIZE="0.9042236763831053" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" LOG_CI_END="0.1193731438955111" LOG_CI_START="-0.20682139488490803" LOG_EFFECT_SIZE="-0.04372412549469844" ORDER="199" O_E="0.0" SE="0.19160828676862654" STUDY_ID="STD-Greenman-1991" TOTAL_1="164" TOTAL_2="152" VAR="0.03671373555840822" WEIGHT="10.204330616197018"/>
<DICH_DATA CI_END="1.056952622264477" CI_START="0.021513476234119873" EFFECT_SIZE="0.15079365079365079" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="0.02405552056168233" LOG_CI_START="-1.66728940889115" LOG_EFFECT_SIZE="-0.821616944164734" ORDER="203" O_E="0.0" SE="0.9935043838530212" STUDY_ID="STD-Lachman-1984" TOTAL_1="14" TOTAL_2="19" VAR="0.9870509607351714" WEIGHT="0.571070996594511"/>
<DICH_DATA CI_END="1.2008673000111854" CI_START="0.9651795749629176" EFFECT_SIZE="1.0765930476329775" ESTIMABLE="YES" EVENTS_1="427" EVENTS_2="387" LOG_CI_END="0.07949501901241571" LOG_CI_START="-0.015391877163951137" LOG_EFFECT_SIZE="0.03205157092423231" ORDER="201" O_E="0.0" SE="0.05573703251170915" STUDY_ID="STD-McCloskey-1994" TOTAL_1="1113" TOTAL_2="1086" VAR="0.0031066167932113234" WEIGHT="25.29180324024354"/>
<DICH_DATA CI_END="0.9206318163593459" CI_START="0.4496323620615442" EFFECT_SIZE="0.6433862433862434" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="45" LOG_CI_END="-0.035914020284396116" LOG_CI_START="-0.3471424381886598" LOG_EFFECT_SIZE="-0.191528229236528" ORDER="202" O_E="0.0" SE="0.1828171132824797" STUDY_ID="STD-Ziegler-1991" TOTAL_1="105" TOTAL_2="95" VAR="0.03342209690893902" WEIGHT="10.837541461828227"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.016983877561417" CI_END="0.9728648211011376" CI_START="0.8632633659997789" DF="8" EFFECT_SIZE="0.9164270620876169" ESTIMABLE="YES" EVENTS_1="1518" EVENTS_2="1306" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.011947500459640615" LOG_CI_START="-0.06385668869815964" LOG_EFFECT_SIZE="-0.0379020945789001" MODIFIED="2009-03-15 00:55:49 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7557594109526872" P_Z="0.004207368558561233" STUDIES="9" TAU2="0.0" TOTAL_1="4429" TOTAL_2="3464" WEIGHT="100.0" Z="2.8621807750848567">
<NAME>Anti-cytokines</NAME>
<DICH_DATA CI_END="1.113041319203701" CI_START="0.7559083030491796" EFFECT_SIZE="0.9172552397358599" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="108" LOG_CI_END="0.04651128685859071" LOG_CI_START="-0.12153088425419555" LOG_EFFECT_SIZE="-0.037509798697802424" ORDER="204" O_E="0.0" SE="0.09870880313381312" STUDY_ID="STD-Abraham-1995" TOTAL_1="645" TOTAL_2="326" VAR="0.009743427816109877" WEIGHT="9.542274524785933"/>
<DICH_DATA CI_END="1.048284143601728" CI_START="0.8457281521994383" EFFECT_SIZE="0.9415749634247186" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="398" LOG_CI_END="0.020479016686226436" LOG_CI_START="-0.0727692125784469" LOG_EFFECT_SIZE="-0.026145097946110227" ORDER="205" O_E="0.0" SE="0.054774471456248336" STUDY_ID="STD-Abraham-1998" TOTAL_1="948" TOTAL_2="930" VAR="0.0030002427233113637" WEIGHT="30.988980428603497"/>
<DICH_DATA CI_END="1.185527453886834" CI_START="0.7515949102759769" EFFECT_SIZE="0.9439472444653791" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="66" LOG_CI_END="0.07391161561787904" LOG_CI_START="-0.12401616955946045" LOG_EFFECT_SIZE="-0.02505227697079071" ORDER="206" O_E="0.0" SE="0.1162637607715072" STUDY_ID="STD-Cohen-1996" TOTAL_1="386" TOTAL_2="167" VAR="0.013517262068734255" WEIGHT="6.878202298733856"/>
<DICH_DATA CI_END="1.8471494517265552" CI_START="0.5874291565472495" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.26650203536137207" LOG_CI_START="-0.2310445014405088" LOG_EFFECT_SIZE="0.017728766960431616" ORDER="207" O_E="0.0" SE="0.29226129861250305" STUDY_ID="STD-Dhainaut-1995" TOTAL_1="32" TOTAL_2="10" VAR="0.08541666666666667" WEIGHT="1.0884815184439716"/>
<DICH_DATA CI_END="0.9438377182459127" CI_START="0.284111063459301" EFFECT_SIZE="0.5178365937859609" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="-0.02510267109271768" LOG_CI_START="-0.5465118542539278" LOG_EFFECT_SIZE="-0.28580726267332274" ORDER="210" O_E="0.0" SE="0.3062783352059776" STUDY_ID="STD-Fisher-1994a" TOTAL_1="79" TOTAL_2="25" VAR="0.09380641861654518" WEIGHT="0.9911311443816007"/>
<DICH_DATA CI_END="1.0834483890228104" CI_START="0.7257330229524048" EFFECT_SIZE="0.8867323579177864" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="102" LOG_CI_END="0.03480822816487772" LOG_CI_START="-0.13922311481330904" LOG_EFFECT_SIZE="-0.05220744332421568" ORDER="211" O_E="0.0" SE="0.10222687233442822" STUDY_ID="STD-Fisher-1994b" TOTAL_1="591" TOTAL_2="302" VAR="0.010450333427279485" WEIGHT="8.8967939330104"/>
<DICH_DATA CI_END="1.1158232745383854" CI_START="0.7423275539791412" EFFECT_SIZE="0.9101133786848072" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="126" LOG_CI_END="0.0475954159542297" LOG_CI_START="-0.12940441885051662" LOG_EFFECT_SIZE="-0.040904501448143456" ORDER="212" O_E="0.0" SE="0.10397057912762085" STUDY_ID="STD-Opal-1997" TOTAL_1="350" TOTAL_2="346" VAR="0.010809881324132868" WEIGHT="8.600877312703894"/>
<DICH_DATA CI_END="0.9998475731832024" CI_START="0.8080208647661402" EFFECT_SIZE="0.8988312971396901" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="477" LOG_CI_END="-6.620317112678931E-5" LOG_CI_START="-0.0925774247009" LOG_EFFECT_SIZE="-0.046321813936013374" ORDER="208" O_E="0.0" SE="0.05434154946452086" STUDY_ID="STD-Panacek-2004" TOTAL_1="1305" TOTAL_2="1329" VAR="0.002953003998204968" WEIGHT="31.484706112918225"/>
<DICH_DATA CI_END="1.8540278334274565" CI_START="0.70510973363209" EFFECT_SIZE="1.1433691756272402" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="12" LOG_CI_END="0.2681162496645851" LOG_CI_START="-0.15174329009741797" LOG_EFFECT_SIZE="0.05818647978358358" ORDER="209" O_E="0.0" SE="0.2466275719944414" STUDY_ID="STD-Reinhart-1996" TOTAL_1="93" TOTAL_2="29" VAR="0.06082515926787338" WEIGHT="1.5285527264186407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.318654290373395" CI_END="0.9989735411877483" CI_START="0.8995661265243812" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9479676993160723" ESTIMABLE="YES" EVENTS_1="1827" EVENTS_2="1825" I2="0.0" I2_Q="30.879675886157298" ID="CMP-001.02" LOG_CI_END="-4.4601434492008273E-4" LOG_CI_START="-0.045966906438401615" LOG_EFFECT_SIZE="-0.023206460391660817" METHOD="MH" MODIFIED="2013-03-31 21:13:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5019723060777371" P_Q="0.2269894541557873" P_Z="0.04567639970114273" Q="4.3402574256725615" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5050" TOTAL_2="4790" WEIGHT="400.0" Z="1.998371494253895">
<NAME>Low risk of bias studies, all-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.553518918452617" CI_END="1.1806507318596433" CI_START="0.7443912299387341" DF="4" EFFECT_SIZE="0.9374785599772757" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="162" I2="12.155849758514108" ID="CMP-001.02.01" LOG_CI_END="0.07212144066167081" LOG_CI_START="-0.12819875216089757" LOG_EFFECT_SIZE="-0.02803865574961336" MODIFIED="2009-03-15 00:39:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3362487449025937" P_Z="0.5832325202597299" STUDIES="5" TAU2="0.011209776730029675" TOTAL_1="488" TOTAL_2="457" WEIGHT="100.0" Z="0.5486691548149093">
<NAME>Polyclonal IVIG, adults</NAME>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="181" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="2.8989593710831296"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" ORDER="182" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="1.293656155911976"/>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" ORDER="183" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="21.869455348057844"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" ORDER="184" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="9.777354507338153"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" ORDER="185" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="64.16057461760889"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9132626399130301" CI_END="1.0824580977495848" CI_START="0.9174393502212603" DF="2" EFFECT_SIZE="0.996538837096237" ESTIMABLE="YES" EVENTS_1="690" EVENTS_2="684" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.034411093692051295" LOG_CI_START="-0.03742263632366558" LOG_EFFECT_SIZE="-0.0015057713158071711" MODIFIED="2013-03-31 21:13:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6334138553299296" P_Z="0.9345122211507324" STUDIES="3" TAU2="0.0" TOTAL_1="1792" TOTAL_2="1769" WEIGHT="100.00000000000001" Z="0.08216912994187542">
<NAME>Polyclonal IVIG, neonates</NAME>
<DICH_DATA CI_END="1.0852452498970298" CI_START="0.9194106027857412" EFFECT_SIZE="0.9988923812794802" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="677" LOG_CI_END="0.03552789361414855" LOG_CI_START="-0.036490492205473325" LOG_EFFECT_SIZE="-4.8129929566238035E-4" MODIFIED="2012-08-08 17:40:00 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.042303956327205204" STUDY_ID="STD-Brocklehurst-2011" TOTAL_1="1759" TOTAL_2="1734" VAR="0.0017896247209340855" WEIGHT="99.48785557405627"/>
<DICH_DATA CI_END="6.030568663480067" CI_START="0.1488262509376406" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7803582666620361" LOG_CI_START="-0.8273204583610819" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="187" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" VAR="0.8918128654970761" WEIGHT="0.1996449397136835"/>
<DICH_DATA CI_END="2.1324645428702045" CI_START="0.11063178899537662" EFFECT_SIZE="0.4857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32888181875452704" LOG_CI_START="-0.9561200646985305" LOG_EFFECT_SIZE="-0.31361912297200173" ORDER="188" O_E="0.0" SE="0.7548164672022357" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" VAR="0.5697478991596638" WEIGHT="0.31249948623006013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.045168063874159" CI_START="0.42353054853189753" DF="0" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" MODIFIED="2009-03-15 00:59:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07701851756136492" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="138" WEIGHT="100.0" Z="1.7682535974030373">
<NAME>Anti-endotoxins</NAME>
<DICH_DATA CI_END="1.045168063874159" CI_START="0.42353054853189753" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" ORDER="213" O_E="0.0" SE="0.23043977855938225" STUDY_ID="STD-Derkx-1999" TOTAL_1="131" TOTAL_2="138" VAR="0.053102491542497125" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40874700923358565" CI_END="0.9907627093526368" CI_START="0.8582959710911087" DF="2" EFFECT_SIZE="0.9221538059047847" ESTIMABLE="YES" EVENTS_1="947" EVENTS_2="941" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-0.004030347894790909" LOG_CI_START="-0.06636292608279516" LOG_EFFECT_SIZE="-0.035196636988793016" MODIFIED="2009-03-15 01:00:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8151579340727768" P_Z="0.026868585335496936" STUDIES="3" TAU2="0.0" TOTAL_1="2639" TOTAL_2="2426" WEIGHT="100.0" Z="2.213421709171032">
<NAME>Anti-cytokines</NAME>
<DICH_DATA CI_END="1.048284143601728" CI_START="0.8457281521994383" EFFECT_SIZE="0.9415749634247186" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="398" LOG_CI_END="0.020479016686226436" LOG_CI_START="-0.0727692125784469" LOG_EFFECT_SIZE="-0.026145097946110227" ORDER="214" O_E="0.0" SE="0.054774471456248336" STUDY_ID="STD-Abraham-1998" TOTAL_1="948" TOTAL_2="930" VAR="0.0030002427233113637" WEIGHT="44.68368626553661"/>
<DICH_DATA CI_END="1.185527453886834" CI_START="0.7515949102759769" EFFECT_SIZE="0.9439472444653791" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="66" LOG_CI_END="0.07391161561787904" LOG_CI_START="-0.12401616955946045" LOG_EFFECT_SIZE="-0.02505227697079071" ORDER="215" O_E="0.0" SE="0.1162637607715072" STUDY_ID="STD-Cohen-1996" TOTAL_1="386" TOTAL_2="167" VAR="0.013517262068734255" WEIGHT="9.917829800680751"/>
<DICH_DATA CI_END="0.9998475731832024" CI_START="0.8080208647661402" EFFECT_SIZE="0.8988312971396901" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="477" LOG_CI_END="-6.620317112678931E-5" LOG_CI_START="-0.0925774247009" LOG_EFFECT_SIZE="-0.046321813936013374" ORDER="217" O_E="0.0" SE="0.05434154946452086" STUDY_ID="STD-Panacek-2004" TOTAL_1="1305" TOTAL_2="1329" VAR="0.002953003998204968" WEIGHT="45.398483933782636"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-04-12 09:42:56 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Polyclonal IVIG versus placebo or no intervention</NAME>
<DICH_OUTCOME CHI2="24.938018878984778" CI_END="0.8692897975387408" CI_START="0.677437180561969" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7673911841661523" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="347" I2="35.84093396655831" I2_Q="49.19196692453662" ID="CMP-002.01" LOG_CI_END="-0.06083541746285681" LOG_CI_START="-0.16913097115496492" LOG_EFFECT_SIZE="-0.11498319430891087" METHOD="MH" MODIFIED="2009-03-14 23:43:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07092564993901462" P_Q="0.1606401392156478" P_Z="3.1547560645016924E-5" Q="1.9681927039268285" RANDOM="NO" SCALE="18.79" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1015" TOTAL_2="943" WEIGHT="100.00000000000003" Z="4.161997644216473">
<NAME>All-cause mortality, adults, by type of polyclonal IVIG</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.41693997133176" CI_END="0.9341640641466984" CI_START="0.7023738883950179" DF="9" EFFECT_SIZE="0.8100200282299256" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="250" I2="48.326169724337475" ID="CMP-002.01.01" LOG_CI_END="-0.02957684336698068" LOG_CI_START="-0.15343164222830102" LOG_EFFECT_SIZE="-0.09150424279764086" MODIFIED="2008-09-15 08:28:38 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="1" P_CHI2="0.04257329274146682" P_Z="0.003778887783100394" STUDIES="10" TAU2="0.0" TOTAL_1="746" TOTAL_2="684" WEIGHT="72.24041293385747" Z="2.89605282903566">
<NAME>Standard polyclonal IVIG, adults</NAME>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="59" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="1.1044457729722146"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" MODIFIED="2008-09-15 08:23:20 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="60" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="1.0658778253446135"/>
<DICH_DATA CI_END="1.3879016937774824" CI_START="0.43586536014554794" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.14235870577160212" LOG_CI_START="-0.36064764462173815" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="61" O_E="0.0" SE="0.29546842014263947" STUDY_ID="STD-De-Simone-1988" TOTAL_1="12" TOTAL_2="12" VAR="0.08730158730158731" WEIGHT="2.5181363623766497"/>
<DICH_DATA CI_END="0.802984194413105" CI_START="0.3675499459107326" EFFECT_SIZE="0.5432649420160571" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.09529300309831536" LOG_CI_START="-0.4346836368258802" LOG_EFFECT_SIZE="-0.26498831996209776" ORDER="62" O_E="0.0" SE="0.1993597382623034" STUDY_ID="STD-Dominioni-1996" TOTAL_1="59" TOTAL_2="58" VAR="0.03974430524001412" WEIGHT="10.72300422497331"/>
<DICH_DATA CI_END="1.0285780969192506" CI_START="0.5091677901111401" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.012237271989362255" LOG_CI_START="-0.2931390775624573" LOG_EFFECT_SIZE="-0.14045090278654748" ORDER="63" O_E="0.0" SE="0.17937957936404844" STUDY_ID="STD-Grundmann-1988" TOTAL_1="24" TOTAL_2="22" VAR="0.03217703349282296" WEIGHT="5.547198943206532"/>
<DICH_DATA CI_END="1.7009784942522388" CI_START="0.39579647297179105" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23069882279150838" LOG_CI_START="-0.4025280802046948" LOG_EFFECT_SIZE="-0.08591462870659325" ORDER="64" O_E="0.0" SE="0.3719606173436925" STUDY_ID="STD-Just-1986" TOTAL_1="13" TOTAL_2="16" VAR="0.13835470085470086" WEIGHT="2.257639497303203"/>
<DICH_DATA CI_END="64.14118825764045" CI_START="0.11523954830411988" EFFECT_SIZE="2.71875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8071370012574697" LOG_CI_START="-0.9383984526600444" LOG_EFFECT_SIZE="0.4343692742987125" MODIFIED="2008-09-15 08:28:38 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="65" O_E="0.0" SE="1.6127411162508312" STUDY_ID="STD-Lindquist-1981" TOTAL_1="31" TOTAL_2="28" VAR="2.600933908045977" WEIGHT="0.14677661857204516"/>
<DICH_DATA CI_END="0.9203155854314344" CI_START="0.4055968592076615" EFFECT_SIZE="0.6109640831758034" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="46" LOG_CI_END="-0.03606322318744081" LOG_CI_START="-0.3919054166778336" LOG_EFFECT_SIZE="-0.2139843199326372" MODIFIED="2008-09-15 08:22:46 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="66" O_E="0.0" SE="0.20902346590352275" STUDY_ID="STD-Masaoka-2000" TOTAL_1="230" TOTAL_2="202" VAR="0.043690809298321136" WEIGHT="13.704672177955223"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" MODIFIED="2008-09-15 08:23:49 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="207" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="32.5286183306582"/>
<DICH_DATA CI_END="0.952349284331303" CI_START="0.09550582120988776" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.021203740232210368" LOG_CI_START="-1.0199701567692951" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="68" O_E="0.0" SE="0.5866803370473809" STUDY_ID="STD-Yakut-1998" TOTAL_1="21" TOTAL_2="19" VAR="0.3441938178780284" WEIGHT="2.6440431804954816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.778596203984772" CI_END="0.8485929036927855" CI_START="0.507821814729501" DF="6" EFFECT_SIZE="0.656455625552746" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="97" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.07130060431575122" LOG_CI_START="-0.29428864687869316" LOG_EFFECT_SIZE="-0.1827946255972222" MODIFIED="2008-09-13 11:45:51 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="2" P_CHI2="0.4484435055435836" P_Z="0.0013118987640386237" STUDIES="7" TAU2="0.0" TOTAL_1="269" TOTAL_2="259" WEIGHT="27.759587066142558" Z="3.213364076568468">
<NAME>IgM-enriched polyclonal IVIG, adults</NAME>
<DICH_DATA CI_END="1.34641588167828" CI_START="0.3235255955663814" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.12917922572813692" LOG_CI_START="-0.4900913546443995" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="69" O_E="0.0" SE="0.3637626043496395" STUDY_ID="STD-Behre-1995" TOTAL_1="30" TOTAL_2="22" VAR="0.13232323232323234" WEIGHT="3.228379951764935"/>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" ORDER="70" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="8.11399494543587"/>
<DICH_DATA CI_END="1.1822694599672872" CI_START="0.27618967020761315" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.07271647116439893" LOG_CI_START="-0.5587925685369879" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="71" O_E="0.0" SE="0.37095153594075697" STUDY_ID="STD-Karatzas-2002" TOTAL_1="34" TOTAL_2="34" VAR="0.1376050420168067" WEIGHT="3.917101008141455"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" ORDER="72" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="3.7672119389523684"/>
<DICH_DATA CI_END="0.7827420455370592" CI_START="0.044754242705140404" EFFECT_SIZE="0.18716577540106952" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10638133712135041" LOG_CI_START="-1.349165787251096" LOG_EFFECT_SIZE="-0.7277735621862234" MODIFIED="2008-09-13 11:45:51 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="73" O_E="0.0" SE="0.730017737888457" STUDY_ID="STD-Schedel-1991" TOTAL_1="34" TOTAL_2="35" VAR="0.53292589763178" WEIGHT="3.033117550817607"/>
<DICH_DATA CI_END="1.8942671028263436" CI_START="0.26934115092396554" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27744121706681374" LOG_CI_START="-0.5696972884232897" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="74" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Tugrul-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.24761904761904763" WEIGHT="1.9585505040707274"/>
<DICH_DATA CI_END="1.0379469340474572" CI_START="0.32544001520134536" EFFECT_SIZE="0.5811965811965812" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.016175150391546773" LOG_CI_START="-0.48752904847139733" LOG_EFFECT_SIZE="-0.23567694903992528" ORDER="75" O_E="0.0" SE="0.29587833978809036" STUDY_ID="STD-Wesoly-1990" TOTAL_1="18" TOTAL_2="17" VAR="0.08754399195575667" WEIGHT="3.7412311669595937"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.553518918452617" CI_END="1.1499384654062674" CI_START="0.811924342312814" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9662624034004377" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="162" I2="12.155849758514108" I2_Q="1.85513845895292" ID="CMP-002.02" LOG_CI_END="0.06067460135403621" LOG_CI_START="-0.09048443781166218" LOG_EFFECT_SIZE="-0.01490491822881301" METHOD="MH" MODIFIED="2009-03-15 01:14:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3362487449025937" P_Q="0.3127798784921505" P_Z="0.6991105459243943" Q="1.0189020436712017" RANDOM="NO" SCALE="18.497643681198568" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="488" TOTAL_2="457" WEIGHT="100.0" Z="0.3865214158839029">
<NAME>Sensitivity analysis, low risk of bias adult studies, by type of polyclonal IVIG, mortality all-cause</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0428306975556856" CI_END="1.237721003313542" CI_START="0.8359719254674313" DF="2" EFFECT_SIZE="1.0172020499052794" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="120" I2="2.0966347141216315" ID="CMP-002.02.01" LOG_CI_END="0.09262276069656683" LOG_CI_START="-0.07780830727307361" LOG_EFFECT_SIZE="0.007407226711746605" MODIFIED="2009-03-15 01:14:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36008506865868295" P_Z="0.8647216826019979" STUDIES="3" TAU2="0.0" TOTAL_1="356" TOTAL_2="327" WEIGHT="74.49298212422269" Z="0.17036679700830754">
<NAME>Standard IVIG, adults, low risk of bias</NAME>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="191" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="2.3710653596180933"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" ORDER="192" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="2.2882662518219057"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" ORDER="190" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="69.83365051278268"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.293529197411262" CI_END="1.1910046270349641" CI_START="0.5611195133767453" DF="1" EFFECT_SIZE="0.8174936921783011" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="22.692119976781466" ID="CMP-002.02.02" LOG_CI_END="0.07591344871354917" LOG_CI_START="-0.2509446280983831" LOG_EFFECT_SIZE="-0.08751558969241698" MODIFIED="2009-03-15 01:14:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25539869774789503" P_Z="0.2939237856387016" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="25.507017875777308" Z="1.0495527940196234">
<NAME>IgM-enriched IVIG, adults, low risk of bias</NAME>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" MODIFIED="2009-03-11 07:13:24 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="17.41942684199426"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" ORDER="198" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="8.087591033783049"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.252952797633035" CI_END="1.0671613487750031" CI_START="0.9064860798012836" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9835481216323393" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="715" I2="0.0" I2_Q="69.35810330324092" ID="CMP-002.03" LOG_CI_END="0.028230087264269763" LOG_CI_START="-0.04263886063841963" LOG_EFFECT_SIZE="-0.007204386687074943" METHOD="MH" MODIFIED="2012-08-08 17:42:59 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="3" P_CHI2="0.6291246207534987" P_Q="0.07083759904419318" P_Z="0.6902678869871193" Q="3.2635055522061323" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1925" TOTAL_2="1906" WEIGHT="100.00000000000003" Z="0.39849154969128253">
<NAME>All-cause mortality, neonates, by type of polyclonal IVIG</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2519733910422304" CI_END="1.082414297674836" CI_START="0.9180701345694715" DF="4" EFFECT_SIZE="0.9968611939112971" ESTIMABLE="YES" EVENTS_1="699" EVENTS_2="692" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.03439352024909632" LOG_CI_START="-0.03712414026602783" LOG_EFFECT_SIZE="-0.0013653100084657652" MODIFIED="2012-08-08 17:42:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8694696594118385" P_Z="0.9403471869409696" STUDIES="5" TAU2="0.0" TOTAL_1="1845" TOTAL_2="1822" WEIGHT="96.91317864699043" Z="0.0748335005661736">
<NAME>Standard polyclonal IVIG, neonates</NAME>
<DICH_DATA CI_END="1.0852452498970298" CI_START="0.9194106027857412" EFFECT_SIZE="0.9988923812794802" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="677" LOG_CI_END="0.03552789361414855" LOG_CI_START="-0.036490492205473325" LOG_EFFECT_SIZE="-4.8129929566238035E-4" MODIFIED="2012-08-08 17:42:59 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.042303956327205204" STUDY_ID="STD-Brocklehurst-2011" TOTAL_1="1759" TOTAL_2="1734" VAR="0.0017896247209340855" WEIGHT="94.88559227424878"/>
<DICH_DATA CI_END="20.81663045077274" CI_START="0.19215405727930934" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3184104324239632" LOG_CI_START="-0.7163504410960009" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="219" O_E="0.0" SE="1.1952286093343936" STUDY_ID="STD-Chen-1996" TOTAL_1="28" TOTAL_2="28" VAR="1.4285714285714284" WEIGHT="0.13915997902912094"/>
<DICH_DATA CI_END="6.030568663480067" CI_START="0.1488262509376406" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7803582666620361" LOG_CI_START="-0.8273204583610819" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="217" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" VAR="0.8918128654970761" WEIGHT="0.285842119086843"/>
<DICH_DATA CI_END="2.4325889590333376" CI_START="0.4110846578853914" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38606873124701274" LOG_CI_START="-0.38606873124701274" LOG_EFFECT_SIZE="0.0" ORDER="220" O_E="0.0" SE="0.4535573676110726" STUDY_ID="STD-Shenoi-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.20571428571428568" WEIGHT="0.9741198532038466"/>
<DICH_DATA CI_END="2.1324645428702045" CI_START="0.11063178899537662" EFFECT_SIZE="0.4857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32888181875452704" LOG_CI_START="-0.9561200646985305" LOG_EFFECT_SIZE="-0.31361912297200173" ORDER="218" O_E="0.0" SE="0.7548164672022357" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" VAR="0.5697478991596638" WEIGHT="0.6284644214218366"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0419471682318053" CI_END="1.0402494402595988" CI_START="0.3074971035682453" DF="2" EFFECT_SIZE="0.5655737704918034" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" I2="2.054272945177562" ID="CMP-002.03.02" LOG_CI_END="0.017137490778627824" LOG_CI_START="-0.5121589706536136" LOG_EFFECT_SIZE="-0.24751073993749287" MODIFIED="2008-06-28 23:24:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3602441760696282" P_Z="0.06679586803710162" STUDIES="3" TAU2="0.0" TOTAL_1="80" TOTAL_2="84" WEIGHT="3.086821353009592" Z="1.8330450755391943">
<NAME>IgM-enriched polyclonal IVIG, neonates</NAME>
<DICH_DATA CI_END="1.863388515769675" CI_START="0.34346031146148137" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.27030341456536977" LOG_CI_START="-0.4641234405814825" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="223" O_E="0.0" SE="0.4314059701848262" STUDY_ID="STD-Erdem-1993" TOTAL_1="20" TOTAL_2="24" VAR="0.18611111111111114" WEIGHT="1.1385816466018985"/>
<DICH_DATA CI_END="1.3019564567260682" CI_START="0.021335412282242117" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11459645971618479" LOG_CI_START="-1.670898960483472" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="221" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Haque-1988" TOTAL_1="30" TOTAL_2="30" VAR="1.0999999999999999" WEIGHT="0.8349598741747257"/>
<DICH_DATA CI_END="1.6924505528238085" CI_START="0.23080437968970652" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.22851598905616716" LOG_CI_START="-0.6367559543680167" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="222" O_E="0.0" SE="0.5082650227325636" STUDY_ID="STD-Samatha-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.25833333333333336" WEIGHT="1.1132798322329676"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9132626399130301" CI_END="1.0812133467094167" CI_START="0.9163460985452887" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9953721072806233" ESTIMABLE="YES" EVENTS_1="690" EVENTS_2="684" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.03391139807596188" LOG_CI_START="-0.037940464869830395" LOG_EFFECT_SIZE="-0.002014533396934232" METHOD="MH" MODIFIED="2013-04-02 17:00:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6334138553299296" P_Q="1.0" P_Z="0.9124853042490672" Q="0.0" RANDOM="NO" SCALE="18.497643681198568" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1792" TOTAL_2="1769" WEIGHT="100.0" Z="0.10990425973013553">
<NAME>Sensitivity analysis, low risk of bias, standard polyclonal IVIG, neonates, mortality all-cause</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0852452498970298" CI_START="0.9194106027857412" EFFECT_SIZE="0.9988923812794802" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="677" LOG_CI_END="0.03552789361414855" LOG_CI_START="-0.036490492205473325" LOG_EFFECT_SIZE="-4.8129929566238035E-4" MODIFIED="2013-04-02 17:00:14 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.042303956327205204" STUDY_ID="STD-Brocklehurst-2011" TOTAL_1="1759" TOTAL_2="1734" VAR="0.0017896247209340855" WEIGHT="99.04560803109341"/>
<DICH_DATA CI_END="6.030568663480067" CI_START="0.1488262509376406" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7803582666620361" LOG_CI_START="-0.8273204583610819" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-02 16:52:01 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" VAR="0.8918128654970761" WEIGHT="0.29837413465285473"/>
<DICH_DATA CI_END="2.1324645428702045" CI_START="0.11063178899537662" EFFECT_SIZE="0.4857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32888181875452704" LOG_CI_START="-0.9561200646985305" LOG_EFFECT_SIZE="-0.31361912297200173" MODIFIED="2013-04-02 16:52:01 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.7548164672022357" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" VAR="0.5697478991596638" WEIGHT="0.65601783425373"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.574951439610993" CI_END="0.727169339875141" CI_START="0.3338960584393934" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4927463611253615" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="63" I2="58.22433121224779" I2_Q="30.40170475064143" ID="CMP-002.05" LOG_CI_END="-0.13836444084735466" LOG_CI_START="-0.4763887076545995" LOG_EFFECT_SIZE="-0.3073765742509771" METHOD="MH" MODIFIED="2008-10-01 01:34:54 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="5" P_CHI2="0.04822977691197594" P_Q="0.23065541215634666" P_Z="3.645235990166443E-4" Q="1.4368168019305274" RANDOM="NO" SCALE="112.06898259086518" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="230" WEIGHT="200.0" Z="3.564519322316919">
<NAME>Mortality from sepsis / septic shock</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.79529592759503" CI_END="0.6925811453528337" CI_START="0.288269319696557" DF="3" EFFECT_SIZE="0.44682199543612844" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="54" I2="65.8908577414937" ID="CMP-002.05.01" LOG_CI_END="-0.1595293357445163" LOG_CI_START="-0.5402015768123144" LOG_EFFECT_SIZE="-0.34986545627841537" MODIFIED="2008-09-15 12:36:43 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="1" P_CHI2="0.03214016152834298" P_Z="3.149304980136479E-4" STUDIES="4" TAU2="0.0" TOTAL_1="208" TOTAL_2="206" WEIGHT="99.99999999999999" Z="3.6026986985806455">
<NAME>Polyclonal IVIG, adult</NAME>
<DICH_DATA CI_END="0.6891715164355308" CI_START="0.08753445665323673" EFFECT_SIZE="0.24561403508771928" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.16167268031063517" LOG_CI_START="-1.0578209596778718" LOG_EFFECT_SIZE="-0.6097468199942534" MODIFIED="2008-09-15 12:36:43 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="83" O_E="0.0" SE="0.5264019353058406" STUDY_ID="STD-Dominioni-1996" TOTAL_1="57" TOTAL_2="56" VAR="0.27709899749373434" WEIGHT="29.487822094395124"/>
<DICH_DATA CI_END="1.353530779639571" CI_START="0.4630379453048" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.13146813618752273" LOG_CI_START="-0.3343834177050769" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2008-09-15 12:33:46 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="84" O_E="0.0" SE="0.27364350875889554" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.07488076988587974" WEIGHT="43.843735482455905"/>
<DICH_DATA CI_END="0.8490350597590559" CI_START="0.015637880543563416" EFFECT_SIZE="0.11522633744855967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.07107437578017387" LOG_CI_START="-1.805822108732012" LOG_EFFECT_SIZE="-0.9384482422560929" ORDER="85" O_E="0.0" SE="1.0189994054756795" STUDY_ID="STD-Schedel-1991" TOTAL_1="27" TOTAL_2="28" VAR="1.0383597883597884" WEIGHT="16.14246624581331"/>
<DICH_DATA CI_END="1.4018819214813067" CI_START="0.004872118292554628" EFFECT_SIZE="0.08264462809917356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.14671143516509377" LOG_CI_START="-2.312282175797994" LOG_EFFECT_SIZE="-1.08278537031645" MODIFIED="2008-09-15 12:36:40 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="86" O_E="0.0" SE="1.444425019294403" STUDY_ID="STD-Yakut-1998" TOTAL_1="21" TOTAL_2="19" VAR="2.0863636363636364" WEIGHT="10.525976177335645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8633885157696748" CI_START="0.3434603114614814" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.2703034145653697" LOG_CI_START="-0.46412344058148247" LOG_EFFECT_SIZE="-0.09691001300805639" NO="2" P_CHI2="1.0" P_Z="0.604983574742741" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="0.5172472490786553">
<NAME>Polyclonal IVIG, neonate</NAME>
<DICH_DATA CI_END="1.863388515769675" CI_START="0.34346031146148137" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.27030341456536977" LOG_CI_START="-0.4641234405814825" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="87" O_E="0.0" SE="0.4314059701848262" STUDY_ID="STD-Erdem-1993" TOTAL_1="20" TOTAL_2="24" VAR="0.18611111111111114" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.469460781239711" CI_END="-1.6685955799170662" CI_START="-6.763159923751968" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.215877751834517" ESTIMABLE="YES" I2="26.078156278254497" I2_Q="14.502664006123629" ID="CMP-002.06" MODIFIED="2009-03-22 13:09:36 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2206837304344893" P_Q="0.2794779294949503" P_Z="0.0011793114765829384" Q="1.169627086476266" RANDOM="NO" SCALE="17.599991030804258" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="216" UNITS="" WEIGHT="200.0" Z="3.243837156289383">
<NAME>Length of hospital stay, survivors</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.2131205417135518" CI_END="0.3773122395336568" CI_START="-6.368885468412451" DF="3" EFFECT_SIZE="-2.995786614439397" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" MODIFIED="2008-09-09 13:03:56 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="1" P_CHI2="0.5293687485057468" P_Z="0.08173198280862859" STUDIES="6" TAU2="0.0" TOTAL_1="136" TOTAL_2="116" WEIGHT="100.0" Z="1.740723922974392">
<NAME>Polyclonal IVIG, adult</NAME>
<CONT_DATA CI_END="1.8535856095979337" CI_START="-15.853585609597934" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="26.0" ORDER="88" SD_1="17.0" SD_2="16.0" SE="4.517218520051331" STUDY_ID="STD-Dominioni-1996" TOTAL_1="38" TOTAL_2="20" WEIGHT="14.515090769694394"/>
<CONT_DATA CI_END="10.408081556646314" CI_START="-7.408081556646314" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="22.8" MEAN_2="21.3" ORDER="89" SD_1="16.7" SD_2="14.1" SE="4.545023085583268" STUDY_ID="STD-Grundmann-1988" TOTAL_1="24" TOTAL_2="22" WEIGHT="14.338039388561597"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="21.0" MEAN_2="16.9" ORDER="90" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Just-1986" TOTAL_1="13" TOTAL_2="16" WEIGHT="0.0"/>
<CONT_DATA CI_END="4.2806603774092835" CI_START="-17.280660377409284" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="20.9" MEAN_2="27.4" MODIFIED="2008-09-09 13:03:56 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="91" SD_1="14.1" SD_2="20.6" SE="5.500437999088635" STUDY_ID="STD-Lindquist-1981" TOTAL_1="22" TOTAL_2="20" WEIGHT="9.789655490124106"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="29.0" MEAN_2="22.0" ORDER="92" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Tugrul-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.766220379579889" CI_START="-6.846220379579891" EFFECT_SIZE="-2.540000000000001" ESTIMABLE="YES" MEAN_1="13.28" MEAN_2="15.82" ORDER="93" SD_1="5.75" SD_2="7.13" SE="2.197091586144851" STUDY_ID="STD-Wesoly-1990" TOTAL_1="18" TOTAL_2="17" WEIGHT="61.3572143516199"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.086713153049894" CI_END="-1.9492438912811396" CI_START="-9.721005416182123" DF="3" EFFECT_SIZE="-5.835124653731632" ESTIMABLE="YES" I2="50.71231509411976" ID="CMP-002.06.02" MODIFIED="2008-09-09 13:19:28 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="2" P_CHI2="0.10746687991379189" P_Z="0.003249168331057999" STUDIES="5" TAU2="0.0" TOTAL_1="98" TOTAL_2="100" WEIGHT="100.00000000000001" Z="2.9431253468013385">
<NAME>Polyclonal IVIG, neonate</NAME>
<CONT_DATA CI_END="16.92664100192201" CI_START="-12.926641001922011" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="94" SD_1="16.0" SD_2="18.0" SE="7.615773105863909" STUDY_ID="STD-Chen-1996" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.777269640663598"/>
<CONT_DATA CI_END="-5.095369943853668" CI_START="-15.904630056146328" EFFECT_SIZE="-10.499999999999998" ESTIMABLE="YES" MEAN_1="13.9" MEAN_2="24.4" ORDER="95" SD_1="5.7" SD_2="10.3" SE="2.7575149843453053" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" WEIGHT="51.6948162844509"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="20.0" MEAN_2="29.0" ORDER="96" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Samatha-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="4.8362838396250725" CI_START="-7.436283839625074" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="18.3" MODIFIED="2008-09-09 13:19:28 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="97" SD_1="10.4" SD_2="11.7" SE="3.130814590485997" STUDY_ID="STD-Shenoi-1999" TOTAL_1="25" TOTAL_2="25" WEIGHT="40.10218722286153"/>
<CONT_DATA CI_END="31.0440280561113" CI_START="-34.0440280561113" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="62.1" MODIFIED="2008-09-09 12:59:57 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="98" SD_1="34.0" SD_2="57.3" SE="16.60440105676147" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" WEIGHT="1.4257268520239752"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03670894459297581" CI_END="14.959285846912504" CI_START="-12.175925153422558" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3916803467449723" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2009-03-22 13:10:44 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8480589159135796" P_Q="1.0" P_Z="0.8406666085940047" Q="0.0" RANDOM="NO" SCALE="36.59" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="57" UNITS="" WEIGHT="99.99999999999999" Z="0.201040880616604">
<NAME>Sensitivity analysis by quality, length of hospital stay, neonates</NAME>
<GROUP_LABEL_1>Favours Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.92664100192201" CI_START="-12.926641001922011" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="254" SD_1="16.0" SD_2="18.0" SE="7.615773105863909" STUDY_ID="STD-Chen-1996" TOTAL_1="10" TOTAL_2="10" WEIGHT="82.61943847842777"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="20.0" MEAN_2="29.0" ORDER="253" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Samatha-1997" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="31.0440280561113" CI_START="-34.0440280561113" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="62.1" ORDER="252" SD_1="34.0" SD_2="57.3" SE="16.60440105676147" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" WEIGHT="17.38056152157222"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.938018878984774" CI_END="0.8692897975387407" CI_START="0.6774371805619689" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7673911841661522" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="347" I2="35.840933966558296" I2_Q="88.41138961294803" ID="CMP-002.08" LOG_CI_END="-0.06083541746285687" LOG_CI_START="-0.16913097115496498" LOG_EFFECT_SIZE="-0.11498319430891094" METHOD="MH" MODIFIED="2009-03-22 11:25:47 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.07092564993901485" P_Q="1.7881519221485398E-4" P_Z="3.154756064501657E-5" Q="17.25832462393087" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1015" TOTAL_2="943" WEIGHT="100.00000000000001" Z="4.161997644216475">
<NAME>All-cause mortality, adults, by type of patients</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0697755024830147" CI_END="0.7168098721052492" CI_START="0.44780487505896877" DF="4" EFFECT_SIZE="0.566560636842277" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="92" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="-0.14459602208015176" LOG_CI_START="-0.34891118275412014" LOG_EFFECT_SIZE="-0.24675360241713598" MODIFIED="2009-03-22 11:25:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5462173883544783" P_Z="2.1998705471307864E-6" STUDIES="5" TAU2="0.0" TOTAL_1="151" TOTAL_2="143" WEIGHT="26.42268945458728" Z="4.734138888154675">
<NAME>Surgical patients</NAME>
<DICH_DATA CI_END="0.802984194413105" CI_START="0.3675499459107326" EFFECT_SIZE="0.5432649420160571" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.09529300309831536" LOG_CI_START="-0.4346836368258802" LOG_EFFECT_SIZE="-0.26498831996209776" MODIFIED="2009-03-22 11:25:45 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.1993597382623034" STUDY_ID="STD-Dominioni-1996" TOTAL_1="59" TOTAL_2="58" VAR="0.03974430524001412" WEIGHT="10.723004224973309"/>
<DICH_DATA CI_END="1.0285780969192506" CI_START="0.5091677901111401" EFFECT_SIZE="0.7236842105263158" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.012237271989362255" LOG_CI_START="-0.2931390775624573" LOG_EFFECT_SIZE="-0.14045090278654748" MODIFIED="2009-03-22 11:25:46 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.17937957936404844" STUDY_ID="STD-Grundmann-1988" TOTAL_1="24" TOTAL_2="22" VAR="0.03217703349282296" WEIGHT="5.5471989432065305"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" ORDER="164" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="3.7672119389523675"/>
<DICH_DATA CI_END="1.0379469340474572" CI_START="0.32544001520134536" EFFECT_SIZE="0.5811965811965812" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.016175150391546773" LOG_CI_START="-0.48752904847139733" LOG_EFFECT_SIZE="-0.23567694903992528" MODIFIED="2009-03-22 11:25:47 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.29587833978809036" STUDY_ID="STD-Wesoly-1990" TOTAL_1="18" TOTAL_2="17" VAR="0.08754399195575667" WEIGHT="3.741231166959593"/>
<DICH_DATA CI_END="0.952349284331303" CI_START="0.09550582120988776" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.021203740232210368" LOG_CI_START="-1.0199701567692951" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2009-03-22 11:25:47 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.5866803370473809" STUDY_ID="STD-Yakut-1998" TOTAL_1="21" TOTAL_2="19" VAR="0.3441938178780284" WEIGHT="2.644043180495481"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.098550505920583" CI_END="0.8305444405487603" CI_START="0.514923341621658" DF="8" EFFECT_SIZE="0.6539623220741835" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="124" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="-0.08063712447841102" LOG_CI_START="-0.28825742103405566" LOG_EFFECT_SIZE="-0.18444727275623335" MODIFIED="2009-03-22 11:22:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5260383875407527" P_Z="4.969130517695003E-4" STUDIES="9" TAU2="0.0" TOTAL_1="518" TOTAL_2="469" WEIGHT="36.272916355074685" Z="3.48241494349243">
<NAME>Medical patients</NAME>
<DICH_DATA CI_END="1.34641588167828" CI_START="0.3235255955663814" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.12917922572813692" LOG_CI_START="-0.4900913546443995" LOG_EFFECT_SIZE="-0.1804560644581313" MODIFIED="2009-03-22 11:22:42 +0000" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.3637626043496395" STUDY_ID="STD-Behre-1995" TOTAL_1="30" TOTAL_2="22" VAR="0.13232323232323234" WEIGHT="3.2283799517649348"/>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="154" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="1.1044457729722144"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" MODIFIED="2009-03-15 15:04:39 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="1.0658778253446133"/>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" ORDER="159" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="8.113994945435868"/>
<DICH_DATA CI_END="1.1822694599672872" CI_START="0.27618967020761315" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.07271647116439893" LOG_CI_START="-0.5587925685369879" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2009-03-22 11:22:44 +0000" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.37095153594075697" STUDY_ID="STD-Karatzas-2002" TOTAL_1="34" TOTAL_2="34" VAR="0.1376050420168067" WEIGHT="3.917101008141454"/>
<DICH_DATA CI_END="64.14118825764045" CI_START="0.11523954830411988" EFFECT_SIZE="2.71875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8071370012574697" LOG_CI_START="-0.9383984526600444" LOG_EFFECT_SIZE="0.4343692742987125" MODIFIED="2009-03-22 11:22:45 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="1.6127411162508312" STUDY_ID="STD-Lindquist-1981" TOTAL_1="31" TOTAL_2="28" VAR="2.600933908045977" WEIGHT="0.14677661857204513"/>
<DICH_DATA CI_END="0.9203155854314344" CI_START="0.4055968592076615" EFFECT_SIZE="0.6109640831758034" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="46" LOG_CI_END="-0.03606322318744081" LOG_CI_START="-0.3919054166778336" LOG_EFFECT_SIZE="-0.2139843199326372" MODIFIED="2009-03-22 11:22:46 +0000" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.20902346590352275" STUDY_ID="STD-Masaoka-2000" TOTAL_1="230" TOTAL_2="202" VAR="0.043690809298321136" WEIGHT="13.704672177955219"/>
<DICH_DATA CI_END="0.7827420455370592" CI_START="0.044754242705140404" EFFECT_SIZE="0.18716577540106952" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10638133712135041" LOG_CI_START="-1.349165787251096" LOG_EFFECT_SIZE="-0.7277735621862234" MODIFIED="2009-03-22 11:22:46 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.730017737888457" STUDY_ID="STD-Schedel-1991" TOTAL_1="34" TOTAL_2="35" VAR="0.53292589763178" WEIGHT="3.0331175508176065"/>
<DICH_DATA CI_END="1.8942671028263436" CI_START="0.26934115092396554" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27744121706681374" LOG_CI_START="-0.5696972884232897" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2009-03-22 11:22:47 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Tugrul-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.24761904761904763" WEIGHT="1.958550504070727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2790356134329715" CI_END="1.226418846299286" CI_START="0.8482103040159237" DF="2" EFFECT_SIZE="1.0199319107030507" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="131" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.08863881567288097" LOG_CI_START="-0.07149645605683726" LOG_EFFECT_SIZE="0.008571179808021849" MODIFIED="2009-03-22 11:16:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5275467699962155" P_Z="0.8338138912097668" STUDIES="3" TAU2="0.0" TOTAL_1="346" TOTAL_2="331" WEIGHT="37.304394190338044" Z="0.20981266084956018">
<NAME>Mixed medical-surgical</NAME>
<DICH_DATA CI_END="1.3879016937774824" CI_START="0.43586536014554794" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.14235870577160212" LOG_CI_START="-0.36064764462173815" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="170" O_E="0.0" SE="0.29546842014263947" STUDY_ID="STD-De-Simone-1988" TOTAL_1="12" TOTAL_2="12" VAR="0.08730158730158731" WEIGHT="2.518136362376649"/>
<DICH_DATA CI_END="1.7009784942522388" CI_START="0.39579647297179105" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23069882279150838" LOG_CI_START="-0.4025280802046948" LOG_EFFECT_SIZE="-0.08591462870659325" MODIFIED="2009-03-22 11:16:53 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.3719606173436925" STUDY_ID="STD-Just-1986" TOTAL_1="13" TOTAL_2="16" VAR="0.13835470085470086" WEIGHT="2.2576394973032023"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" ORDER="167" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="32.52861833065819"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.487271442680648" CI_END="1.0664939733883658" CI_START="0.9184418574998111" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9897033423865784" ESTIMABLE="YES" EVENTS_1="856" EVENTS_2="846" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.02795840565364037" LOG_CI_START="-0.0369483317547356" LOG_EFFECT_SIZE="-0.004494963050547604" METHOD="MH" MODIFIED="2013-04-12 09:42:56 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6007197095911997" P_Q="0.5816613299682942" P_Z="0.786033132285824" Q="1.083734207934893" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2280" TOTAL_2="2226" WEIGHT="300.0" Z="0.27146536839408936">
<NAME>Sensitivity analysis, high quality trials, all-cause mortality polyclonal IVIG</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0428306975556856" CI_END="1.237721003313542" CI_START="0.8359719254674313" DF="2" EFFECT_SIZE="1.0172020499052794" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="120" I2="2.0966347141216315" ID="CMP-002.09.01" LOG_CI_END="0.09262276069656683" LOG_CI_START="-0.07780830727307361" LOG_EFFECT_SIZE="0.007407226711746605" MODIFIED="2013-04-12 09:42:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36008506865868295" P_Z="0.8647216826019979" STUDIES="3" TAU2="0.0" TOTAL_1="356" TOTAL_2="327" WEIGHT="100.0" Z="0.17036679700830754">
<NAME>Standard IVIG, adults</NAME>
<DICH_DATA CI_END="2.6440134761285137" CI_START="0.1818111425872876" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.42226366435117296" LOG_CI_START="-0.7403795038649748" LOG_EFFECT_SIZE="-0.15905791975690087" MODIFIED="2013-04-12 09:29:59 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.6829423521866661" STUDY_ID="STD-Burns-1991" TOTAL_1="25" TOTAL_2="13" VAR="0.4664102564102563" WEIGHT="3.182937898316599"/>
<DICH_DATA CI_END="2.0669141557984174" CI_START="0.03658836037667333" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3153224396474909" LOG_CI_START="-1.4366570519869655" LOG_EFFECT_SIZE="-0.5606673061697374" MODIFIED="2013-04-12 09:29:59 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="1.0291214258244306" STUDY_ID="STD-Darenberg-2003" TOTAL_1="10" TOTAL_2="11" VAR="1.059090909090909" WEIGHT="3.071787685994432"/>
<DICH_DATA CI_END="1.2850269592060968" CI_START="0.8620791796305302" EFFECT_SIZE="1.0525184021172773" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="113" LOG_CI_END="0.10891223903822936" LOG_CI_START="-0.06445284357507715" LOG_EFFECT_SIZE="0.022229697731576112" MODIFIED="2013-04-12 09:29:59 +0100" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.10183550769805559" STUDY_ID="STD-Werdan-2007" TOTAL_1="321" TOTAL_2="303" VAR="0.010370470628120741" WEIGHT="93.74527441568897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.293529197411262" CI_END="1.1910046270349641" CI_START="0.5611195133767453" DF="1" EFFECT_SIZE="0.8174936921783011" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="22.692119976781466" ID="CMP-002.09.02" LOG_CI_END="0.07591344871354917" LOG_CI_START="-0.2509446280983831" LOG_EFFECT_SIZE="-0.08751558969241698" MODIFIED="2013-04-12 09:42:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25539869774789503" P_Z="0.2939237856387016" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="1.0495527940196234">
<NAME>IgM enriched IVIG, adults</NAME>
<DICH_DATA CI_END="1.4563322161999215" CI_START="0.5952111739637688" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.16326045684841206" LOG_CI_START="-0.22532892432834958" LOG_EFFECT_SIZE="-0.03103423373996879" MODIFIED="2013-04-12 09:32:31 +0100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.2282593260516892" STUDY_ID="STD-Hentrich-2006" TOTAL_1="103" TOTAL_2="103" VAR="0.05210231992957136" WEIGHT="68.29268292682927"/>
<DICH_DATA CI_END="1.1627682060253572" CI_START="0.28231350483957923" EFFECT_SIZE="0.5729442970822282" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.06549314819598118" LOG_CI_START="-0.549268346305705" LOG_EFFECT_SIZE="-0.24188759905486193" MODIFIED="2013-04-12 09:32:31 +0100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.361113944988767" STUDY_ID="STD-Rodriguez-2005" TOTAL_1="29" TOTAL_2="27" VAR="0.13040328126535022" WEIGHT="31.70731707317073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9132626399130301" CI_END="1.0812133467094167" CI_START="0.9163460985452887" DF="2" EFFECT_SIZE="0.9953721072806233" ESTIMABLE="YES" EVENTS_1="690" EVENTS_2="684" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.03391139807596188" LOG_CI_START="-0.037940464869830395" LOG_EFFECT_SIZE="-0.002014533396934232" MODIFIED="2013-04-12 09:42:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6334138553299296" P_Z="0.9124853042490672" STUDIES="3" TAU2="0.0" TOTAL_1="1792" TOTAL_2="1769" WEIGHT="100.0" Z="0.10990425973013553">
<NAME>Standard IVIG, neonates</NAME>
<DICH_DATA CI_END="1.0852452498970298" CI_START="0.9194106027857412" EFFECT_SIZE="0.9988923812794802" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="677" LOG_CI_END="0.03552789361414855" LOG_CI_START="-0.036490492205473325" LOG_EFFECT_SIZE="-4.8129929566238035E-4" MODIFIED="2013-04-12 09:35:14 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.042303956327205204" STUDY_ID="STD-Brocklehurst-2011" TOTAL_1="1759" TOTAL_2="1734" VAR="0.0017896247209340855" WEIGHT="99.04560803109341"/>
<DICH_DATA CI_END="6.030568663480067" CI_START="0.1488262509376406" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7803582666620361" LOG_CI_START="-0.8273204583610819" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-12 09:35:14 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Mancilla_x002d_Ramirez-1992" TOTAL_1="19" TOTAL_2="18" VAR="0.8918128654970761" WEIGHT="0.29837413465285473"/>
<DICH_DATA CI_END="2.1324645428702045" CI_START="0.11063178899537662" EFFECT_SIZE="0.4857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32888181875452704" LOG_CI_START="-0.9561200646985305" LOG_EFFECT_SIZE="-0.31361912297200173" MODIFIED="2013-04-12 09:35:14 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.7548164672022357" STUDY_ID="STD-Weisman-1992" TOTAL_1="14" TOTAL_2="17" VAR="0.5697478991596638" WEIGHT="0.65601783425373"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-27 09:36:04 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Monoclonal antibodies versus placebo</NAME>
<DICH_OUTCOME CHI2="16.11693122300367" CI_END="1.0638003865790167" CI_START="0.7902822482964237" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9168983374640124" ESTIMABLE="YES" EVENTS_1="860" EVENTS_2="854" I2="56.56741408681504" I2_Q="54.88905467950595" ID="CMP-003.01" LOG_CI_END="0.026860143804737453" LOG_CI_START="-0.10221777328473307" LOG_EFFECT_SIZE="-0.03767881473999781" METHOD="MH" MODIFIED="2009-03-15 00:08:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02406928658571106" P_Q="0.10896201041817699" P_Z="0.25251731593030113" Q="4.433513830824985" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01962337645902437" TOTALS="YES" TOTAL_1="2363" TOTAL_2="2313" WEIGHT="100.0" Z="1.1442564543300466">
<NAME>Anti-endotoxins vs. placebo, all-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6829770121689251" CI_END="1.100535053127756" CI_START="0.8803707503179691" DF="3" EFFECT_SIZE="0.9843164483403234" ESTIMABLE="YES" EVENTS_1="376" EVENTS_2="375" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.04160387981759528" LOG_CI_START="-0.055334394999340154" LOG_EFFECT_SIZE="-0.0068652575908724365" MODIFIED="2009-03-14 11:29:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6407250839249633" P_Z="0.7813095315695052" STUDIES="4" TAU2="0.0" TOTAL_1="1000" TOTAL_2="975" WEIGHT="55.39479701195299" Z="0.2776128964149765">
<NAME>E5 vs. placebo, all- cause mortality</NAME>
<DICH_DATA CI_END="1.1071607470677283" CI_START="0.8244269757727571" EFFECT_SIZE="0.9553916403231472" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="219" LOG_CI_END="0.04421068004433363" LOG_CI_START="-0.08384780626984648" LOG_EFFECT_SIZE="-0.019818563112756402" ORDER="99" O_E="0.0" SE="0.07522218876068007" STUDY_ID="STD-Angus-2000" TOTAL_1="546" TOTAL_2="544" VAR="0.005658377681947383" WEIGHT="22.739028066725425"/>
<DICH_DATA CI_END="1.3179373374606722" CI_START="0.8875225274738863" EFFECT_SIZE="1.0815262718932444" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="109" LOG_CI_END="0.11989476181944855" LOG_CI_START="-0.05182061468590067" LOG_EFFECT_SIZE="0.03403707356677393" ORDER="100" O_E="0.0" SE="0.10086646216406454" STUDY_ID="STD-Bone-1995" TOTAL_1="264" TOTAL_2="266" VAR="0.010174043189494664" WEIGHT="19.293030194182627"/>
<DICH_DATA CI_END="1.6522614078856277" CI_START="0.34044249736476156" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.21807875909878463" LOG_CI_START="-0.4679562323153845" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-03-14 11:29:30 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.40298034988465925" STUDY_ID="STD-Greenberg-1992" TOTAL_1="26" TOTAL_2="13" VAR="0.1623931623931624" WEIGHT="3.1584081348479156"/>
<DICH_DATA CI_END="1.3163553531431313" CI_START="0.6211244212890562" EFFECT_SIZE="0.9042236763831053" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" LOG_CI_END="0.1193731438955111" LOG_CI_START="-0.20682139488490803" LOG_EFFECT_SIZE="-0.04372412549469844" ORDER="102" O_E="0.0" SE="0.19160828676862654" STUDY_ID="STD-Greenman-1991" TOTAL_1="164" TOTAL_2="152" VAR="0.03671373555840822" WEIGHT="10.20433061619702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.6908092478131" CI_END="1.1970214102315977" CI_START="0.5369213938076549" DF="2" EFFECT_SIZE="0.8016897180325777" ESTIMABLE="YES" EVENTS_1="483" EVENTS_2="470" I2="81.29234229476951" ID="CMP-003.01.02" LOG_CI_END="0.07810191837824221" LOG_CI_START="-0.2700892910870448" LOG_EFFECT_SIZE="-0.09599368635440135" MODIFIED="2008-09-15 11:51:08 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="2" P_CHI2="0.004770033861709266" P_Z="0.2798330329463755" STUDIES="3" TAU2="0.09907541345209317" TOTAL_1="1349" TOTAL_2="1319" WEIGHT="44.034131991452504" Z="1.0806945315293361">
<NAME>HA-1A vs. placebo, all-cause mortality</NAME>
<DICH_DATA CI_END="1.045168063874159" CI_START="0.42353054853189753" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" MODIFIED="2008-09-15 11:51:08 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="103" O_E="0.0" SE="0.23043977855938225" STUDY_ID="STD-Derkx-1999" TOTAL_1="131" TOTAL_2="138" VAR="0.053102491542497125" WEIGHT="7.904787289380738"/>
<DICH_DATA CI_END="1.2008673000111854" CI_START="0.9651795749629176" EFFECT_SIZE="1.0765930476329775" ESTIMABLE="YES" EVENTS_1="427" EVENTS_2="387" LOG_CI_END="0.07949501901241571" LOG_CI_START="-0.015391877163951137" LOG_EFFECT_SIZE="0.03205157092423231" MODIFIED="2008-09-15 08:54:19 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="104" O_E="0.0" SE="0.05573703251170915" STUDY_ID="STD-McCloskey-1994" TOTAL_1="1113" TOTAL_2="1086" VAR="0.0031066167932113234" WEIGHT="25.29180324024354"/>
<DICH_DATA CI_END="0.9206318163593459" CI_START="0.4496323620615442" EFFECT_SIZE="0.6433862433862434" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="45" LOG_CI_END="-0.035914020284396116" LOG_CI_START="-0.3471424381886598" LOG_EFFECT_SIZE="-0.191528229236528" MODIFIED="2008-09-15 11:45:37 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="105" O_E="0.0" SE="0.1828171132824797" STUDY_ID="STD-Ziegler-1991" TOTAL_1="105" TOTAL_2="95" VAR="0.03342209690893902" WEIGHT="10.837541461828229"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0569526222644772" CI_START="0.021513476234119873" DF="0" EFFECT_SIZE="0.1507936507936508" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.02405552056168242" LOG_CI_START="-1.66728940889115" LOG_EFFECT_SIZE="-0.8216169441647339" NO="3" P_CHI2="1.0" P_Z="0.05688258501452921" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="19" WEIGHT="0.5710709965945112" Z="1.9042119577249053">
<NAME>Anti-LPS vs placebo, all-cause mortality</NAME>
<DICH_DATA CI_END="1.056952622264477" CI_START="0.021513476234119873" EFFECT_SIZE="0.15079365079365079" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="0.02405552056168233" LOG_CI_START="-1.66728940889115" LOG_EFFECT_SIZE="-0.821616944164734" ORDER="106" O_E="0.0" SE="0.9935043838530212" STUDY_ID="STD-Lachman-1984" TOTAL_1="14" TOTAL_2="19" VAR="0.9870509607351714" WEIGHT="0.5710709965945112"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.455451663638151" CI_END="1.0942524337468986" CI_START="0.9380412603737948" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0131406280073034" ESTIMABLE="YES" EVENTS_1="827" EVENTS_2="800" I2="22.546085688106448" I2_Q="71.34665592664723" ID="CMP-003.02" LOG_CI_END="0.039117521208544864" LOG_CI_START="-0.027778058466818717" LOG_EFFECT_SIZE="0.005669731370863083" METHOD="MH" MODIFIED="2009-03-14 22:09:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2643880360981389" P_Q="0.06174093051304619" P_Z="0.7397131081751577" Q="3.4899940385317425" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2244" TOTAL_2="2199" WEIGHT="100.0" Z="0.3322332908343443">
<NAME>Sensitivity analysis by quality, anti-endotoxin, all-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.045168063874159" CI_START="0.42353054853189753" DF="0" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" MODIFIED="2009-03-14 21:44:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07701851756136492" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="138" WEIGHT="4.584501258511004" Z="1.7682535974030373">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="1.045168063874159" CI_START="0.42353054853189753" EFFECT_SIZE="0.6653274407392528" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="0.01918613096810395" LOG_CI_START="-0.37311525928756767" LOG_EFFECT_SIZE="-0.17696456415973186" ORDER="211" O_E="0.0" SE="0.23043977855938225" STUDY_ID="STD-Derkx-1999" TOTAL_1="131" TOTAL_2="138" VAR="0.053102491542497125" WEIGHT="4.584501258511004"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.945331079498451" CI_END="1.1135481315954807" CI_START="0.9524471149958257" DF="4" EFFECT_SIZE="1.0298522735553424" ESTIMABLE="YES" EVENTS_1="803" EVENTS_2="762" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.04670899356094876" LOG_CI_START="-0.021159129356407035" LOG_EFFECT_SIZE="0.012774932102270879" MODIFIED="2009-03-14 22:09:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5670154618004424" P_Z="0.460602753351944" STUDIES="5" TAU2="0.0" TOTAL_1="2113" TOTAL_2="2061" WEIGHT="95.41549874148899" Z="0.7378547025938872">
<NAME>Unclear risk of bias</NAME>
<DICH_DATA CI_END="1.1071607470677283" CI_START="0.8244269757727571" EFFECT_SIZE="0.9553916403231472" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="219" LOG_CI_END="0.04421068004433363" LOG_CI_START="-0.08384780626984648" LOG_EFFECT_SIZE="-0.019818563112756402" MODIFIED="2009-03-14 22:01:18 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.07522218876068007" STUDY_ID="STD-Angus-2000" TOTAL_1="546" TOTAL_2="544" VAR="0.005658377681947383" WEIGHT="27.176889190883447"/>
<DICH_DATA CI_END="1.3179373374606722" CI_START="0.8875225274738863" EFFECT_SIZE="1.0815262718932444" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="109" LOG_CI_END="0.11989476181944855" LOG_CI_START="-0.05182061468590067" LOG_EFFECT_SIZE="0.03403707356677393" MODIFIED="2009-03-14 22:01:50 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.10086646216406454" STUDY_ID="STD-Bone-1995" TOTAL_1="264" TOTAL_2="266" VAR="0.010174043189494664" WEIGHT="13.450673760702374"/>
<DICH_DATA CI_END="1.6522614078856277" CI_START="0.34044249736476156" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.21807875909878463" LOG_CI_START="-0.4679562323153845" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-03-14 22:04:28 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.40298034988465925" STUDY_ID="STD-Greenberg-1992" TOTAL_1="26" TOTAL_2="13" VAR="0.1623931623931624" WEIGHT="0.9909448280750984"/>
<DICH_DATA CI_END="1.3163553531431313" CI_START="0.6211244212890562" EFFECT_SIZE="0.9042236763831053" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" LOG_CI_END="0.1193731438955111" LOG_CI_START="-0.20682139488490803" LOG_EFFECT_SIZE="-0.04372412549469844" ORDER="213" O_E="0.0" SE="0.19160828676862654" STUDY_ID="STD-Greenman-1991" TOTAL_1="164" TOTAL_2="152" VAR="0.03671373555840822" WEIGHT="5.2714501771969635"/>
<DICH_DATA CI_END="1.2008673000111854" CI_START="0.9651795749629176" EFFECT_SIZE="1.0765930476329775" ESTIMABLE="YES" EVENTS_1="427" EVENTS_2="387" LOG_CI_END="0.07949501901241571" LOG_CI_START="-0.015391877163951137" LOG_EFFECT_SIZE="0.03205157092423231" ORDER="216" O_E="0.0" SE="0.05573703251170915" STUDY_ID="STD-McCloskey-1994" TOTAL_1="1113" TOTAL_2="1086" VAR="0.0031066167932113234" WEIGHT="48.525540784631104"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.016983877561417" CI_END="0.9716780240585926" CI_START="0.8620137291739838" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9152047842287295" ESTIMABLE="YES" EVENTS_1="1518" EVENTS_2="1306" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.012477619373704176" LOG_CI_START="-0.06448581717178373" LOG_EFFECT_SIZE="-0.038481718272743944" METHOD="MH" MODIFIED="2009-03-14 23:47:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7557594109526872" P_Q="0.4812655317149842" P_Z="0.0037266417038347367" Q="0.49599434061386527" RANDOM="NO" SCALE="6.24" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4429" TOTAL_2="3464" WEIGHT="100.0" Z="2.900418975124729">
<NAME>Anti-cytokines vs. placebo, all-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3254238961521998" CI_END="0.9884544497781519" CI_START="0.8655986489303902" DF="5" EFFECT_SIZE="0.9249891006153534" ESTIMABLE="YES" EVENTS_1="1207" EVENTS_2="1067" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-0.005043339163455729" LOG_CI_START="-0.06268343010549808" LOG_EFFECT_SIZE="-0.03386338463447691" MODIFIED="2009-03-14 08:57:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9322939733663219" P_Z="0.021281870147921475" STUDIES="6" TAU2="0.0" TOTAL_1="3409" TOTAL_2="2791" WEIGHT="80.33534249764884" Z="2.30294620266781">
<NAME>Anti-TNF-alpha vs. placebo, all-cause mortality</NAME>
<DICH_DATA CI_END="1.113041319203701" CI_START="0.7559083030491796" EFFECT_SIZE="0.9172552397358599" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="108" LOG_CI_END="0.04651128685859071" LOG_CI_START="-0.12153088425419555" LOG_EFFECT_SIZE="-0.037509798697802424" MODIFIED="2009-03-14 08:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.09870880313381312" STUDY_ID="STD-Abraham-1995" TOTAL_1="645" TOTAL_2="326" VAR="0.009743427816109877" WEIGHT="10.133046174374671"/>
<DICH_DATA CI_END="1.048284143601728" CI_START="0.8457281521994383" EFFECT_SIZE="0.9415749634247186" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="398" LOG_CI_END="0.020479016686226436" LOG_CI_START="-0.0727692125784469" LOG_EFFECT_SIZE="-0.026145097946110227" ORDER="108" O_E="0.0" SE="0.054774471456248336" STUDY_ID="STD-Abraham-1998" TOTAL_1="948" TOTAL_2="930" VAR="0.0030002427233113637" WEIGHT="28.37733472375293"/>
<DICH_DATA CI_END="1.185527453886834" CI_START="0.7515949102759769" EFFECT_SIZE="0.9439472444653791" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="66" LOG_CI_END="0.07391161561787904" LOG_CI_START="-0.12401616955946045" LOG_EFFECT_SIZE="-0.02505227697079071" ORDER="109" O_E="0.0" SE="0.1162637607715072" STUDY_ID="STD-Cohen-1996" TOTAL_1="386" TOTAL_2="167" VAR="0.013517262068734255" WEIGHT="6.507016235732339"/>
<DICH_DATA CI_END="1.8471494517265552" CI_START="0.5874291565472495" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.26650203536137207" LOG_CI_START="-0.2310445014405088" LOG_EFFECT_SIZE="0.017728766960431616" ORDER="110" O_E="0.0" SE="0.29226129861250305" STUDY_ID="STD-Dhainaut-1995" TOTAL_1="32" TOTAL_2="10" VAR="0.08541666666666667" WEIGHT="0.6456954405688236"/>
<DICH_DATA CI_END="0.9998475731832024" CI_START="0.8080208647661402" EFFECT_SIZE="0.8988312971396901" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="477" LOG_CI_END="-6.620317112678931E-5" LOG_CI_START="-0.0925774247009" LOG_EFFECT_SIZE="-0.046321813936013374" MODIFIED="2008-06-23 12:10:53 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.05434154946452086" STUDY_ID="STD-Panacek-2004" TOTAL_1="1305" TOTAL_2="1329" VAR="0.002953003998204968" WEIGHT="33.38019746888512"/>
<DICH_DATA CI_END="1.8540278334274565" CI_START="0.70510973363209" EFFECT_SIZE="1.1433691756272402" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="12" LOG_CI_END="0.2681162496645851" LOG_CI_START="-0.15174329009741797" LOG_EFFECT_SIZE="0.05818647978358358" ORDER="111" O_E="0.0" SE="0.2466275719944414" STUDY_ID="STD-Reinhart-1996" TOTAL_1="93" TOTAL_2="29" VAR="0.06082515926787338" WEIGHT="1.2920524543349514"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.093913701375844" CI_END="1.0055808163811029" CI_START="0.7617818879643014" DF="2" EFFECT_SIZE="0.8752332562257218" ESTIMABLE="YES" EVENTS_1="311" EVENTS_2="239" I2="35.35695584816692" ID="CMP-003.03.02" LOG_CI_END="0.002416979654732499" LOG_CI_START="-0.11816935728634752" LOG_EFFECT_SIZE="-0.057876188815807514" MODIFIED="2008-09-16 00:46:33 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="2" P_CHI2="0.21289495452178875" P_Z="0.05991825173342195" STUDIES="3" TAU2="0.0" TOTAL_1="1020" TOTAL_2="673" WEIGHT="19.66465750235117" Z="1.881394667404957">
<NAME>Human interleukin-1receptor antagonist vs. placebo, all-cause mortality</NAME>
<DICH_DATA CI_END="0.9438377182459127" CI_START="0.284111063459301" EFFECT_SIZE="0.5178365937859609" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="-0.02510267109271768" LOG_CI_START="-0.5465118542539278" LOG_EFFECT_SIZE="-0.28580726267332274" MODIFIED="2008-09-16 00:46:33 +0100" MODIFIED_BY="Marissa M. Alejandria" ORDER="112" O_E="0.0" SE="0.3062783352059776" STUDY_ID="STD-Fisher-1994a" TOTAL_1="79" TOTAL_2="25" VAR="0.09380641861654518" WEIGHT="1.1802179582272097"/>
<DICH_DATA CI_END="1.0834483890228104" CI_START="0.7257330229524048" EFFECT_SIZE="0.8867323579177864" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="102" LOG_CI_END="0.03480822816487772" LOG_CI_START="-0.13922311481330904" LOG_EFFECT_SIZE="-0.05220744332421568" ORDER="113" O_E="0.0" SE="0.10222687233442822" STUDY_ID="STD-Fisher-1994b" TOTAL_1="591" TOTAL_2="302" VAR="0.010450333427279485" WEIGHT="9.534808504989808"/>
<DICH_DATA CI_END="1.1158232745383854" CI_START="0.7423275539791412" EFFECT_SIZE="0.9101133786848072" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="126" LOG_CI_END="0.0475954159542297" LOG_CI_START="-0.12940441885051662" LOG_EFFECT_SIZE="-0.040904501448143456" ORDER="114" O_E="0.0" SE="0.10397057912762085" STUDY_ID="STD-Opal-1997" TOTAL_1="350" TOTAL_2="346" VAR="0.010809881324132868" WEIGHT="8.949631039134152"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9999491160607006" CI_END="0.968721017201802" CI_START="0.858166217515851" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9117695164679384" ESTIMABLE="YES" EVENTS_1="1460" EVENTS_2="1289" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.013801277783821167" LOG_CI_START="-0.06642858585930873" LOG_EFFECT_SIZE="-0.04011493182156494" METHOD="MH" MODIFIED="2009-03-14 23:02:40 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6766835098929171" P_Q="0.6274507023269797" P_Z="0.0028085762673939695" Q="0.23553371330061562" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4323" TOTAL_2="3429" WEIGHT="99.99999999999999" Z="2.9879476829698595">
<NAME>Sensitivity analysis by quality, anti-cytokine, all-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.40874700923358565" CI_END="0.9895354086440422" CI_START="0.857025542139986" DF="2" EFFECT_SIZE="0.9209001683460987" ESTIMABLE="YES" EVENTS_1="947" EVENTS_2="941" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-0.004568660776853616" LOG_CI_START="-0.06700623450019805" LOG_EFFECT_SIZE="-0.03578744763852585" MODIFIED="2009-03-14 23:02:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8151579340727768" P_Z="0.024653348061720554" STUDIES="3" TAU2="0.0" TOTAL_1="2639" TOTAL_2="2426" WEIGHT="69.50611907783508" Z="2.246791612400487">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="1.048284143601728" CI_START="0.8457281521994383" EFFECT_SIZE="0.9415749634247186" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="398" LOG_CI_END="0.020479016686226436" LOG_CI_START="-0.0727692125784469" LOG_EFFECT_SIZE="-0.026145097946110227" ORDER="217" O_E="0.0" SE="0.054774471456248336" STUDY_ID="STD-Abraham-1998" TOTAL_1="948" TOTAL_2="930" VAR="0.0030002427233113637" WEIGHT="28.893451313024972"/>
<DICH_DATA CI_END="1.185527453886834" CI_START="0.7515949102759769" EFFECT_SIZE="0.9439472444653791" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="66" LOG_CI_END="0.07391161561787904" LOG_CI_START="-0.12401616955946045" LOG_EFFECT_SIZE="-0.02505227697079071" ORDER="219" O_E="0.0" SE="0.1162637607715072" STUDY_ID="STD-Cohen-1996" TOTAL_1="386" TOTAL_2="167" VAR="0.013517262068734255" WEIGHT="6.625363468078754"/>
<DICH_DATA CI_END="0.9998475731832024" CI_START="0.8080208647661402" EFFECT_SIZE="0.8988312971396901" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="477" LOG_CI_END="-6.620317112678931E-5" LOG_CI_START="-0.0925774247009" LOG_EFFECT_SIZE="-0.046321813936013374" ORDER="218" O_E="0.0" SE="0.05434154946452086" STUDY_ID="STD-Panacek-2004" TOTAL_1="1305" TOTAL_2="1329" VAR="0.002953003998204968" WEIGHT="33.98730429673135"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.297864715616427" CI_END="0.9970310185428943" CI_START="0.7961692524109644" DF="3" EFFECT_SIZE="0.8909575975678296" ESTIMABLE="YES" EVENTS_1="513" EVENTS_2="348" I2="9.032047743072782" ID="CMP-003.04.02" LOG_CI_END="-0.0012913301813601832" LOG_CI_START="-0.09899459862594624" LOG_EFFECT_SIZE="-0.05014296440365321" MODIFIED="2009-03-14 23:02:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34794001349380865" P_Z="0.04424385931467569" STUDIES="4" TAU2="0.0" TOTAL_1="1684" TOTAL_2="1003" WEIGHT="30.49388092216491" Z="2.011773114120013">
<NAME>Uncertain risk of bias</NAME>
<DICH_DATA CI_END="1.1158891479546422" CI_START="0.7601869501413356" EFFECT_SIZE="0.921023543716149" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="109" LOG_CI_END="0.047621054079379194" LOG_CI_START="-0.1190795900476389" LOG_EFFECT_SIZE="-0.03572926798412986" ORDER="221" O_E="0.0" SE="0.09792078354170725" STUDY_ID="STD-Abraham-1995" TOTAL_1="664" TOTAL_2="330" VAR="0.009588479849421884" WEIGHT="10.471569818511252"/>
<DICH_DATA CI_END="0.9438377182459127" CI_START="0.284111063459301" EFFECT_SIZE="0.5178365937859609" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="-0.02510267109271768" LOG_CI_START="-0.5465118542539278" LOG_EFFECT_SIZE="-0.28580726267332274" MODIFIED="2009-03-14 22:55:41 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.3062783352059776" STUDY_ID="STD-Fisher-1994a" TOTAL_1="79" TOTAL_2="25" VAR="0.09380641861654518" WEIGHT="1.201683330966672"/>
<DICH_DATA CI_END="1.0834483890228104" CI_START="0.7257330229524048" EFFECT_SIZE="0.8867323579177864" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="102" LOG_CI_END="0.03480822816487772" LOG_CI_START="-0.13922311481330904" LOG_EFFECT_SIZE="-0.05220744332421568" ORDER="220" O_E="0.0" SE="0.10222687233442822" STUDY_ID="STD-Fisher-1994b" TOTAL_1="591" TOTAL_2="302" VAR="0.010450333427279485" WEIGHT="9.708224116176094"/>
<DICH_DATA CI_END="1.1158232745383854" CI_START="0.7423275539791412" EFFECT_SIZE="0.9101133786848072" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="126" LOG_CI_END="0.0475954159542297" LOG_CI_START="-0.12940441885051662" LOG_EFFECT_SIZE="-0.040904501448143456" ORDER="179" O_E="0.0" SE="0.10397057912762085" STUDY_ID="STD-Opal-1997" TOTAL_1="350" TOTAL_2="346" VAR="0.010809881324132868" WEIGHT="9.112403656510892"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3086073528418933" CI_START="0.9054242959078131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0885058066297388" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="141" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.11680935619594414" LOG_CI_START="-0.043147855945111876" LOG_EFFECT_SIZE="0.03683075012541612" METHOD="MH" MODIFIED="2008-10-01 02:14:34 +0100" MODIFIED_BY="Marissa M. Alejandria" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.36674982777492415" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="411" TOTAL_2="415" WEIGHT="100.0" Z="0.9025781682885625">
<NAME>Monoclonal antibody to Enterobacteriaceae common antigen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3086073528418933" CI_START="0.9054242959078131" EFFECT_SIZE="1.0885058066297388" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="141" LOG_CI_END="0.11680935619594414" LOG_CI_START="-0.043147855945111876" LOG_EFFECT_SIZE="0.03683075012541612" MODIFIED="2008-06-23 12:57:01 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.09395965821262638" STUDY_ID="STD-Albertson-2003" TOTAL_1="411" TOTAL_2="415" VAR="0.008828417371433568" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-03 02:59:55 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-03 02:59:09 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Search flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0kAAALsCAYAAAA23/ypAACAAElEQVR42uzdD+RX5//H/y9JkiSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-03 02:23:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUsAAAYkCAIAAADs0LrIAABWO0lEQVR42u2dvY4TyxaFLSEhAgcT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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-03 02:23:42 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-09-03 02:59:41 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.09" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Polyclonal IVIG versus placebo or no intervention, outcome: all-cause mortality by type of polyclonal IVIG, sensitivity analysis, low risk of bias trials.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAAHwCAMAAACRyleCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-09-03 02:59:55 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.1 All-cause mortality, adults, by type of polyclonal IVIG.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-04-12 09:49:46 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.03" SETTINGS="SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.3 All-cause mortality, neonates, by type of polyclonal IVIG.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-09-03 03:13:29 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-09-03 03:04:09 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Inclusion and omission of trials</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-09-03 03:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>The following points were raised about this review in a commentary by Doctors Cui and Eichacker (1999) published in the ACP Journal Club, 1999; 129: 70.</P>
<P>1. Inclusion of two RCTs in the monoclonal IVIG group (which provided 20% of the 4800 patients in the meta-analysis) on interleukin-1-receptor antagonist, a recombinant protein that is different from IVIG (<LINK REF="STD-Fisher-1994a" TYPE="STUDY">Fisher 1994a</LINK>; <LINK REF="STD-Fisher-1994b" TYPE="STUDY">Fisher 1994b</LINK>).<BR/>2. Omission of two large RCTs of 392 patients that showed that polyclonal IVIG did not reduce mortality in surgical patients with severe infection (<LINK REF="STD-Just-1986" TYPE="STUDY">Just 1986</LINK>; <LINK REF="STD-Jesdinsky-1987" TYPE="STUDY">Jesdinsky 1987</LINK>).<BR/>3. Omission of a large RCT of 653 patients, where the preliminary results showed that polyclonal IVIG did not reduce mortality in sepsis (<LINK REF="REF-Werdan-1997" TYPE="REFERENCE">Werdan 1997</LINK> (abstract a).<BR/>4. Failure to cite a meta-analysis of 20 studies assessing six mediator-specific anti-inflammatory agents in 8808 patients with sepsis (<LINK REF="STD-Freeman-1999" TYPE="STUDY">Freeman 1999</LINK>). A reduction in mortality was shown in eight of these studies that assessed anti-TNF monoclonal antibodies in more than 4000 patients.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-09-03 03:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Interleukin-1-receptor antagonist is functionally an anti-cytokine. Technically, it is a soluble inhibitor of IL-1activity. We recognize the structural heterogeneity of these monoclonal IVIGs, which accounts for the subgroup analyses. Even with inclusion or non-inclusion of these two trials, the overall conclusion would not significantly change with regards to the lack of benefit of anti-cytokines. Subgroup analyses of anti-TNF alpha and interleukin-1-receptor antagonist trials both yielded no significant reduction in mortality.</P>
<P>2. The trial by Jesdinsky (1987) was excluded because it did not fulfil the pre-specified inclusion criteria of our meta-analysis, i.e. study participants should be patients with sepsis or septic shock (protocol issue 2, 1998). Specifically, the trial by Jesdinsky (1987) was on patients with diffuse fibrinopurulent peritonitis, not necessarily sepsis. The trial by Just (1986), was initially excluded because of similar reasons; i.e. its inclusion criteria was severe infections in intensive care units. On English translation of the trial, there was a subgroup of 29 patients with sepsis and septic shock. This trial has now been moved into the included list and we have incorporated the outcome of this subgroup of sepsis patients in the updated version of the meta-analysis. The demonstrable benefit from polyclonal IVIG was maintained with the addition of this subgroup of patients.</P>
<P>3. The complete results of this large polyclonal RCT was supposed to be available by end of 1996 as stated in Werdan's (1996) review article. However, we were unable to retrieve this RCT in our most recent MEDLINE search (January 2000).</P>
<P>4. This meta-analysis included randomized and non-randomized trials and there was no mention whether a test for heterogeneity was done among the 20 studies on six different anti-inflammatory agents. Among the eight studies on anti-TNF that were included in this meta-analysis, five were included in the June 29, 1999 (Issue 4) updated version of our meta-analysis (<LINK REF="STD-Abraham-1995" TYPE="STUDY">Abraham 1995</LINK>; <LINK REF="STD-Abraham-1998" TYPE="STUDY">Abraham 1998</LINK>; <LINK REF="STD-Cohen-1996" TYPE="STUDY">Cohen 1996</LINK>; <LINK REF="STD-Dhainaut-1995" TYPE="STUDY">Dhainaut 1995</LINK>; <LINK REF="STD-Reinhart-1996" TYPE="STUDY">Reinhart 1996</LINK>). One trial (<LINK REF="STD-Fisher-1993" TYPE="STUDY">Fisher 1993</LINK>) was excluded because there was no control group and was mainly a dose-ranging study. We do not have access yet to the full articles of the two other studies (Kay n.d.; <LINK REF="STD-Zeni-1997" TYPE="STUDY">Zeni 1997</LINK>). The article by Zeni et al (1997) is indexed as a review article, not an RCT in the MEDLINE database, while the other article (Kay n.d.) is a presentation handout in a conference proceeding and is also not indexed in MEDLINE. It is also important to note that the largest (n = 1878) and most recent trial on anti-TNF alpha (Abraham 1998) did not show benefit in both the overall mortality analysis and various subgroups studied.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Cui X, Eichacker PQ. National Institutes of Health, Bethesda, Maryland, USA (1999) published in the ACP Journal Club 1999; 129: 70.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2013-09-03 03:08:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Quality of the studies</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-09-03 03:05:18 +0100" MODIFIED_BY="[Empty name]">
<P>The following issues were raised about this review in a commentary by Dr Peter C Gotzsche of the Nordic Cochrane Centre, received November 2001.</P>
<P>1. No description on how the reviewers assessed whether a trial had adequate concealment. This information is important, as trials with inadequate allocation concealment exaggerate the estimated effect by 30 to 40% on the average.<BR/>2. The expression good quality trials was used and analyses done accordingly, but it was not defined in the review in relation to the term high quality trials.<BR/>3. Exclusion of a trial written in Russian, which should be translated and included, as language bias has been demonstrated to exist.<BR/>4. Results section does not take the authors' quality assessment into account. There appears to be only two high quality trials with small sample sizes but a significant reduction in all-cause mortality using polyclonal IVIG was reported in the abstract and results section. Thus the result is somewhat doubtful, as it could have been influenced by publication bias and other biases related to small samples.<BR/>5. An effect on adults is reported but not on neonates. However, relative risk for adults and neonates are the same (RR = 0.60). It is therefore not reasonable to distinguish between the two situations, e.g. a test for interaction would not have yielded a significant result.<BR/>6. Lack of caution in the reporting of results in the abstract, i.e. the problem of small sample sizes was mentioned in the discussion but not in the abstract.<BR/>8. References could not be checked because the journal citation is missing, specifically for <LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK> and <LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>.<BR/>7. Discrepancy in the classification of the trial of <LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK> as having unclear allocation concealment in the main text, but with adequate allocation concealment in the table of included studies. It is suggested that the randomization be explained carefully in the table of included studies, as this information is essential for judging the quality of studies and for judging the robustness of the review's findings.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-09-03 03:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Trials were assessed by the reviewers to have adequate allocation concealment if randomization was administered by an independent third party through a central facility or the use of sealed opaque envelopes. This statement has been added in the methods section.<BR/>2. We recognize that the term good quality was not defined explicitly. The term good quality in the sensitivity analyses actually referred to both high quality and fair quality trials. For consistency and clarity we have removed the term good quality and used the actual terms: high quality, fair quality and low quality. Fair quality referred to those trials which have any one or more of the following biases: unclear allocation concealment, absence of blinding and lack of intention-to-treat analysis. We have made the necessary corrections in the text, particularly in the methods section and in the graphs. Low quality trials are those which have any one of the following biases: significant differences in the baseline characteristics of the treatment and control groups which are known predictors of outcome; marked differences in the dropout rates and overt differences in the general quality of care received by both groups such as differential administration of co-interventions. These definitions have been added in the methods section.<BR/>3. The Russian study has been translated previously and found to have been published originally in Engish (<LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>). The English version is already included in our analyses. For clarity, we have revised the statement pertaining to this in the section of excluded studies.<BR/>4. Sensitivity analysis of the two high quality trials on polyclonal IVIG has been incorporated. This likewise showed significant reduction of mortality, although the confidence interval was wide (RR 0.30; 95% CI 0.09, 0.99; n = 91). Further subanalysis according to allocation concealment also showed a significant reduction of mortality (RR 0.43; 95% CI 0.25, 0.75, n =170).<BR/>5. A subanalysis on the effect of IVIG according to age group, i.e. adults and neonates was done based on clinical grounds. Physiologically, adults and neonates inherently differ from each other. The point estimates of the relative risks for adults (RR = 0.62) and neonates (RR = 0.70) differ, although their 95% CIs overlap. Statistically there may be no significant interaction between the two groups, but clinically adult and neonatal sepsis differ pathophysiologically , which is the main reason for the subgroup analysis.<BR/>6. We have revised the conclusion in the abstract to caution the readers with regards to the small sample sizes of the trials. One of the main reasons, however, for doing a meta-analysis is to increase the power of trials with small sample sizes.<BR/>7. Thank you for pointing this out. We have put in the proper citation, which was missed out in the reference section of included studies. The trial by Lachman (<LINK REF="STD-Lachman-1984" TYPE="STUDY">Lachman 1984</LINK>) was published in the Lancet, while the trial by Haque (<LINK REF="STD-Haque-1988" TYPE="STUDY">Haque 1988</LINK>) was published in the American Journal of Diseases in Childhood.<BR/>8. Again thank you for this. The inadvertent discrepancy has been corrected in the text. On review of our files and the original article, the trial by Schedel (<LINK REF="STD-Schedel-1991" TYPE="STUDY">Schedel 1991</LINK>) was definitely assessed to have adequate allocation concealment.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Gotzsche, Peter C. The Nordic Cochrane Centre. October 2001 </P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-03" MODIFIED="2013-09-03 03:13:29 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-03-22 10:55:18 +0000" MODIFIED_BY="[Empty name]">Mortality data</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-09-03 03:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>The following issues were raised about this review by Dr Peter C Gotzsche and Dr Julie Pildal of the Nordic Cochrane Centre, received July 2006.</P>
<P>You reported an effect of polyclonal immunoglobulin on overall mortality (11 trials, 176 deaths, relative risk (RR) 0.64 (95% confidence interval (CI) 0.51 to 0.80) but also noted that the trials were small and that the evidence was insufficient to support a robust conclusion of benefit.</P>
<P>We have replicated this part of your review (1) and found 21 trials and three times as many deaths. One of the trials was large, was of high quality, and had a pre-published protocol. Until the publication of our review, its results had only been available in an abstract that stated that the mortality was not reduced (2), but we obtained mortality data from the author.</P>
<P>We found that the apparent effect of polyclonal immunoglobulin was conveyed by trials at higher risk of being biased. These trials (292 deaths) showed RR 0.61 (95% CI 0.50 to 0.73), whereas the high quality trials (255 deaths) showed RR 1.02 (95% CI 0.84 to 1.24). The difference between the estimates from the trials of high methodological quality versus those from the trials of lower methodological quality was highly statistically significant (P = 0.0002).</P>
<P>In July 2004, we sent you our paper (1) where all the additional mortality data are available and also the additional trial reports. We anticipated that you would update your review or quote our research if the update was delayed because of lack of time. As this has not yet happened, we wish with this comment to warn clinicians against using polyclonal immunoglobulin for bacterial sepsis as we believe there is no reliable evidence that it works, and as it is very expensive.<BR/>
<BR/>1. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39(1):38-46.<BR/>2. Werdan K, Pilz Gat SSG. Polyvalent immune globulins [abstract 18]. Shock 1997; 7(Suppl):5.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-09-03 03:13:02 +0100" MODIFIED_BY="[Empty name]">
<P>Thank you for the cautionary note on the absence of reliable evidence on the use of polyclonal immunoglobulin for bacterial sepsis. We concur, as stated in the conclusion of our 2003 update, which provides the same recommendation that "the trials were small and the totality of evidence is insufficient to provide a robust conclusion of benefit".</P>
<P>We note that Pildal and Gotzsche's (2004) main arguments and conclusion primarily hinged on a large trial (N = 653) by Werdan et al (1997), which remains unpublished to date. Our 2003 update did mention that we were awaiting the publication of this trial. However, we wonder why a large RCT such as this remains unpublished, despite the increasing awareness of editors on the importance of negative trials and the advent of open-access electronic journals. Unfortunately unlike Pildal and Gotzsche who were able to communicate directly with Werdan et al, we do not have access to the full text of Werdan's study and are unable to review this pivotal work. Nevertheless, we will do a sensitivity analysis with and without the unpublished trial of Werdan et al in the update that we are currently doing.</P>
<P>Since our 2003 update, we and the Cochrane Anesthesia Review Group Trial Search Coordinator have updated the search of MEDLINE, EMBASE and the Cochrane CENTRAL databases using additional free text and MeSH terms and the highly sensitive search strategy in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. In addition to the studies in Pildal and Gotzsche's review (<LINK REF="STD-Behre-1995" TYPE="STUDY">Behre 1995</LINK>; <LINK REF="STD-Burns-1991" TYPE="STUDY">Burns 1991</LINK>; <LINK REF="STD-Darenberg-2003" TYPE="STUDY">Darenberg 2003</LINK>; <LINK REF="STD-Dominioni-1996" TYPE="STUDY">Dominioni 1996</LINK>; <LINK REF="STD-Karatzas-2002" TYPE="STUDY">Karatzas 2002</LINK>; <LINK REF="STD-Lindquist-1981" TYPE="STUDY">Lindquist 1981</LINK>; <LINK REF="STD-Mancilla_x002d_Ramirez-1992" TYPE="STUDY">Mancilla-Ramirez 1992</LINK>; <LINK REF="STD-Samatha-1997" TYPE="STUDY">Samatha 1997</LINK>; <LINK REF="STD-Tugrul-2002" TYPE="STUDY">Tugrul 2002</LINK>; <LINK REF="REF-Werdan-1997" TYPE="REFERENCE">Werdan 1997</LINK>; <LINK REF="STD-Yakut-1998" TYPE="STUDY">Yakut 1998</LINK>), we have identified another five potentially relevant trials (<LINK REF="STD-El-Nawawy-2005" TYPE="STUDY">El Nawawy 2005</LINK>; <LINK REF="STD-Gunes-2006" TYPE="STUDY">Gunes 2006</LINK>; <LINK REF="STD-Hentrich-2006" TYPE="STUDY">Hentrich 2006</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Yildizdas-2005" TYPE="STUDY">Yildizdas 2005</LINK>). We have also obtained mortality data for the trial of Masaoka et al (2000). These will be included in the 2006 update.</P>
<P>Please watch out for the results of the upcoming update of our review.<BR/>
<BR/>References:<BR/>Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial. Antiinfect Drugs Chemother 1995; 13: 129-34<BR/>
<BR/>Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol 1991; 11: 363-8<BR/>
<BR/>Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind placebo-controlled trial. Clin Infect Dis 2003; 37: 333-40<BR/>
<BR/>Dominioni L, Bianchi B, Imperatori A, Minoia G, Dionigi R. High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 1996; 13: 430-4<BR/>
<BR/>El Nawawy A, El Kinany H, Hamdy El Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J-Trop-Pediatr 2005; 51: 271-8.<BR/>
<BR/>Gunes T, Koklu E, Buyukkayhan D, Kurtoglu S, Karakukcu M, Patiroglu T. Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study. Ann-Trop-Paediatr 2006; 26: 39-42.<BR/>
<BR/>Hentrich M, Fehnle K, Ostermann H, Klenast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial. Crit Care Med 2006; 34: 1319-25<BR/>
<BR/>Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit Care 2002; 6: 543-5<BR/>
<BR/>Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human globulin in bacterial infections: a randomized study in patients with septicaemia and pneumonia. Vox Ang 1981; 40: 329-37<BR/>
<BR/>Mancilla-Ramirez J, Gonzalez-Yunes R, Castellanos-Cruz C, Garcia-Roca P, Santos-Preciado J. Intravenous immunoglobulin in the treatment of neonatal septicemia. Boletin medico del Hospital Infantil de Mexico 1992; 49: 4-11<BR/>
<BR/>Masaoka T Hazegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother 2000; 48: 199-217<BR/>
<BR/>Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39:38-46.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-09-03 03:13:29 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Peter C Gotzsche and Dr Julie Pildal of the Nordic Cochrane Centre, received July 2006<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2013-09-13 06:45:08 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2009-11-04 13:15:23 +0000" MODIFIED_BY="Jane Cracknell">Search strategy for CENTRAL, The Cochrane Library</TITLE>
<APPENDIX_BODY MODIFIED="2009-01-07 14:22:13 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>#1 MeSH descriptor Immunoglobulins explode all trees<BR/>#2 MeSH descriptor Immunoglobulins, Intravenous explode all trees<BR/>#3 immunoglobulin* in All Text<BR/>#4 immunoglobulin* in All Text near/6 monoclon* in All Text)<BR/>#5 (immunoglobulin* in All Text near/6 polyclon* in All Text)<BR/>#6 IVIG in All Text<BR/>#7 (#1 or #2 or #3 or #4 or #5 or #6)<BR/>#8 (sept* in All Text near/6 shock* in All Text)<BR/>#9 (septicem* in All Text or septicaem* in All Text or seps* in All Text)<BR/>#10 MeSH descriptor Sepsis explode all trees<BR/>#11 MeSH descriptor Septicemia explode all trees<BR/>#12 MeSH descriptor Shock, Septic explode all trees<BR/>#13 (#8 or #9 or #10 or #11 or #12)<BR/>#14 (#7 and #13)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2013-09-03 03:13:40 +0100" MODIFIED_BY="Jane Cracknell">Search strategy for MEDLINE (OvidSP)</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-04 13:15:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>#1 exp Immunoglobulins/<BR/>#2 exp Immunoglobulin - Intravenous/<BR/># 3 immunoglobulin$.mp.<BR/>#4 (immunoglobulin$ adj6 (monoclon$ or polyclon$)).mp.<BR/>#5 IVIG.mp.<BR/>#6 1 or 2 or 3 or 4 or 5<BR/>#7 ((sept$ adj6 shock$) or septicem$ or septicaem$ or seps$).mp.<BR/>#8 exp Sepsis/<BR/>#9 exp Septicemia/<BR/>#10 exp Shock-Septic/<BR/>#11 7 or 8 or 9 or#10<BR/>#12 6 and 11<BR/>#13 (randomized controlled trial.pt. or controlled clinical trial.pt.or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) and humans.sh.<BR/>#14 12 and 13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-09-13 06:46:58 +0100" MODIFIED_BY="Jane Cracknell" NO="3">
<TITLE MODIFIED="2013-09-03 03:13:53 +0100" MODIFIED_BY="Jane Cracknell">Search strategy for EMBASE (OvidSP)</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-04 13:15:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>#1 immunoglobulin/<BR/>#2 immunoglobulin$.mp.<BR/>#3 ivig.mp.<BR/>#4 1 or 2 or 3<BR/>#5 sepsis/<BR/>#6 sepsis.mp.<BR/>#7 septic shock/<BR/>#8 (septic shock).mp.<BR/>#9 septicemia/<BR/>#10 septicaemia.mp.<BR/>#11 septicemia.mp.<BR/>#12 5 or 6 or 7 or 8 or 9 or 10 or 11<BR/>#13 4 and 12<BR/>#14 ((RANDOMIZED-CONTROLLED-TRIAL/ or RANDOMIZATION/ or CONTROLLED-STUDY/ or MULTICENTER-STUDY/ or PHASE-3-CLINICAL-TRIAL/ or PHASE-4-CLINICAL-TRIAL/ or DOUBLE-BLIND-PROCEDURE/ or SINGLE-BLIND-PROCEDURE/) or ((RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) or ((SINGL* or DOUBL* or TREBL* or TRIPL*) adj3 (BLIND* or MASK*))).ti,ab) and human*.ec,hw,fs.<BR/>#15 13 and 14</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Included 43 trials&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Polyclonal IVIG vs placebo or no treatment&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25&lt;/p&gt;&lt;p&gt;&amp;#160;&amp;#160;Standard IVIG, adults -&amp;#160;&amp;#160; &amp;#160;10&lt;/p&gt;&lt;p&gt;&amp;#160;&amp;#160;IgM-enriched, adults -&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 7&lt;/p&gt;&lt;p&gt;&amp;#160;&amp;#160;Standard IVIG, neonates &amp;#8211; 5&lt;/p&gt;&lt;p&gt;&amp;#160;&amp;#160;IgM-enriched, neonates&amp;#160;&amp;#160; -&amp;#160; 3&lt;/p&gt;&lt;p&gt;Anti-endotoxins vs placebo&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160; 8&lt;/p&gt;&lt;p&gt;Anti-cytokines vs placebo&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 9&lt;/p&gt;&lt;p&gt;Monoclonal antibody to Enterobacteriaceae&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1&amp;#160;&amp;#160;&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Full paper / abstract review 88&lt;/b&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Database search 2003-2012&lt;/b&gt;&lt;/p&gt;&lt;p&gt;MEDLINE 316&lt;/p&gt;&lt;p&gt;EMBASE 1331&lt;/p&gt;&lt;p&gt;CENTRAL 360&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Other sources&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Conference Proceedings 0&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 44&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/b&gt;&lt;/p&gt;&lt;p&gt;Review&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 8&lt;/p&gt;&lt;p&gt;Not RCT&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 15&lt;/p&gt;&lt;p&gt;Participants not relevant&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2&lt;/p&gt;&lt;p&gt;Intervention not relevant&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 7&lt;/p&gt;&lt;p&gt;Outcomes not relevant&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6&lt;/p&gt;&lt;p&gt;Duplicate publication&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2&lt;/p&gt;&lt;p&gt;Interim analysis&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2&lt;/p&gt;&lt;p&gt;Subgroup of a larger study&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Awaiting assessment&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Polyclonal IVIG neonate trial 1&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>